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ABSTRACT 
Myeloproliferative Neoplasms (MPN) are a biologically and clinically heterogeneous group of 
hematological malignancies, consisting in clonal disorders of the hematopoietic stem/progenitor cell 
(HSC/PC). Molecular alterations and inflammatory microenvironment represent the two main 
etiopathogenic factors of MPN. 
The overall aim of this study was the molecular characterization of patients diagnosed with Ph- 
negative Chronic MPN and the study of interactions between HSC/PC and the inflammatory cell micro-
environment.  
We investigated young (< 40 years at diagnosis) patients with ET and early-PMF, and patients with a 
low (0,1-3%) JAK2V617F allele burden (AB), demonstrating that the determination of JAK2V617F AB is 
relevant both at diagnosis and during follow up. Indeed, it allows to prove the presence of a clonal 
hematopoiesis and, also, to predict clinical outcome. Of note, an AB 0,8% always corresponds to an 
overt MPN phenotype. In this context, coordinating a network of 19 Italian laboratories, we identified 
the ipsogen JAK2 MutaQuant kit as the most sensitive and efficient assay for the quantification of 
samples with different mutation loads (in particular those with AB ≤1%). With regard to the role of 
inflammatory microenvironment in the pathogenesis of MF, IL-1 and TIMP-1 seemed to confer a 
survival advantage to MF-derived HSPCs, enhancing their proliferation and in vitro migration, as well 
as their clonogenic ability. Finally, in this study we tested three different gene panels for mutations 
detection, obtaining promising results in terms of coverage analysis (more than 95% of target regions 
with depth greater than 500X) and identifying gene variants with very low mutation load (<1%) in all 
patients. 
In conclusion, this study set the basis for the standardization of molecular techniques for the 
determination of JAK2V617F AB, and for the validation of a robust NGS approach to be translated into a 
diagnostic setting. Moreover, IL-1 and TIMP-1 emerged as novel promoting factors of the in vitro 
maintenance of MF-derived HSPC, which may be exploited as potential targets of therapy.  
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Myeloproliferative Neoplasms 
The first formal classification of chronic myeloid neoplasms is credited to William 
Dameshek, who in 1951 described the concept of "myeloproliferative disorders (MPD)" by 
grouping together Chronic Myelogenous Leukemia (CML), Polycythemia Vera (PV), Essential 
Thrombocythemia (ET), and Primary Myelofibrosis (PMF). In 2001, the World Health 
Organization (WHO) classification of myeloid neoplasms included the Dameshek-defined 
MPDs under the broader category of chronic myeloproliferative diseases (CMPDs). Finally, in 
the revised 2008 WHO classification system, the word “disease” was replaced by “neoplasm” 
(MPNs). MPNs represent a biologically and clinically heterogeneous group of hematological 
malignancies. To date, we refer to PV, ET and MF [both primary (PMF) and secondary (post-
PV/ET-MF)] with the term “classical” MPNs, which differ from CML for the absence of the 
transcript BCR-ABL (Philadelphia chromosome)1-6. 
The estimated incidence of PMF ranges from 0.8–2.1 per 100.000/year with a 
comparable overall incidence between men and women; PV has an incidence ranged from 
0.4–2.8 per 100.000/year with a prevalence higher in male than in female (male-to-female 
ratio, 1.8:1), whereas ET is more prevalent in women than men (male-to-female ratio, 1:2) 
with an incidence ranged from 0.4–3.4 per 100.000/year. Most patients are diagnosed with 
MPNs after age 60; however, the diseases can occur at any age. Median age of diagnosis of 
PMF, ET and PV is 65, 56 and 61 years, respectively7-12. 
Classical MPNs are clonal disorders of the hematopoietic stem/progenitor cell 
(HSC/PC) characterized by abnormal proliferation of one or more myeloid lineages, because 
of hypersensitivity or independence from normal cytokine regulation. This proliferation 
results in increased numbers of mature erythrocytes (for PV), megakaryocytes (MK)/platelets 
(for ET), and MK/granulocytes (for PMF) in the peripheral blood. MPNs are associated with a 
normal maturation but increased numbers of mature blood cells, except in PMF, in which 
abnormalities in MK differentiation might be responsible for the bone marrow (BM) fibrosis. 
The BM fibrosis is the hallmark of this disease and is associated with extramedullary 
hematopoiesis with resultant enlargement of liver and spleen, dysregulated hematopoiesis, 
and overexpression of inflammatory cytokines accounting for many of the symptoms. They all 
carry an increased risk of vascular thrombosis and a potential to evolve into life-threatening 
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marrow dysfunction resembling myelodysplastic syndrome (MDS) or acute myeloblastic 
leukemia (AML)13. 
The etiopathogenesis of MPNs is multifactorial, and genetic mutations are among 
crucial factors to be studied. Indeed, their phenotypic diversity is attributed to differences in 
the specific genetic rearrangements or mutation(s) that underlie the clonal 
myeloproliferation2,14-15. The molecular pathogenesis of classical MPNs has been enigmatic 
until 2005, when William Vainchenker et al. described a Janus kinase 2 mutation (JAK2V617F) in 
MPN. This discovery was followed by a series of additional descriptions of mutations that 
directly or indirectly activate JAK-STAT signaling: JAK2 exon 12, myeloproliferative leukemia 
virus oncogene (MPL) and calreticulin (CALR) mutations. The discovery of these, mostly 
mutually exclusive, “driver” mutations has contributed to revisions of the WHO diagnostic 
criteria and risk stratification in MPN. However, the panorama of mutations in MPN has 
become more complex as a result of the emergence of several other mutations, which are 
usually expressed in a subclone of hematopoietic compartment and affect genes involved in 
DNA regulation and transcription, as well as some oncogenes; these mutations, which are 
present both in MDS and in some case of acute leukemia, suggest a hierarchy of mutational 
events that should be considered for a more complete definition of disease mechanism and, 
more importantly, in view of a personalized therapeutic approach16-29. MPNs are not thought 
to be inherited; however, some evidence suggests a genetic predisposition to developing MPN 
in general. The JAK2 46/1 haplotype has been shown to predispose patients to developing 
JAK2V617F-positive MPN, and an association has been reported between a single nucleotide 
polymorphism in the TERT gene and risk of developing an MPN30. 
In addition to molecular abnormalities, the inflammatory microenvironment has 
emerged in the last few years as a key-player in MPNs pathogenesis31-32. Up-regulated 
production of proinflammatory cytokines by HSPCs and surrounding stromal cells generates a 
microenvironment that selects for the malignant clone33-38. This correlates with more severe 
marrow fibrosis39,40, worsening systemic symptoms41 and decreased survival42. However, the 
key players linking inflammation and cancer in MF are still to be defined. 
Current drug therapy in PV, ET, or MF is neither curative nor capable of prolonging life 
or preventing disease progression43,44. Accordingly, treatment indications in PV and ET are, 
primarily, directed at prevention of thrombohemorrhagic complications and, secondarily, 
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towards alleviation of symptoms, and in PMF mostly at alleviation of symptoms with the 
possibility of cure limited to patients undergoing allogeneic stem cell transplant (ASCT)45. This 
is, perhaps, because of the clonal complexity of these disorders and the increasing molecular 
evidence of the need for JAK2V617F mutation to cooperate with other genetic aberrations in 
the initiation and progression of the disease. This clonal complexity needs to be elucidated 
further in order to recognize clinically relevant candidate therapeutic targets46. 
Ruxolitinib is a JAK1/2 inhibitor that represents the first and only targeted therapy in 
MF, in the context of an otherwise orphan disease. Ruxolitinib suppresses clonal 
myeloproliferation and also the release of pro-inflammatory cytokines. It is effective in 
reducing splenomegaly and constitutional symptoms, but is burdened by on-target 
haematological toxicity and by increased susceptibility to potentially severe infections. In 
Phase 3 studies, most patients discontinued therapy due to adverse events or disease 
progression. Optimal use of the drug is of utmost concern in younger patients suitable for 
allogeneic stem cell transplantation, in which a delay of transplant in favour of targeted 
therapy may be detrimental47,48. 
The perspectives of chronic inflammation as the driver of mutagenesis in MPNs intend 
to be a new target for therapy. Indeed, early intervention with interferon-alpha2 and potent 
anti-inflammatory agents (e.g. JAK1-2 inhibitors, histone deacetylase inhibitors, DNA-
hypomethylators and statins) may disrupt the self-perpetuating chronic inflammation state 
and accordingly eliminate a potential trigger of clonal evolution and disease progression49. 
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Molecular pathogenesis of MPNs 
The molecular landscape of the chronic MPN is much more complex than was initially 
assumed on the basis of a relatively large number of studies. Indeed, it encompassed defined 
driver or phenotypic mutations (i.e., mutations that are sufficient per se to determine the clinic 
phenotype of these disease), such as mutations in JAK2, CALR and MPL, which constitute 
major diagnostic criteria in the 2016 revision of the WHO classification of myeloid neoplasms; 
and additional mutations, which are usually acquired in variably sized sub-clones of 
hematopoietic progenitors and which can occur most commonly concurrently with one of the 
phenotypic mutations.  
Overall, most mutant genes in MPN fall in three functional classes: JAK/STAT signaling 
(mutations in JAK2, CALR, MPL, CBL, LNK, and rare mutations in SOCS), epigenetic gene 
regulation (TET2, EZH2, ASXL1, DNMT3A, IDH1) and spliceosome factors (SF3B1, U2AF1 and 
SRSF2)27. Patients with MPN who transform to acute myeloid leukemia (AML) often acquire 
additional mutations, such as TP53, NPM1, FLT3, RUNX-1 and several others50,51. 
  
JAK2 mutations 
Frequency and distribution in MPN 
Although by 1951, William Dameshek had highlighted the common pathogenic and clinical 
characteristics of PV, ET and PMF, the molecular pathogenesis of these disease remains 
unknown until 2005. In that year, four different groups described a mutation (c.1849 G>T) in 
exon 14 of the Janus kinase 2 (JAK2) gene resulting in a valine to phenylalanine amino acid 
substitution at codon 617 (V617F) of the corresponding protein.  
The JAK2 gene maps to 9p24 and codes for a member of the tyrosine kinase proteins 
family. With JAK2, three other members of this family (JAK1, JAK3 and TYK2) form functional 
complexes with the intracellular domain of cytokine receptors of hematopoietic cells to whom 
are associated, thus allowing to transduce the specific ligand signal. Indeed, binding of the 
cytokine to the receptor causes receptor dimerization or modifies the three-dimensional 
structure with the juxtaposition and transactivation of the receptor-associated JAK molecules. 
Once activated, these phosphorylate tyrosine residues of the receptor, creating “anchor sites” 
for adapter or effector proteins containing Src-homology-2 (SH2) domains, including one or 
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more proteins of the seven-membered STAT family (STAT-1, -2, -3, -4, -5a, -5b, and 6). Thus, 
the JAK/STAT pathway, through the four JAK members and seven STAT members, is the main 
system of intracellular signaling. The type of STAT dimers that are recruited by activated 
receptors, as well as the kinetics and the extent of STAT activation, and the possible parallel 
activation of other signaling pathway (e.g. the mitogen-activated protein kinase (MAPK) 
pathway and phosphatydilinositol-3’-kinase (PI3K) pathway) ensure transduction specificity 
for individual cytokines. JAK1, JAK2 and TYK2 proteins are expressed ubiquitously, while JAK3 
is exclusive to hematopoietic cells. JAK2 has an important role in maintaining stem cell viability 
and function through transmission of the thrombopoietin (TPO) receptor signal, and is also 
crucial for the various stage of myeloid differentiation through binding to erythropoietin 
(EPO), TPO, granulocyte colony-stimulating factor (G-CSF), granulocyte-macrofage colony-
stimulating factor (GM-CSF), interleukine-3 (IL-3) and interleukine-5 (IL-5) receptors (Figure 
1).  
The JAK2V617F mutation represents the most common molecular feature of the three main 
types of MPN, being found in 95% of PV, and between 50 and 60% of ET and PMF. Therefore, 
JAK2V617F mutation can be used as a unique molecular marker for distinguishing PV, ET, and 
MF from reactive hematopoietic disorders. It leads to a “gain of function” of the JAK2 protein, 
hence, the constitutive tyrosine kinase activation of molecular signaling pathway, providing 
hematopoietic precursors with their proliferative characteristic. 
Figure 2A shows the structure of JAK2 protein. Starting from the N terminus, JAK protein 
contains four main domains: the FERM domain, through which JAK interacts with the 
intracellular part of the cytokine receptor, the SH2 domain, through which it interacts with 
effector proteins, a pseudo-kinase domain (JH2), and a JAK homology 1 carboxy-terminal 
domain (JH1), with tyrosine-kinase activity. The pseudo-kinase domain, which is most likely 
inactive, plays a crucial role in regulating JAK2 protein function, as it interacts with JH1 
inhibiting its catalytic activity. The majority of JAK2 mutations described in MPN (Table 1), 
including V617F, falls within the JH2 domain, activating the enzymatic function of JAK2 by 
decreasing the capacity of this domain to interact with the tyrosine-kinase domain, resulting 
in a dysregulation of self-inhibitory capacity52 (Figure 2B) and in the cytokine-independent 
activation of the various membrane receptors in the corresponding hematopoietic MPN clone. 
This concept was further strengthened by the subsequent identification of various other 
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mutations (amino acid substitutions, deletions and duplications, predominantly affect exon 
12 of the gene), described in PV patients (but not in ET and PMF) V617F- wild type, as well as 
in congenital forms of MPN. The most frequent of these, present in about 40% of JAK2V617F -
negative patients with PV, causes an in-frame deletion of six nucleotides between codons 542 
and 543 (N542_E543del)53. Finally, mutations causing exon 14 splicing variants are much rare 
and lead to the production of a truncated JAK2 protein54.  
The JAK2V617F mutation is also infrequently present (3–5 %) in refractory anemia with 
ringed sideroblasts associated with thrombocytosis (RARS-T), CMML, and other atypical 
chronic myeloid disorders. Additionally, this mutation is occasionally detected even in patients 
with primary AML, MDS and CML55,56.  
The JAK2V617F mutation can be present in a heterozygous state or can progress to 
homozygosity most frequently by a mitotic recombination event resulting in uniparental 
disomy (UPD). Given the acquired growth advantage with respect to the rest of MPN clone, 
the homozygous cells quickly constitute a large portion of the bone marrow neoplastic clone, 
bringing the allele burden (AB), i.e. the number of mutant alleles, over the 50% threshold. 
Homozygous JAK2V617F mutation is present in about 30% of PV and PMF patients, and in only 
2-4% of ET patients. Interestingly, homozygosity leads to greater activation of JAK/STAT 
pathway by increasing the amount of intracellular mutated JAK2 protein, contributing to the 
different phenotypes (clinical features) of the three forms of MPN57.  
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Figure 1. JAK2 plays an important role in maintaining stem cell viability and function and 
myeloid differentiation (Springuel L., Haematologica. 2015 Oct;100(10):1240-53) 
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Figure 2. (A) Structural domain of the Jak2 protein. Numbers indicate amino acid positions 
within the Jak2 protein. Arrows indicate the positions of the most frequently mutated regions. 
The auto-inhibitory effect of the JH2 domain is indicated in yellow. FERM = N-terminal domain; 
JH1 (Kinase (K) domain) and JH2 = Jak homology 1 and 2 domains; SH2 = Src homology 2 
domain. (B) Example of the interactions JAK2 protein with the erythropoietin receptor 
(EpoR). The V617F mutation in JH2 domain causes constitutive activation of JAK2.  
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Table 1. Principal JAK2 mutations in MPNs 
 
 
Amino acid  
substitution 
Exon 
Protein 
Domain 
Frequency 
(%) 
Ref 
PV V617F 14 JH2 97 17, 19 
PV with  
concurrent  
V617F mutation 
V617F, C618R 14 JH2 <1 59 
V617F, D620E 14 JH2 <1 60 
V617F, L611V 14 JH2 <1 61 
PV 
V617F NEGATIVE 
N542_E543del 12 SH2-JH2 40 58 
E543_D544del 12 SH2-JH2 10 62 
F537_K539delinsL 12 SH2-JH2 10 58 
R541_E543delinsK 12 SH2-JH2 10 63 
K539L 12 SH2-JH2 10 64 
H538_K539delinsL 12 SH2-JH2 5 63,64 
I540_E543delinsMK 12 SH2-JH2 5 63 
V536_I546dup 12 SH2-JH2 <1 65 
F537I, K539I 12 SH2-JH2 <1 67 
F537_I546dup10, F547L 12 SH2-JH2 <1 65 
F537_F547dup 12 SH2-JH2 <1 68 
H538_K539delinsF 12 SH2-JH2 <1 67 
H538_K539delinsI 12 SH2-JH2 <1 69 
K539, L545V 12 SH2-JH2 <1 66 
I540T 12 SH2-JH2 <1 67 
I540_E543delinsKK 12 SH2-JH2 <1 70 
R541K, A542_G543del 12 SH2-JH2 <1 71 
R541_E543delinsK 12 SH2-JH2 <1 72 
D544G 12 SH2-JH2 <1 73 
D544_L545del 12 SH2-JH2 <1 66 
547insL, I540_F547dup8 12 SH2-JH2 <1 74 
ET V617F 14 JH2 50-60 17 
ET with  
concurrent  
V617F mutation 
V617F, C618F 14 JH2 <1 59 
V617F, C616C 14 JH2 <1 75 
PMF 
V617F 14 JH2 50-60 17, 19 
D620E 14 JH2 <1 76 
MDS-RARS-T V617F 14 JH2 50-80 55 
CMML V617F 14 JH2 8 56 
AML V617F 14 JH2 <1 56 
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Clinical features of JAK2 mutations carriers 
 In all cases of primary erythrocytosis, i.e., cases that cannot be identified as secondary to 
acquired diseases (most frequently pulmonary or renal conditions) or, more rarely, congenital 
diseases (hemoglobinopathies, or alteration of tissue oxygenation protein sensors), the search 
for mutations in the JAK2 gene is of fundamental importance for the diagnosis of PV. In fact, 
virtually 100% of PV patients have the V617F mutation (96%) or one of the more rarely 
described mutations in JAK2 exon 12 (3-4%) or exon 14 (really rare) and, consequently, the 
finding of a clonal JAK2 mutation has been one of the major criteria for the diagnosis of this 
pathology since 2008. Mutational analysis of JAK2 exon 14 (both V617F and more rarely one 
mutations) is also requiring in the diagnostic process of confirming ET, in patients with 
thrombocytosis not secondary to other pathological conditions such as inflammatory 
processes, acute hemorrhage (or, more rarely, chronic blood loss) and iron deficiencies, as 
well as in the diagnostic confirmation of PMF in cases of leukocytosis (or leukopenia) and/or 
splenomegaly not attributable to other causes.  
 Compared to the V617F mutation, mutations of exon 12 (found in no more than 1-2% 
of all patients with PV), like the even rare ones of exon 14 (1-2% of the total), cause greater 
ligand-independent activation of the JAK/STAT pathway. Consequently, compared to patients 
JAK2V617F- mutated, those with exon 12 mutations have significantly higher levels of 
hemoglobin and lower platelets and leukocytes count at diagnosis58. However, there are some 
evidences that the incidence of thrombotic events, leukemic transformation and survival do 
not differ significantly between the two subgroup of patients77. 
 The presence of JAK2V617F mutation in ET and PMF not only has a diagnostic 
significance, but also appears to have clinical and prognostic relevance. Indeed, ET patients 
with a JAK2 mutation are older than those with wild-type JAK2, have higher levels of 
hemoglobin but lower platelet counts and a higher risk of venous thromboembolic events, 
and also a higher degree of leukocytosis78,79. Finally, although the probability of 
transformation to MF is similar in ET patients with or without any JAK2 mutations, the 
likelihood of progression to PV is 29% in those with the mutation, while it is negligible in the 
remaining80. As in ET patients, PMF patients with the JAK2V617F mutation tend to be older and 
have higher white blood cell counts at diagnosis than patients with mutations of CALR and 
MPL. Moreover, the overall survival of the latter is significantly better than that of patients 
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with JAK2V617F mutation. Finally, the probability of thromboembolic events is higher in PMF 
patients with the JAK2V617F mutation than in PMF patients harboring mutations in CALR or 
MPL79,81. 
The determination of JAK2V617F AB might be useful for prognostic evaluation of the 
disease itself, as demonstrated in a prospective study of 338 patients with PV. Indeed, the AB 
at diagnosis was found to be correlated with hemoglobin concentration, degree of 
leukocytosis, spleen size and bone marrow cellularity, while it was inversely correlated with 
platelet count. Moreover, JAK2V617F AB seems to be correlated with risk of progression to PPV-
MF, but not with the probability of thrombotic events, evolution to acute leukemia or with 
reduced overall survival82. On the contrary, it appears to be of poor prognostic significance in 
ET, probably because of the small number of patients with high AB, whereas it is more relevant 
in PMF. In fact, patients with a lower AB have a higher probability to leukemic progression and 
a lower probability of survival83. 
Finally, JAK2 mutation might represent a potential target to monitor the effect of 
therapy. However, the lack of real methodological standardization and the possibility that the 
mutation is present in a subclone rather than in the whole neoplastic mass and that, therefore, 
reduction of the AB in response to therapy does not necessarily imply a reduction in tumor 
mass, have limited the application of this strategy in clinical practice. Two different studies 
aim to investigate if the mutation burden varies in response to therapy with interferon-2a 
and both showed little encouraging results84,85. On the opposite, in a recent study the role of 
quantitative analysis of AB in patients treated with Ruxolitinib has been evaluated, registering 
a significant reduction of it in the context of clinical response, as well as a correlation with the 
reduction of spleen volume in individual patients86.  
Nevertheless, to date, the only curative treatment for MF is allogenic stem cell 
transplantation (ASCT). Determination of JAK2V617F AB has been demonstrated to be a useful 
tool for monitoring effectiveness of the transplant. Studies reported that JAK2V617F mutation 
disappears after ASCT and reappears in the case of ensuring relapse, and the value of this 
mutation as a minimal residual disease marker to guide donor lymphocyte infusion is well 
established87-90.  
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MPL mutations 
Frequency and distribution in MPN 
The MPL mutation were discovered in 2006 in patients with a diagnosis of Ph negative 
MPN who were negative for JAK2V617F mutation. These studies showed that 1-10% of patients 
with ET and PMF have a MPL mutation. MPL-mutated PV patients have been occasionally 
reported91,92. 
The MPL gene maps to 1p34 and codes for the TPO receptor, the cytokine that regulates 
megakaryocytopoiesis and the formation of platelets. The majority of identified MPL 
mutations affect exon 10 of the gene and cause a substitution of the amino acid tryptophan 
in position 515 (W515L, W515K, W515A, W515R). This amino acidic residue belongs to the 
RWQFP domain, a group of five amino acid of the juxtamembrane portion of the TPO receptor 
(MPL), which prevents its spontaneous activation in the absence of ligand. The substitution of 
tryptophan W515 by another amino acid causes the loss of this inhibitory control mechanism 
and leads to spontaneous activation of the MPL receptor93. This mutation has been found also 
in rare cases of RARS-T94-95. 
Other MPL mutations (e.g., L510P, A506T, W519T, S204P) have been found, but they do 
not appear to have a pathogenic role63,96. The S505N mutation, initially identified as a germline 
mutation in hereditary thrombocytosis97, has been described some years later as an acquired 
mutation in rare cases of ET98. 
 
Clinical features of mutation carriers 
 The MPL mutation load differs between ET and PMF, with the median AB being lower in 
ET than in PMF (32,8% vs 59,4%, respectively) or post-ET myelofibrosis (58,2%), while there 
does not seem to be any differences in AB between PMF and post-ET myelofibrosis. W515L 
mutations are typically associated with lower AB than W515K and W515A mutations99. 
Patients with a high AB acquire a loss of heterozygosity of chromosome 1p in granulocytes, 
with transition to homozygosity, which seems to underlie fibrotic evolution in patients with 
MPL-mutated MPN. 
 The MPL mutations are the third most frequent in Ph-negative MPN, after JAK2V617F and 
CALR mutations. Screening for MPL mutations is therefore indicated in patients with a 
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suspicion of ET or MF, especially if JAK2 and CALR mutations have already been excluded. MPL 
mutations are among diagnostic criteria for ET and PMF in the 2016 revision of the WHO 
classification24,29.  
 Compared to ET patients with wild-type MPL, those with MPL mutations have higher 
platelet counts, lower hemoglobin levels, and less total bone marrow and erythroid 
cellularity100. PMF patients with MPL mutations are more often female, older, more anemic 
and have greater transfusion needs compared to patients with wild-type MPL. Moreover, they 
do not show different overall survival and leukemia-free survival compared to patients with 
JAK2-mutated MF101, but they have a shorter survival than CALR-mutated patients80. 
 
CALR mutations 
Frequency and distribution in MPN 
 Until 2013 approximately one third of cases of ET and PMF did not have a known 
molecular basis. In 2013 two different research groups, using whole-exome sequencing 
technique, identified recurrent somatic mutations in CALR gene in 20-35% of patients with ET 
and PMF who were negative for JAK2 and MPL mutations21,22. CALR mutations are therefore 
the second most frequent mutations, after the JAK2V617F mutation, in Ph-negative MPN. With 
rare exception, CALR and JAK2 mutations are mutually exclusive81,102. CALR mutations do not 
seem to be present in PV; to date, only two isolated cases of JAK2V617F-negative PV with CALR 
mutation have been reported in the whole literature103. Additionally, CALR mutations have 
been reported rarely in some forms of MDS, CMML, RARS-T and atypical CML21,22, while no 
CALR mutation have been described in other myeloid/lymphoid malignancies, solid tumors or 
in healthy controls, indicating a specificity for ET and PMF. 
 The CALR gene maps to 19p13.3-p13.2 and encodes a protein, calreticulin, that is highly 
conserved from an evolutionary point of view, multi- compartmental and multifunctional 
protein best known for its role as a Ca2+ binding chaperone in the endoplasmic reticulum (ER) 
lumen. Mature CALR protein consists of three structurally and functionally distinct domains: 
the globular N-terminal domain (residues 1-180) is lectin binding and consists of a signal 
sequence for targeting to the ER; the middle proline-rich or P-domain (residues 181–290) 
contains high affinity, low capacity, binding sites for Ca2+; the C-terminal domain (residues 
291–400) is rich in negatively charged residues and contains a number of high capacity, low-
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affinity Ca2+ binding sites. The acidic C-terminal domain terminates with the KDEL sequence, 
maybe involved in in the retrieval of CALR protein from the cis-Golgi back to ER (Figure 3). 
 
 
 
 
 
Figure 3. Calreticulin structure and exposure. Linear representation of calreticulin domains is 
shown. The protein contains an N-terminal amino-acid signal sequence (in grey), N-domain, 
P-domain, C-domain, and a C-terminal KDEL ER retrieval signal. The N- and P-domains of 
calreticulin are responsible for the chaperone function of the protein. The C-terminal C-
domain contains a large number of negatively charged amino acids and is involved in high-
capacity Ca2+ storage.  
 
From the functional point of view, calreticulin is involved in a large number of intra- 
and extra-cellular processes. Within the lumen of ER, and in concert with other chaperone 
proteins, CALR plays an essential role in ensuring proper protein and glycoprotein folding. 
Moreover, calreticulin regulates calcium homeostasis, by acting as a binding and deposit 
protein. In addition to canonical ER related functions, CALR is reported to be found in the 
cytosol, nucleus, at the cell surface as well as extracellularly, where it accomplishes multiple 
functions as a critical mediator of physiological and pathological processes, such as the 
immune response, proliferation and apoptosis, cell phagocytosis, wound healing, and 
fibrosis104. 
CALR mutations consist of a wide variety of deletions or insertions in exon 9. To date, 
more than 60 different CALR mutations have been identified and classified according to their 
effect on DNA sequence: deletions have been designated as type 1 or type 1–like, of which 
c.1092_1143del, L367fs*46 (a 52-bp deletion) is the most common, and insertions as type 2 
or type 2– like, of which c.1154_1155insTTGTC, K385fs*47 (a 5-bp insertion), is the most 
common. Together, these account for 85% of the CALR mutations; type 1 mutations are more 
common in PMF, whereas type 1 and type 2 occur with similar frequency in ET. Various other 
infrequent insertions and deletions in exon 9 account for up to 15% of CALR mutations. 
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All CALR mutations have the same consequence: a 1-bp frame- shift, which removes 
KDEL motif, and leads to the synthesis of a novel C-terminal peptide sequence, characterized 
by the acquisition of a minimal 36 amino acid stretch in place of 27 amino acids that are lost 
from the normal sequence. Remarkably, the C-terminus of the mutant protein contains 
several positively or neutrally charged amino acids whilst the equivalent region of the wildtype 
protein is largely negatively charged (Figure 4). This causes reduced capacity of calcium 
binding and subcellular relocation resulting in abnormal proliferation of cell harboring the 
mutant protein. There is evidence that mutant CALR binds to the TPO receptor inducing 
phosphorylation of JAK2 and activating downstream signaling, but the mechanism by which it 
happens is still to be clarify. Through clonal analysis, CALR mutations were shown to occur in 
a multipotent progenitor capable of both erythroid and myeloid differentiation as well as in 
hematopoietic stem cells22. Finally, by using hierarchical analysis of individual hematopoietic 
clones the early acquisition of CALR mutations was demonstrated, consistent with it being an 
initiating event in the cases characterized21,22. Single nucleotide variants have been reported 
in rare patients (e.g. E379D and RE398D)21, however, whether they are true somatically 
acquired mutations and what significance they carry remain unclear at present. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Altered protein reading frame with novel C-terminal associated with CALR 
mutations. 
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Clinical features of mutation carriers 
The impact of CALR mutation burden on clinical features and prognosis is still to be 
elucidated. The median AB of the two most frequent CALR mutations was 32% in ET and 50% 
in post-ET MF, suggesting that disease evolution could be associated with an increased 
mutation burden105. Homozygosity for the CALR mutation is a rare event in MPNs, unlike the 
JAK2 UPD that is associated with distinct phenotypic traits and more frequent evolution to 
post-PV/ET-MF. However, similar frequencies of homozygous CALR mutated patients due to 
acquired 19p UPD were found21. Since CALR mutations are the second most frequent mutation 
in MPN after JAK2V617F mutation, they have been included among the major diagnostic criteria 
for ET and PMF in the 2016 revision of WHO classification24,29. 
CALR-mutated ET patients are more often male, are younger, have higher platelet counts, 
lower white blood cell counts and hemoglobin concentrations, and higher level of serum EPO, 
compared to those with JAK2 mutations80,81. Despite their marked thrombocytosis, ET 
patients with CALR mutations have a lower risk of thrombotic complications than JAK2-
mutated ET patients. This may depend on the presence of lower hemoglobin and white blood 
cells levels but also on reduced leukocyte activation. No differences in terms of risk of disease 
evolution (both to MF and to leukemia) or overall survival have been found. ET patients with 
CALR Type 2 mutation or Type 2- like mutations (i.e., CALR mutations that cause a change in 
amino acid chain similar to that of the type 2 mutation) have a more marked thrombocytosis 
but a lower risk of thrombosis during follow up, compared to CALR Type 1-mutated ET 
patients106. Patients carried CALR Type 1-like mutations are associated with an increased risk 
of evolution to MF107. 
Patients with CALR-mutated PMF are younger, have higher platelet counts, lower 
transfusion requirements, and tend to have a more indolent course with anemia, 
thrombocytopenia and leukocytosis appearing later in the follow-up. The median survival 
(about 17 years) is longer than that patients with JAK2- and MPL-mutated MF (about 9 years) 
and patients with triple-negative (TN) PMF (about 2-3 years)24,105. The benefits of CALR 
mutations in terms of survival are greater for CALR Type 1 and Type 1-like mutations108. 
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The additional mutations 
Table 2 show the genes most commonly involved in additional mutations in chronic MPN. 
Approximately 5-30% of patients with chronic MPN have mutations in genes coding epigenetic 
regulation (TET2, ASXL1, IDH1/2, EZH2, DNMT3A), in spliceosome genes (SRSF2, SF3B1, 
U2AF1), or in oncogene or tumor suppressor genes (TP53, RUNX1, IKZF1, NRAS, KRAS)28,109. 
The order of their acquisition contributes to the clinical phenotype of the disease14,110,111 
(Figure 5), but, since these mutations are also commonly present in MDS and other myeloid 
malignancies, including acute leukemia, they do not have a specific diagnostic value. However, 
they are particularly associated with patients with PMF, characterized by reduced survival or 
increased risk of leukemic transformation, thereby acquiring a very specific prognostic 
significance112. 
897 patients with PMF have been sequenced in a recent study112, and it was found that 
the most frequently mutated genes were ASXL1, EZH2, TET2, SRSF2 and IDH1/2. No 
correlation was found between these genes and a specific clinical phenotype. On the contrary, 
they correlated with reduced overall survival and increased risk of evolution to acute 
leukemia. Indeed, the presence of at least one mutated gene among these identifies patients 
at high molecular risk (HMR). This molecular status is associated with a very poor survival (HR 
= 2.29, 95%CI, 1.6-3.2) and a high probability of leukemic transformation (HR = 2.96, 95%CI, 
1.8-4.7) (Figure 6). Interestingly, mutation burden did not change during follow-up, suggesting 
that most of the mutations defining HMR status are already present at diagnosis of the 
disease. For this reason, deep molecular characterization of PMF patients at diagnosis could 
be of utmost importance to define the prognosis. On the other hand, it could not be excluded 
the acquisition of additional mutations during follow-up in a subset of patients. Similar results 
on the impact of the number of mutated genes, including but not limited to the genes that 
define HMR category, were obtained in a larger study conducted in patients with MPN113. In 
PMF, mutations in ASXL1 are those with greatest diagnostic impact. Interestingly, it was found 
that PMF patients with mutations in ASXL1 without a concurrent CALR mutation had a median 
survival of 2.3 years compared to 10.4 years for those with a CALR mutation without any 
additional ASXL1 mutations114 (Figure 7). On the contrary, mutations in splicing genes, such as 
U2AF1, SRSF2, SF3B1, are rarely associated with CALR mutations, leading to think that it may 
contribute to better survival of these latter mutations115. 
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Table 2. Genes most commonly involved in addition mutations in chronic MPN. 
PV: Polycythemia vera; ET:essential thrombocytemia; PMF:primary myelofibrosis; CDS: 
complete coding sequence; EX: exon; LoF: Loss of Function; GoF: Gain of Function; >: increase; 
<: decrease; OS: overall survival; LFS: leukemia free survival; sAML: secondary AML.
Gene Function Mutations 
site 
Mutational 
frequency (%) 
Type of 
mutation 
Clinical 
correlation 
Ref 
PV ET PMF 
Signaling         
CBL 
JAK2  
Signaling 
EX 8-9 rare rare 5-10 LoF sAML 116 
SH2B3 EX 2-4 1-2 - rare LoF sAML 117 
Epigenetic         
TET2 
DNA  
methylation 
CDS 10-20 5 10-20 LoF sAML (26%) 116 
ASXL1 EX 12 2-5 2-5 15-30 
LoF <OS, <LFS, 
sAML (19%) 
112 
EZH2 CDS 1-3 rare 5-10 LoF <OS, <LFS 112 
Splicing         
SRSF2 
Spliceosome 
EX 1 rare rare 10-20 
LoF <OS, <LFS, 
sAML 
112 
SF3B1 EX 12-16 rare rare 5-10 LoF >OS 118 
U2AF1 EX 2-8 rare rare 5-15 LoF <OS 119 
Leukemic 
evolution 
        
IDH1 
Metabolic 
regulation 
EX 4 rare rare 2-5 
Neo-
Enzyme 
<OS, <LFS, 
sAML (8%) 
112 
IDH2 EX 4 rare rare 2-5 
<OS, <LFS, 
sAML (18%) 
112 
TP53 Apoptosis,  
Cell cycling 
CDS rare rare rare 
LoF <OS, <LFS, 
sAML (20%) 
14 
DNMT3A Chromatin 
modification 
EX 7-23 5-10 1-5 5-10 LoF <OS, sAML 120 
IKZF1 
Transcriptional 
factors 
CDS - - rare Del sAML (21%) 121 
RUNX1 CDS - - rare LoF sAML (37%) 121 
NRAS 
GTPase,  
Signaling 
CDS rare rare rare GoF 
sAML  
(7-13%) 
121 
KRAS CDS rare rare rare GoF 
sAML  
(5-10%) 
121 
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Figure 5. Clonal evolution in MPN patients carrying somatic mutations in epigenetic modifier 
genes. Single erythroid or granulocytic colonies (BFU-Es and CFU-G) grown in methylcellulose 
were individually picked and analyzed for the presence or absence of JAK2V617F and other 
somatic mutations. (A) Examples of 3 patients who acquired an ASXL1 mutation before 
JAK2V617F (left panel), after JAK2V617F (middle panel), or in a clone separate from JAK2V617F (right 
panel) are shown. Each dot represents a single colony that was genotyped and placed into the 
corresponding quadrant. (B) Summary of the temporal order of acquisition of mutations in 
relation to JAK2V617F. Each dot represents 1 patient analyzed as shown in panel A and placed 
into the corresponding quadrant. Events in ET patients are depicted in yellow, PV patients in 
red, and PMF patients in brown. (C) Patterns of clonal evolution in 8 MPN patients carrying 
multiple somatic mutations. Dotted lines denote the time of analysis and the y-axis indicates 
the percentage of the colonies with or without the corresponding somatic mutations. %VF, 
JAK2V617F mutant allele burden in purified granulocytes from peripheral blood. Al- though the 
order of events depicted can be de- duced from the single-clone analysis (dotted line), the 
exact timing of the acquisition of the individual mutations and the time needed for the clonal 
expansion remains unknown and is shown only schematically. GRA, granulocytes (Lundberg P. 
et al, Blood. 2014;123(14):2220-2228). 
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Figure 6. Overall survival and risk of transformation to leukemia of patients with PMF, 
stratified according to mutational status for EZH2, ASXL1, SRSF2, IDH1/2 (mutations 
belonging to HMR category) (Vannucchi et al, Leukemia 2013). 
 
 
 
 
 
 
 
 
 
 
Figure 7. Overall survival of patients with PMF, stratified by the presence or absence of CALR 
and ASXL1 mutations (Tefferi A et al., Leukemia 2014). 
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Clinical features of mutations carriers 
A modern and efficient prognostic model (MIPSS, Molecular International Prognostic 
Score System) has been recently proposed and validated: it integrates mutational information 
with clinical data, proving to be more efficient in risk prediction and prognostication than 
“classical” models, based on clinical variables alone (IPSS and Dinamic IPSS, DIPSS). It remains 
to clarify whether therapeutic choices based on a prognostic stratification achieved by 
defining the HMR status might actually result in an improvement of patients’ management 
and overall survival Patients currently classified in the low-risk or intermediate-1 category, 
according to IPSS or DIPSS, but who have one or more mutations in the genes of HMR 
category, might particularly take advantages from modern MIPSS. Indeed, since the predicted 
overall survival for these patients would be comparable to that of higher risk IPSS categories, 
a more aggressive therapeutic approach, such as stem cell transplantation, could be used. 
Finally, as regards the impact of additional mutations on response to therapy, no differences 
have been observed in terms of reduction in splenic volume and improvements of symptoms 
between high- and low-HMR. Additionally, patients belonging to both risk categories and 
treated with Ruxolitinib have reached longer survival. Similar results were registered in 
patients with two or fewer mutated genes (including either driver mutations or additional 
ones) who showed a nine-fold higher probability of a clinical response, in term of reduction of 
splenomegaly, than in patients with three or more mutations122,123. So that, an extensive 
molecular profiling of PMF patients may be useful in planning the treatment of patients 
receiving Ruxolitinib or other JAK inhibitors. 
Mutations in most of the genes shown in Table 2, such as TET2, ASXL1, IDH1/2, TP53, 
SRSF2, U2AF1, SF3B1, are present during both the accelerated and the blastic phase of the 
disease. However the mechanisms through which these mutations contribute to leukemic 
transformation have to be clarify. More information has been obtained recently about TP53 
mutations14. In a study conducted in 22 subjects with secondary AML, it was found that TP53 
mutations were already present during the chronic phase in heterozygous state. After loss of 
the wild-type allele (loss of heterozygosity, LOH), through mitotic recombination or deletion, 
the hemi- or homozygous TP53 clone expanded rapidly and patients transformed to AML. 
Therefore, TP53 mutations evaluation could be useful in those cases of suspected evolution 
to AML, while the predictive role of mutations in chronic phase is still unclear. 
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Myelofibrosis: the “malignant” inflammatory microenvironment 
Besides molecular abnormalities, also the inflammatory microenvironment plays a 
key-role in MF pathogenesis. Chronic inflammation (CI) is mediated by increased pro-
inflammatory cytokines production by both stromal and malignant hematopoietic cells 
(activated leukocytes and platelets/megakaryocytes) and is an important driver of clonal 
initiation/evolution33-37 (Figure 8). Consistently, increased serum levels of pro-inflammatory 
cytokines significantly correlate with worse survival in MF patients.  
Experimental evidences suggest that MF stromal cells are primed by the malignant 
hematopoietic clone, which, in turn, conditions the stroma to create a favourable 
microenvironment that nurtures and protect the malignant cells. As a consequence, both 
pathogenic hypothesis and therapeutic attempts should take into account not just the 
malignant clone but also the activity of the stromal cell microenvironment. Interestingly, 
chronic inflammation is an important driver of genomic instability and cancer 
development/progression124,125. 
Recent findings showed that the HSC/PC actively sense pro-inflammatory factors126. 
However, the role of crucial factors of the inflammatory microenvironment such as 
extracellular nucleotides (eNTPs)126,127, selected cytokines (Tumor Necrosis Factor (TNF)-
alpha128 and Tissue Inhibitor of Metalloproteinases (TIMP)-1129-131; or circulating 
microparticles (MP)132-133 in the phenotype/function of the malignant hematopoietic clone of 
MF has been poorly (TNF-alpha) or never (eNTPs, TIMP-1, and MP) investigated. 
Specifically: 
 eNTPs act through specific receptors (P2YR and P2XR) regulating proliferation and 
migration of malignant CD34+ stem/progenitor cells. 
 TNF-alpha facilitate clonal expansion of JAK2V617F-positive cells. 
 TIMP1, through receptor (CD63) binding, has a role in multiple biological processes, 
including cell proliferation, survival, inflammation and immune regulation. 
 MP are a membrane- derived vesicles derived from various cells, most notably platelets, 
but also leukocytes, lymphocytes, erythrocytes, and endothelial cells. MP have a role in 
intercellular communications and systemic inflammation.  
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The concept of chronic inflammation as a major driver of disease progression in MPNs 
opens the avenue for clinical trials in which the two most promising agents within MPNs - IFN 
and Ruxolitinib - are combined and instituted in the early disease stage according to the early 
intervention concept134. The proof of concept and the rationales for this combination therapy 
have most recently been published135: the ability of IFN to induce deep molecular responses 
with normalization of the bone marrow, even years after cessation of IFN, and the role of 
inflammation in the initiation and progression of MPNs make the combination of IFN and 
ruxolitinib one of the most promising new treatment strategies for patients with MPNs33,35,36. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Vicious cycle of inflammation in the biological continuum of ET, PV, and MF. 
Chronic inflammation is proposed as the trigger and driver of clonal evolution in the biologic 
continuum from early disease state (ET and PV) to a more progressive disease state (MF). It is 
possible that combination therapy, using low doses of therapies such as interferon-a, Janus 
kinase inhibitors, and statins at the early disease state will positively influence the vicious cycle 
of disease progression. HGF, hepatocyte growth factor; IL, interleukin; MPN, 
myeloproliferative neoplasms; TNF, tumor necrosis factor (Hasselbalch HC, Cytokine Growth 
Factor Rev. 2013; 24: 133–45). 
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The overall aim of this study was the molecular characterization of patients diagnosed with 
Ph- negative Chronic Mieloproliferative Neoplasms and the study of interactions between 
malignant hematopoietic stem/progenitor cell (HSC/PC) and the inflammatory cell micro-
environment.  
 
The specific aims were the followings: 
I. Mutational status and outcome of young (≤ 40 years old) ET and early-PMF patients 
have never been investigated. To address this issue, we report on a relatively large 
number of WHO-defined ET and early-PMF patients who were younger than 40 years 
of age at the time of diagnosis.  
II. The use of highly sensitive allele-specific assays has significantly increased our ability 
to detect small JAK2V617F mutated clones, with AB below 1%. As a small clonal 
hematopoiesis has been found also in otherwise healthy subjects, the clinical 
significance of a low AB has to be clarify. To address this issue, we analyzed clinical and 
laboratory data of patients with a suspected MPN that presented a low (≤3%) JAK2V617F 
mutation burden. 
III. JAK2V617F AB monitoring is of utmost importance both during follow-up and post-
transplant. In this context, the standardization of molecular techniques is urgently 
needed. To identify the most robust assay for the standardization of the molecular test 
and to allow consistent interpretation of individual patient analysis results, we 
established a network of 19 Italian laboratories and evaluated the analytic 
performances of 5 different molecular approaches.  
IV. The key players linking inflammation and cancer in MF as well as the underlying 
pathogenetic mechanism are still to be elucidated. Therefore, we aimed to address 
the functional effects of several pro-inflammatory factors on the in vitro behaviour of 
HSPCs derived from MF patients.  
V. Finally, we evaluated three different Next Generation Sequencing (NGS) gene panels 
in order to identify the most suitable approach for the molecular characterization of 
MF patients for both diagnostic and research purpose. 
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ABSTRACT 
We investigated the influence of molecular status on disease characteristics and 
clinical outcome in young patients (≤40 years) with World Health Organization (WHO)-defined 
essential thrombocythemia (ET) or early/prefibrotic primary myelofibrosis (early-PMF). 
Overall, 217 patients with ET (number 197) and early-PMF (number 20) were included in the 
analysis. Median follow-up time was 10.2 years. The cumulative incidence of thrombosis, 
hemorrhages and disease evolution into myelofibrosis/acute leukemia were 16.6%, 8.6% and 
3% at 15 years, respectively. No differences were detectable between ET and early-PMF 
patients, although the latter cohort showed a trend for worse combined-event free survival 
(EFS). Mutation frequency were 61% for JAK2V617F, 25% for CALR and 1% for MPLW515K, and 
were comparable across WHO diagnosis; however, JAK2V617F allele burden was higher in the 
early-PMF group. Compared with JAK2V617F-positive patients, CALR-mutated patients 
displayed higher platelet count and lower hemoglobin level. CALR mutations significantly 
correlated with lower thrombotic risk (9.1% versus 21.7%, P = 0.04), longer survival (100% vs 
96%, P = 0.05) and better combined-EFS (86% vs 71%, P = 0.02). 
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However, non-type 1/type 2 CALR mutations (‘minor’ mutations) and abnormal 
karyotype were found to correlate with increased risk of disease evolution. At last contact, six 
patients had died; in five cases, the causes of death were related to the hematological disease 
and occurred at a median age of 64 years (range: 53–68 years). Twenty-eight patients (13%) 
were unmutated for JAK2, CALR and MPL: no event was registered in these ‘triple-negative’ 
patients. 
 
INTRODUCTION  
Diagnosis of essential thrombocythemia (ET) or early primary myelofibrosis (early-
PMF) in subjects younger than 40 years is relatively uncommon.1-4 Nonetheless, young 
patients with ET or early-PMF represent a category of substantial clinical interest, as they are 
projected to a prolonged survival and also to an extended utilization of medical resources. In 
addition, uncertainties remain about their best management and long-term outcome, due to 
the paucity of studies with long follow-up and the absence of specific risk scores.5 In 2012, 
Barbui et al.6 reported on a large series of young patients with ET (n=178) or early-PMF (n=35), 
with the latter cohort showing higher platelet count and worse combined event free survival 
(EFS). JAK2V617F mutation emerged as a significant predictor for vascular events and disease 
evolution into MF; however, at that time molecular analysis was limited to the JAK2V617F 
mutation and no data were available on mutation load. In the last 2 years, a plethora of studies 
have reported the impact of mutations, including those in the CALR gene, on main clinical 
features and outcome in patients with Philadelphia-negative myeloproliferative neoplasms.7-
14 However, no data are yet available on mutational status and outcome in cohorts of young 
patients with ET or early-PMF. To address this issue, we report on a relatively large number of 
World Health Organization (WHO)-defined ET and early-PMF patients who were younger than 
40 years of age at the time of diagnosis, with particular focus on the impact of molecular 
alterations on main clinical features and long-term outcome.  
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SUBJECTS AND METHODS 
Study population and definitions  
A clinico-pathological database of ET patients was created. A total of 217 WHO-
diagnosed15–17 ET or early-PMF patients ≤40 years at diagnosis followed in five Italian 
Hematology Centers were included in the study. Inclusion criteria required the availability of 
demographic, clinical, histological and hematological data at diagnosis and at least one DNA 
sample to assess mutation status of the three driver genes: JAK2, MPL and CALR. Patients with 
unmutated JAK2, MPL and CALR were defined as ‘triple negative’. All bone marrow biopsies 
were performed at diagnosis or before treatment start. Histological diagnosis was assessed at 
a local institution, which also reviewed bone marrow biopsies performed before 2008, for 
diagnostic accuracy according to WHO criteria. Baseline clinical characteristics and outcome 
measures (thrombosis, hemorrhages, secondary MF and acute leukemia (AL), second 
neoplasia, death, overall survival (OS) and EFS) were evaluated. Thrombotic and hemorrhagic 
events were defined as previously described.18  
Diagnosis of post ET-MF (PET-MF) was made in accordance with the International 
Working Group on Myelofibrosis Research and Treatment criteria.19 Diagnosis of AL was made 
according to WHO criteria, with a 20% bone marrow blast threshold for diagnosis.20 The study 
was approved by the Institutional Review Board of each Institution and was conducted 
according to the Helsinki declaration.  
 
JAK2, CALR and MPL mutation analysis  
JAK2V617F allele burden was assessed in granulocyte DNA by quantitative PCR-based 
allelic discrimination assay (ipsogen JAK2 MutaQuant Kit, QIAGEN, Marseille, France) on 7900 
HT Fast Real Time PCR System (Applied Biosystem, Life Technologies, Carlsbad, CA, USA).21 
CALR exon 9 sequencing was performed by next-generation sequencing approach with GS 
Junior (Roche-454 platform, 454 Life Sciences, a Roche company, Branford, CT, USA); analysis 
was carried out with AVA Software (GRCh38 as reference, 454 Life Sciences, a Roche 
company).22 Rare CALR mutations identified by next-generation sequencing were confirmed 
by Sanger sequencing. MPL exon 10 mutations were evaluated using the Ipsogen 
MPLW515L/K MutaScreen Kit (QIAGEN). MPL exon 10 S505N mutations were evaluated by 
Sanger sequencing.23  
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Cytogenetic analysis  
Chromosome banding analysis was performed on bone marrow cells by standard 
banding techniques according to the International System for Human Cytogenetic 
Nomenclature.24 At least 20 metaphases were required.  
Statistical analysis  
Numerical variables have been summarized by their median and range, and categorical 
variables by count and relative frequency (%) of each category. Comparisons of quantitative 
variables between groups of patients were carried out by the non-parametric Wilcoxon rank-
sum test.  
Association between categorical variables (two-way tables) was tested by the Fisher’s 
exact test.  
All survival curves were calculated by the Kaplan–Meier method from the date of 
ET/early-PMF diagnosis to the date of first appearance of the event. Specifically, OS was 
estimated from the date of ET/early-PMF diagnosis to the date of death or last contact, 
whichever came first. Evolution-free survival was calculated to the first documentation of PET-
MF or AL. Combined EFS included all events, explicitly: thrombosis, hemorrhages, disease 
evolution into PET-MF/AL or death, whichever came first. Survival curves of different 
subgroups were compared by the log-rank test.  
Multivariate analysis of survivals were carried out by Cox regression. All P-values were 
considered statistically significant when ≤ 0.05 (two-tailed). Statistical analyses were 
performed using Graphpad (Graphpad Software Inc., La Jolla, CA, USA) and SPSS software 
(PASW Statistics for Windows, Version 18.0., Chicago, IL, USA).  
 
RESULTS 
Disease phenotype, type of treatment and outcome measures according to WHO diagnosis  
Overall, 197 WHO-defined ET and 20 early-PMF (age range: 16–40, median 34 years) 
were included in the study. Table 1 provides a comparative illustration of presenting 
clinical/laboratory features and outcome measures according to WHO diagnosis. No 
significant differences were seen in hematological and clinical data at presentation, except for 
higher frequency of elevated serum lactate dehydrogenase levels in early-PMF patients. A 
total of 6 out of 161 (3.7%) evaluable patients had an abnormal karyotype, specifically: 
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46,XY,inv(9)(p11q13); 46,XX,inv(16) (q21q23); 46,XX,t(2;3)(q13;p25); 47,XY,+9 (2 patients); 
45,XX,-9. Median follow-up was 10.2 years (range: 0.5–37.5). Cytoreductive therapy was 
required in 132 patients (61%), 122 patients with ET (61%) and 10 with early-PMF (50%) (P = 
0.34). The use of cytoreductive and antiplatelet therapy was based on physician’s decision, 
according to local standard clinical practice. Reasons for treatment start were as follows: 
extreme thrombocytosis (94 patients, 71%), thrombotic or hemorrhagic event (18 patients, 
14%) or persistence of microvessel disturbances despite antiplatelet therapy (20 patients, 
15%). The use of cytoreductive and anti- platelet therapy was comparable in the ET and early-
PMF cohorts. During follow-up, ET and early-PMF patients showed comparable incidences of 
thrombosis, hemorrhages, disease evolution into PET-MF or AL and death. However, a trend 
for a worse combined EFS at 15 years was noted in early-PMF patients (65.6% versus 80.9% in 
ET patients, P = 0.27). 
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Disease phenotype according to mutational status  
Among the 217 patients included in the analysis, mutational frequencies were 61% for 
JAK2V617F, 25% for CALR, 1% for MPLW515K and 13% for triple negative.  
Within the 54 CALR-mutant patients, 21 (39%) had the 52-bp deletion 
(c.1099_1150del52, L367fs*46, type 1 mutation), 25 (46%) had the 5-bp insertion 
(c.1154_1155insTTGTC, K385fs*47, type 2 mutation) and 8 (15%) carried other anomalies 
(‘minor’ mutations). Two (25%) of these ‘minor’ mutations were 46-bp deletions (p.L367fs*48: 
c.1100_1145del46; c.10944T,c.1100_1145del46), whereas one was a 48-bp deletion 
(c.1113_1160del48); in one patient, a non-type one 52-bp deletion was detected (c.1092_ 
1142del52, p. E364fs*46).  
The last four patients showed various substitution, deletions or insertions of few base 
pairs (c.1147_11544TGTC; c.1151_11544 TTTGTC; c.1129_11394CTCTGCCTCT; 
c.1129_11394CTCTGTC). ‘Minor’ mutations were detected only in ET patients. Table 2 
provides the details of baseline clinical and laboratory features according to mutational status 
and WHO diagnosis. Given the low number of MPL-mutated patients, these three cases were 
omitted from the analysis. Compared with the JAK2V617F-mutant population, CALR-mutant 
patients had higher platelet count that was probably responsible for higher administration of 
cytoreductive therapy over the follow-up. In addition, CALR-mutant patients had lower 
baseline hemoglobin and hematocrit levels, and presented with a lower incidence of 
thrombosis before ET/early-PMF diagnosis.  
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Impact of mutation load on disease phenotype  
A systematic comparison was performed between ET and early- PMF cohorts in 
relation to the allele burden of driver mutation (CALR or JAK2V617F). Overall, median JAK2V617F 
and CALR mutations allele burden were 21.5% (range: 0.5–97.1%) and 45% (range: 10–63%), 
respectively, (P < 0.001). Twenty out of 54 (37%) CALR-mutated patients and 13 out of 132 
(10%) JAK2V617F-mutated patients had an allele burden ≥ 50% (P = 0.68). Notably, early-PMF 
patients showed a JAK2V617F mutation load significantly higher than ET patients, with a median 
allele burden of 44.5% (versus 21% in ET patients, P<0.001), while CALR allele burden was 
comparable in the two cohorts (P = 0.19).  
Consequently, no significant differences in allele burden of CALR and JAK2 was 
detected in early-PMF patients (P = 0.74) (Figure 1). In addition, CALR mutation load was 
comparable across the different types of CALR mutations. Patients with a JAK2V617F allele 
burden ≥ 50% showed significantly higher hemoglobin levels compared with patients with 
lower mutation load (P<0.001), while platelet and leukocyte count were comparable in the 
two cohorts. On the contrary, CALR mutation load did not influence hematological features at 
diagnosis.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Mutation load in WHO-defined ET and early-PMF patients. The box plot depicts the 
10% and the 90% percentiles with median value; dots represent outside values. JAK2V617F allele 
burden was significantly higher in the early-PMF cohort compared with ET cohort. Median 
CALR allele burden was 40% for type 1 mutations, 47% for type 2 mutations and 48.5% for 
‘minor’ mutations (P>0.05). 
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Cumulative risk of thrombosis and hemorrhages according to mutational status and allele 
burden  
Overall, 22 patients (10%) experienced a total of 31 thrombotic events (arterial: 32%), 
with an incidence rate of 0.91% patients per year. Details concerning thrombotic events are 
reported in Table 3. The 10-year and 15-year cumulative incidence of thrombosis were 
respectively 11% and 21.7% in patients carrying JAK2V617F, and 3.5% and 9.1% in those with 
CALR mutation (P = 0.042; Figure 2a). Moreover, patients with a JAK2V617F allele burden higher 
than 50% had a higher thrombotic risk compared with all other patients (the thrombosis-free 
survival at 15 years was 64.2% versus 97.3% in the other patients, P=0.009). No impact of CALR 
mutations allele burden on thrombotic risk was observed. In multivariate Cox analysis, 
previous thrombosis, male sex and JAK2V617F mutation remained significant (P = 0.039, 0.025 
and 0.05, respectively).  
Twelve hemorrhagic events occurred in 11 patients (1 patient with early-PMF, 5%, and 
10 patients with ET, 5%) with an incidence rate of 0.39% patients per year. The 10-year 
cumulative incidence of hemorrhages was 7.8% in patients carrying JAK2V617F and 5.2% in 
those with CALR mutations. No correlation was detectable.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
Disease evolution and second neoplasia according to mutational status and allele burden  
After a median follow-up of 10.2 years, an evolution to MF was observed in 11 patients 
(5.5%) and to AL in 1 patient (0 5%). No progressions were observed in early-PMF patients. 
The overall cumulative incidence of disease progression into MF/AL was 3% and 13% at 15 
and 20 years, respectively. The incidence rate was 0.43% patients per year. A relationship with 
the type of mutation, JAK2 or CALR, and with allele burden was not detectable. The 15-year 
cumulative incidence of disease evolution was 6.4% and 5.8% in JAK2V617F and CALR-mutated, 
respectively (P=0.68). Interestingly, four of the eight patients carrying ‘minor’ CALR mutations, 
evolved to PET-MF/AL, while disease transformation was not observed in the 46 patients with 
type 1 or type 2 CALR mutations. In addition, 2 out of 6 patients with abnormal karyotype 
developed a PET-MF, while among the 155 patients with normal karyotype disease evolution 
was observed in 9 cases (P=0.04). Ten patients (4.6%) developed a second neoplasia, after a 
median time of 13 years from ET/early-PMF diagnosis, specifically: breast cancer (2), prostate 
cancer, colon-rectal cancer, tymoma, thyroid cancer (2), lung cancer, glioblastoma, non-
melanoma skin cancer. Considering the type of neoplasia, no increase of the risk was 
detectable. Moreover, all the patients survived the second neoplasia, that was not a cause of 
death.  
 
OS and combined EFS according to mutation status  
At last contact, six (2.7%) patients had died, at a median age of 61 years (range: 20–
71), for an OS of 98% at 15 years (Figure 2b). Causes of death were related to the 
myeloproliferative neoplasia in all patients but one (four patients died because of disease 
evolution into MF/AL, one patient because of acute myocardial infarction and one patient 
with uneventful and untreated ET died in a car accident). In multivariate analysis, only 
JAK2V617F mutation was found as a negative predictor of survival.  
The 15-year cumulative incidence of composite outcomes (thrombosis, bleeding, 
evolution to PET-MF/AL and death) were respectively 33% in patients carrying JAK2V617F and 
15.1% in those with CALR mutation (Figure 2c). JAK2 and CALR mutations allele burden did not 
significantly influence OS or combined-EFS (P>0.05).  
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Characteristics and outcome of ‘triple-negative’ patients  
A total of 28 patients were negative for JAK2V617F, MPL and CALR mutations (‘triple 
negative’). WHO diagnosis was early-PMF in 5 out of 28 patients (18%) and ET in 23 patients. 
Presenting clinical and hematological characteristics were fully comparable to those of CALR-
mutated patients. With respect to the JAK2V617F-positive patients, triple-negative patients 
displayed higher platelet count and lower hemoglobin levels at presentation. During a median 
follow-up of 9.7 years (range: 12–32.9), no cases of thrombosis, hemorrhages, disease 
evolution or death occurred in this cohort, for a combined EFS of 100%. In addition, no second 
solid neoplasia was registered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Outcome measures according to mutational status of JAK2 and CALR. (a) At 15 
years, thrombosis-free survival was 91.3% (95% confidence interval (CI): 76–96%) and 77.9% 
(95% CI: 66–84%) in CALR- and JAK2V617F-mutated patients, respectively (P = 0.042)). (b) 
Overall survival at 20 years was 96% in JAK2V617F-mutated patients and 100% in CALR-positive 
patients (P = 0.05). (c) Combined event-free survival (Combined-EFS) at 15 years was 86.3% 
(95% CI: 78–94%) for CALR-mutated patients and 69% (95% CI: 65–80%) for JAK2V617F-positive 
patients (P = 0.02). CALR-mutated patients (n = 54): continuous line. JAK2V617F-mutated 
patients (n = 132): dotted line.  
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DISCUSSION  
It is recognized that an accurate distinction between ET and early- PMF according to 
WHO criteria carries significant prognostic implications; it is also acknowledged that an 
extended molecular evaluation provides further information.6,25–27 However, little data are 
available on selected cohorts of young individuals with an ET/early-PMF diagnosis.  
We hereby report the molecular features, clinical findings and long-term outcome of a 
large series of patients with WHO-defined ET (n=197) or early-PMF (n=20), followed for a 
median time longer than 10 years and quantitatively evaluated for JAK2V617F, MPL and CALR 
mutations. Presenting characteristics and frequency of mutations were comparable between 
ET and early-PMF cohort; however, the JAK2V617F mutation load was significantly higher in 
early-PMF patients. In addition, despite the relatively small number of early-PMF patients, 
which limits the statistical potency of the comparison, a clear trend for significance in 
combined-EFS was observed between ET and early-PMF (80.9% versus 65.6%, respectively). 
CALR-mutated patients were significantly different from JAK2V617F-mutated patients in 
terms of hematologic and clinical features. At presentation, CALR-positive patients were 
characterized by higher platelet count and lower hemoglobin levels, while no significant 
differences in hematological parameters were noted between ET and early-PMF carrying the 
same mutation. Despite the higher platelet count, the incidence of thrombosis was 
significantly lower in CALR-mutated compared with JAK2-positive patients. Although these 
data might reinforce the opinion that platelets have an ancillary role in the pathogenesis of 
thrombotic complications,28,29 the more frequent use of cytoreductive therapy in CALR-
mutated patients may provide a contributory explanation. 
In addition, mutation load was found to influence disease phenotype and outcome, as 
JAK2V617F allele burden higher than 50% identified patients with a more myeloproliferative 
disorder and significantly predicted higher risk of major thrombotic events. Notably, allele 
burden was higher for CALR mutations compared with JAK2V617F. However, none of the CALR-
positive patients had mutant allele burden higher than 75%. This observation confirms prior 
reports and underpins the hypothesis that CALR-positive diseases are characterized by the 
gradual growth of a heterozygous clone rather than by progressive acquisition of 
homozygosis,8,10 as demonstrated in the JAK2V617F mutation.30 
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Despite the young age of the study cohort, 20 patients (9%) presented disease 
evolution or a second solid neoplasia (12 patients had overt MF/AL and 10 patients had a 
second solid neoplasia, with 2 patients experiencing both events). Although the time interval 
between ET/early-PMF diagnosis and these events was relatively long (median: 15.8 years; 
range: 3–35), in most cases patients were younger than 55 years at the time of the disease 
evolution/second cancer. The association of abnormal karyotype with disease evolution may 
reflect an underlying genome instability that favors the accumulation of genetic lesions and 
the development of additional neoplastic events. 
Notably, CALR mutations other than type 1 and type 2 (‘minor’ mutations) seemed to 
correlate with higher probability of disease progression into overt MF/AL. Calreticulin has 
multiple physiological functions, mainly control of calcium homeostasis and glycoprotein 
folding, but also involving immune response, cellular adhesion and proliferation, phagocytosis 
and apoptosis.31,32 CALR mutants seem to result in enhanced JAK-STAT signaling so that a 
shared mechanism of pathogenesis of JAK2 and CALR mutations seems plausible. However, 
the exact role of CALR mutations in myeloproliferative neoplasms has still to be fully 
elucidated; to this regard, the present data point out the possibility that certain subtypes of 
CALR mutations could have an unfavorable prognostic role.33,34 
Despite presenting characteristics were comparable to CALR- mutated patients, in our 
study the outcome of triple-negative patients was remarkably favorable, with no registered 
event after a median follow-up of 10 years. Ongoing studies are aimed at identifying the 
molecular basis of ET/early-PMF with unmutated JAK2, CALR or MPL; however, the possibility 
that some of these patients may not have a clonal thrombocytosis cannot be excluded. 
With the limitations due to the relatively low number of early- PMF patients, the 
present analysis shows that mutational frequencies are comparable in the two groups, 
although JAK2V617F allele burden is higher in early-PMF. The assessment of the molecular 
status is of utmost importance in these cohorts of patients, as both thrombosis and survival 
were significantly influenced by mutation type and burden. Finally, despite a low number of 
events throughout the follow-up, causes of death were mostly related to the hematological 
malignancy, pointing out the substantial impact that this generally indolent disease may 
acquire in young adults. 
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ABSTRACT 
Since low JAK2V617F allele burden (AB) has been detected also in healthy subjects, its 
clinical interpretation may be challenging in patients with chronic myeloproliferative 
neoplasms (MPNs). We tested 1087 subjects for JAK2V617F mutation on suspicion of 
hematological malignancy. Only 497 (45.7%) patients were positive. Here we present clinical 
and laboratory parameters of a cohort of 35/497 patients with an AB ≤ 3%.  
Overall, 22/35 (62.9%) received a WHO-defined diagnosis of MPN and in 14/35 cases 
(40%) diagnosis was supported by bone marrow (BM) histology (‘’Histology- based’’ 
diagnosis). In patients that were unable or refused to perform BM evaluation, diagnosis relied 
on prospective clinical observation (12 cases, 34.3%) and molecular monitoring (6 cases, 
17.1%) (‘’Clinical-based’’ or ‘’Molecular-based’’ diagnosis, respectively). In 11/35 (31.4%) 
patients, a low JAK2V617F AB was not conclusive of MPN. The probability to have a final 
hematological diagnosis (ET/PV/MF) was higher in patients with thrombocytosis than in 
patients with polyglobulia (73.7% vs 57.1%, respectively). The detection of AB ≥ 0.8% always 
corresponded to an overt MPN phenotype. The repetition of JAK2V617F evaluation over time 
timely detected the spontaneous expansion (11 cases) or reduction (4 cases) of JAK2V617F-
positive clones and significantly oriented the diagnostic process.  
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Our study confirms that histology is relevant to discriminate small foci of clonal 
hematopoiesis with uncertain clinical significance from a full blown disease. Remarkably, our 
data suggest that a cut-off of AB ≥ 0.8% is very indicative for the presence of a MPN. 
Monitoring of the AB over time emerged as a convenient and non-invasive method to assess 
clonal hematopoiesis expansion.  
 
INTRODUCTION 
In 2008, the World Health Organization (WHO) classification indicated the positivity of 
the JAK2V617F mutation as a major criterion for the diagnosis of chronic myeloproliferative 
neoplasms (MPNs), specifically Essential Thrombocytemia (ET), Polycythemia Vera (PV) and 
Myelofibrosis (MF) [1-7]. The JAK2V617F mutation is detected in around 50-60% of ET and MF 
patients and in most (95%) patients with PV [8,9]. Also, the JAK2V617F mutation may be found 
in other hematological malignancies. Infrequent occurrence of this unique JAK2 mutation has 
been reported in chronic myelomonocytic leukemia (CMML), atypical or unclassified 
myeloproliferative disorder (MPD), myelodysplastic syndrome (MDS), systemic mastocytosis 
(SM), and chronic neutrophilic leukemia (CNL) [10-16]. A JAK2V617F allele burden (AB) above 
50% identifies patients with a higher thrombotic risk, both in ET and in PV [17-22]. Conversely, 
a low AB seems to correlate with significantly shortened survival and leukemia-free survival in 
MF [23-25]. As a result, the determination of the mutation load is becoming a standard 
diagnostic procedure in most molecular laboratories, though WHO criteria do not specify a 
cut-off value for the diagnosis of a MPN. In the last years, the extensive and generalized use 
of molecular techniques with high sensitivity, specifically allele-specific Real-Time 
Quantitative Polymerase Chain Reaction (RQ-PCR), has significantly increased our ability to 
detect small mutated clones, with AB below 1% [26-32]. Many recent studies have shown that 
a small clonal hematopoiesis may be present also in otherwise healthy subjects at low level 
(0.03-1%) [33-38]. Accordingly, a study of the Myeloproliferative Neoplasms and Related 
Disorders European Network (MPN&MPNr-EuroNet) on 36 subjects carrying low JAK2V617F AB 
has further suggested that the detection of a small JAK2V617F-mutated clone cannot represent 
a sufficient evidence to establish malignant myeloproliferation [39]. As a result, the clinical 
interpretation of a low AB of the JAK2V617F mutation may be challenging.  
Here, we analyzed the results of JAK2V617F molecular tests performed at our Hematology 
Department in subjects with a suspected hematological disease over a 2-year period. 
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Specifically, we analyzed clinical and laboratory data of patients with a suspected MPN that 
presented a low (≤3%) JAK2V617F mutation burden, with the aim to define the frequency and 
the significance of a low AB in the everyday clinical management. 
 
RESULTS 
Study plan 
We tested 1087 subjects for JAK2V617F mutation due to clinical suspicion of 
hematological malignancy. A total of 716 (65.9%) out of 1087 tests were performed due to a 
suspect of classical MPN, including ET (299 cases, 41.8%), PV (272 cases, 38%), MF (133 cases, 
18.6%) and MPN underling atypical splanchnic vein thrombosis (12 cases, 1.6%). The 
remaining 371 (34.1%) out of 1087 tests were performed on suspicion of Myeloproliferative 
Disease (MPDs; 23 cases) or other causes/not specified (348 cases) (data not shown). 
Figure 1 depicts the study population and the study plan. Overall, 497 (45.7%) of the 
1087 subjects that were tested for the JAK2V617F mutation resulted positive for the mutation.  
A total of 455/497 (91.5%) patients had an AB >3% (IC 95%: 88.75-93.71, p =0.05): 52 
(11.4%) were tested because of erythrocytosis, 186 (40.9%) because of thrombocytosis and 
217 (47.7%) for other causes (specifically 94 suspicion of MF, 3 MPN underling atypical 
thrombosis and 120 others/not specified). Overall, the final diagnosis of these patients was: 
WHO-defined ET (91/186, 48.9%), probable ET (95/186, 51.1%), PV (26/52, 50%), probable PV 
(50%).  
The remaining 42/497 (8.5%) patients had a low (0.1-3%, median 0.59%) AB (IC 95%; 
0.62-1.15, p =0.05). In most cases (30 patients, 71.4%), AB was below 1%, while only 8 (28.6%) 
patients had an AB above 2%. Overall, the final diagnosis of these patients was: WHO-defined 
MPDs (7 cases), WHO-defined ET/PMF-0 (11/19, 57.9%), probable ET (3/19, 15.8%), reactive 
thrombocytosis (5/19, 26.3%), PV (8/14, 57.1%), secondary erythrocytosis (6/14, 42.9%). 
Here we present clinical and laboratory parameters of this cohort of 42 patients with 
an AB ≤3%.  
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Low AB patients suspected of MPD 
By bone marrow (BM) histology, 7/42 (16.7%) patients had a confirmed diagnosis of a 
hematological disease that not included classical MPNs, specifically: refractory cytopenia with 
unilineage dysplasia (RCUD, 2 cases); refractory cytopenia with multilineage dysplasia (RCMD, 
1 case); refractory anemia with excess blasts-1 (RAEB-1, 1 case); MDS with isolated del(5q) (1 
case); chronic myelomonocytic leukemia (CMML, 2 cases). Median AB of these patients was 
0.46% (range, 0.12-2.79%). No additional mutations in JAK2 exon 14, CALR and MPL genes 
were detected in these 7 patients.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Schematic representation of the study population and the study plan. ET: Essential 
Thrombocythemia; PV: Polycythemia Vera; MF: primary Myelofibrosis; MPN NOS: 
Myeloproliferative Neoplasm Not Otherwise Specified; MPDs: Myeloproliferative Diseases.  
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Low AB patients suspected of MPN 
Diagnostic workflow of the 35/42 patients with low AB and referred to our Institutions 
with a suspicion of classical MPNs is shown in Figure 2. Specifically, 19 patients were evaluated 
for suspected ET, 14 for probable PV, 1 for probable MF and 1 for MPN underling atypical 
thrombosis. Consequently, they were prospectively followed over time with 
clinical/laboratory data. In 2/35 cases, BM biopsy confirmed the suspect of a primary MF or 
MPN not otherwise specified (NOS) in one subject tested after a splanchnic vein thrombosis. 
Prospective molecular monitoring was performed in 15/35 low AB patients at a 12-
month follow-up A significant increase of JAK2V617F AB over time was observed in 11 cases (p 
<0.05). Indeed, the median value of JAK2V617F AB at diagnosis and during follow-up was 0.49% 
(range, 0.12-2.98) and 1.3% (range, 0.28-9.2), respectively. In the remaining 4 cases, a slight 
decrease of JAK2V617F AB over time was registered (Figure 3). 
   
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Diagnostic work ow of patients with suspected MPN and low JAK2V617F allele 
burden. *Main hematological abnormality motivating the JAK2V617F evaluation. ‘’Histology-
based’’ diagnosis was made when BM histology was available. In patients that were unable or 
refused to perform BM evaluation, prospective clinical observation and prospective molecular 
monitoring were crucial to direct diagnostic uncertainty, allowing to define a ‘’Clinical based’’ 
or ‘’Molecular based’’ diagnosis, respectively.  
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Figure 3: JAK2V617F allele burden over time in patients with suspected Essential 
Thrombocytemia and Polycythemia Vera. Fifteen patients received the second evaluation of 
JAK2V617F allele burden after a period of 12 months from the first mutational test. Dark red line: 
final diagnosis of PV. Light red line: final diagnosis of secondary polyglobulia. Dark blue line: 
final diagnosis of ET. Light blue line: final diagnosis of secondary thrombocytosis.  
 
Among the 19/35 (54.3%) subjects with low AB that received JAK2V617F evaluation for 
thrombocytosis, 14 (73.7%) patients finally had a clinical diagnosis of MPN (Table 1). In 10 
cases, the diagnosis was confirmed by BM histology (patients T1-T8, T10 and T12). In one case, 
an additional Type 1 CALR mutation was detected with an AB of 42% (patient T9). Conversely, 
three additional patients refused or were unable to perform BM biopsy, therefore were 
classified as ‘’Probable ET’’ because presented a persistent thrombocytosis in absence of other 
causes (patients T11,T13-T14). In two of these patients (T11 and T14), JAK2V617F mutation load 
was reassessed after a 12-month follow-up and an increased AB was observed, corroborating 
the diagnosis of MPN (Table 1 and Figure 3); in the remaining case (T13), prospective 
molecular evaluation was not performed because cytoreductive therapy was already ongoing. 
Indeed, despite the absence of BM biopsy, cytoreductive therapy was administered according 
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to standard criteria for treatment start (e.g.: age>60 years and/or previous thrombosis and/or 
massive thrombocytosis). In the remaining 5 patients (patients T15-T19), thrombocytosis was 
transitory and was finally considered as secondary to an inflammatory disease (erysipelas, 1 
case; rheumatoid arthritis, 2 cases) or to iron deficiency (2 cases). In two of these cases, BM 
biopsy excluded a hematological disease (patients T18 and T19). Accordingly, a decrease of 
AB was observed at second evaluation in patients T17 and T18.  
The 14 patients with a final diagnosis of MPN (including WHO-defined ET and 
“probable ET”) showed higher hemoglobin level (median (range): 13.6 (10.9-16.2) vs 10.3 (7.2-
12.1) g/dl) and lower leukocyte count (median (range): 7.4 (4.2-13.3) vs 11.3 (8.2-21) x109/l) 
compared to the 5 patients with reactive thrombocytosis (p <0.001 and p =0.05, respectively). 
Conversely, platelet count was similar in the two groups (median (range): 650 (161-1000) vs 
587 (490-701) x109/l; p =N.S.) (data not shown). The mutation load was significantly higher in 
MPN patients than in subjects finally diagnosed with reactive thrombocytosis (median (range): 
1.18 (0.15-2.98) vs 0.34 (0.12-0.61) %; p =0.02). Overall, no patient with reactive 
thrombocytosis showed an AB ≥0.64% (Table 1). 
Among the 14/35 (40.0%) patients with low AB that performed mutational analysis due 
to erythrocytosis, 8 (57.1%) had a final diagnosis of MPN (Table 2). PV diagnosis was sustained 
by absence of other causes of polyglobulia, JAK2V617F positivity and reduced baseline 
erythropoietin (EPO) levels (patients E1-E8). In patients E1-E3 and E6-E8, the diagnosis was 
also confirmed by the detection of an increased JAK2V617F AB at a 12-month molecular follow-
up. In the remaining 6 cases, the hematological abnormality was finally classified as secondary 
erythrocytosis (patients E9-E14) due to kidney cancer with increased endogenous EPO levels 
(patient E9) and chronic obstructive pulmonary disease (COPD, 5 patients: E10-E14). In two of 
these patients, the diagnosis was supported by a decrease in the JAK2V617F AB over time 
(patients E13 and E14) (Table 2 and Figure 3). In the majority of these patients with diagnosis 
of secondary erythrocytosis, phlebotomy and/or aspirin were administered after 
consideration of the causes of polyglobulia and the overall thrombotic risk of the patients [40-
42]. No additional mutations were found in none of the patients investigated for 
erythrocytosis.  
The 8 patients with a diagnosis of PV showed higher hemoglobin level compared to the 
6 patients with secondary polyglobulia (median (range): 18.8 (17.4-20.1) vs 16.9 (16.2-19.7) 
g/dl; p =0.04), but presented comparable leucocyte (median (range): 7.3 (5.4-10.9) vs 6.2 (4.5-
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9.4) x109/l; p =N.S.) and platelet counts (median (range): 250 (186-703) vs 235 (166-283) 
x109/l; p =N.S.) (data not shown). Median JAK2V617F AB was also similar in the two groups 
(median (range): 0.42 (0.16-2.25) vs 0.49 (0.12-0.74) %; p =N.S.). Nonetheless, 75% of PV 
patients carried a mutation load above the median value of 0.44% (vs 16.7% in patients with 
secondary erythrocytosis, p =0.03) (Table 2). 
As expected, low AB patients investigated for a suspected PV showed significantly 
higher median hemoglobin levels (median (range): 18.2 (16.2-20.1) vs 12.9 (7.2-16.2) g/dl; p 
<0.001) and lower median platelet count (median (range): 238 (166-703) vs 638 (161-1000) 
x109/l; p <0.001) compared to patients with suspected ET (data not shown). Conversely, 
median JAK2V617F burden was similar in the two cohorts both considering all evaluated patients 
(median (range): 0.44 (0.12-2.25) vs 0.64 (0.12-2.98) %; p =N.S.) and only patients with final 
diagnosis of PV and ET/early-PMF/MPN NOS/probable ET (median (range): 1.18 (0.16-2.25) vs 
0.42 (0.15-2.98) %; p =N.S.) (Table 1 and 2).  
Overall, in 11 out of 35 (31.4%) patients the detection of a low JAK2V617F AB was 
considered insufficient to make a diagnosis of MPN (Figure 2). In 6 cases, the exclusion of MPN 
relied only on clinical monitoring over time, with the observation that the hematological 
abnormalities were transient and dependent on other contributing factors. In 2 cases BM 
histology revealed no signs of MPNs (patients T18 and T19), and in 3 additional patients the 
JAK2V617F mutation load spontaneously decreased over time (patients T17, E13 and E14). The 
probability to have a final hematological diagnosis was higher in patients tested for 
thrombocytosis who received a diagnosis of ET/early-PMF in 73.7% of the cases (vs 57.1% of 
patients with polyglobulia finally diagnosed with PV). In the former cohort, BM biopsy was 
fundamental for diagnosis in 62.9% of the cases; also, the detection of a concomitant CALR 
mutation was decisive in confirming ET diagnosis in one patient. Conversely, in patients tested 
for polyglobulia BM biopsy was never performed, thus limiting the diagnostic accuracy. 
However, in 15 cases the repetition of the JAK2V617F mutation load over time was of remarkable 
help in the diagnostic process. Nonetheless, in the low AB cohort, the probability to carry a 
hematological disease directly correlated with a higher mutation load, since all patients with 
a JAK2V617F AB >0.8% were finally diagnosed with a MPN. In order to exclude under-estimation 
of the JAK2V617F AB caused by hampering correct primer or probe annealing, additional 
mutations in JAK2 exon 14 were investigated; however, they were not detected in any patient. 
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Finally, regarding clinical outcome, the frequency of thrombosis was not significantly 
different according to JAK2V617F AB, in both ET and PV. In addition, when we analyzed the 
distribution of low and high AB patients according to risk categories, we did not find any 
significant correlation between the two parameters (data not shown).  
 
 
 
Table 1. Main baseline characteristics and clinical outcome of patients investigated for 
thrombocytosis. Patients with persistent thrombocytosis in absence of other causes that did 
not perform BM biopsy for histological confirmation were classified as ‘’Probable ET’’. PLT: 
platelet (x109/l); BM: bone marrow; N.A.: not available; ET: Essential Thrombocythemia; Early-
PMF: early-primary myelofibrosis; WT: wild-type; HU: hydroxyurea; IFN: interferon-alpha; 
ASA: low-dose aspirin. Patient 19 had received splenectomy for a previous diagnosis of 
immune thrombocytopenia. Only in 5 cases, lactate dehydrogenase (LDH) was elevated. No 
patients had splenomegaly. 
 Oncotarget6www.impactjournals.com/oncotarget
BM biopsy is not feasible in all patients, because of 
old r age and/or patients’ refusal; also, the material may 
result inadequate for a correct histology evaluation. In 
these cases, the repetition of the molecular test over time 
timely detected the spontaneous expansion (11 cases) or 
reduction (4 cases) of the JAK2V617F-positive clones and 
signific
a
nt ly oriented the diagnostic process. Finally, the 
co-existence of additional CALR/MPL or JAK2 exon 
14 and exon 12 mutations was routinely excluded in all 
cases of thrombocytosis or polyglobulia, respectively, that 
present with a low JAK2V617F AB [44]. Accordingly, many 
recent studies have demonstrated that CALR and MPL 
mutations may co-exist with JAK2 mutations in chronic 
MPNs/MDS [45,46].
From the biological point of view, our clinical results 
seem to sustain the hypothesis that a low JAK2V617F AB 
refle
c
t s the presence of a small mutated clone within an 
overall polyclonal hematopoiesis. Indeed, it was recently 
demonstrated that patients with early stage hematological 
m lignancy may harbor distinct clo es, and that such 
clones may arise independently [47]. Alternatively, we 
can also draw the assumption that, depending on whether 
the oncogenic hit marks the stem or the progenitor’s 
compartments, the mutation load might be more or less 
enlarged. In any case, this mutational event represents an 
early molecular onset and is probably not suffici ent  per se 
to induce the malignant MPN phenotype. Consequently, 
the detection of low AB in one single occasion is likely 
not appropriate to determine the diagnosis. Therefore, 
the molecular monitoring over time may allow knowing 
whether this is a temporary clone (a condition which is 
likely to occur in healthy subjects) or may expand and 
give origin to the disease.
In conclusion, our results highlight that the detection 
of a JAK2V617F mutation at low levels is difficu l t to be 
interpreted in everyday clinical practice, since not all 
Table 1: Main baseline characteristics and clinical outcome of patients investigated for 
thrombocytosis
Patient
Age, 
gender
Prior
Thrombosis
(Y/N)
Plt count 
≥ 450
(× 109/l)
BM 
histology
JAK2V617F
AB, %
1st
evaluation
JAK2V617F
AB, %
2nd 
evaluation
CALR
F ulfil
l
ed 2008 WH O 
diagnostic criteria
(Y/N)
Final diagnosis Therapy
Status at 
last follow-
up
T1 20, F N Y Y 0.12 0.36 WT Y ET IFN PLT < 400
T2 46, M Y Y Y 0.79 - WT Y ET IFN PLT < 400
T3 33, F N Y Y 0.20 1.46 WT Y ET - PLT < 1000
T4 25, F N Y Y 2.37 - WT Y ET ASA PLT <1000
T5 62, M Y Y Y 2.98 7.38 WT Y ET HU, ASA PLT < 600
T6 17, M N Y Y 3.00 - WT Y ET - PLT <1000
T7 50, F N Y Y 0.43 - WT Y Early-PMF IFN PLT < 400
T8 31, M N Y Y 2.36 - WT Y Early-PMF IFN PLT < 400
T9 46, M N Y N.A. 0.56 -
Type1
(42%)
N (absence of BM biopsy) ET HU PLT < 600
T10 38, F N Y Y 0.41 - WT Y ET HU PLT < 1000
T11 57, F N Y N.A. 0.64 1.63 WT N (absence of BM biopsy) Probable ET ASA PLT < 1000
T12 66, M N Y Y 1.05 - WT Y ET HU, ASA PLT < 600
T13 71, F N Y N.A. 1.56 - WT N (absence of BM biopsy) Probable ET ASA PLT < 400
T14 91, F Y Y N.A. 2.38 9.20 WT N (absence of BM biopsy) Probable ET HU, ASA PLT <400
T15 72, F Y Y N.A. 0.32 - WT
N (absence of BM biopsy, 
evidence of reactive 
thrombocytosis)
Reactive
(reumatoid arthritis)
- PLT < 600
T16 81, M N Y N.A. 0.34 - WT
N (absence of BM biopsy, 
evidence of reactive 
thrombocytosis)
Reactive
(reumatoid arthritis)
- PLT < 600
T17 43, F N Y N.A. 0.59 0.50 WT
N (absence of BM biopsy, 
evidence of reactive 
thrombocytosis)
Reactive
(iron defic
i
ency)
IRON 
THERAPY
PLT < 400
T18 25, F N Y
Y 
(normal)
0.12 WT WT
N (normal BM histology, 
evidence of reactive 
thrombocytosis)
Reactive 
(erysipelas)
- PLT < 400
T19 35, F N Y
Y 
(normal)
0.61 - WT
N (normal BM histology, 
evidence of reactive 
thrombocytosis)
Reactive
(iron defic
i
ency)
- PLT < 600
Patients with persistent thrombocytosis in absence of other causes that did not perform BM biopsy for histological confirm a t ion were classified  as ‘’Probable ET’’. PLT: platelet (× 109/l); BM: bone marrow; 
N.A.: not available; ET: Essential Thrombocythemia; Early-PMF: early-primary myelofibr os i s;  WT: wild-type; HU: hydroxyurea; IFN: interferon-alpha; ASA: low-dose aspirin. Patient 19 had received 
splenectomy for a previous diagnosis of immune thrombocytopenia. Only in 5 cases, lactate dehydrogenase (LDH) was elevated. No patients had splenomegaly.
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Table 2. Main baseline characteristics and clinical outcome of patients investigated for 
erythrocytosis. Hb: hemoglobin (g/dl); Hct: hematocrit; N.A.: not available; HU: hydroxyurea; 
ASA: low-dose aspirin; COPD: chronic obstructive pulmonary disease. 
 
 
DISCUSSION 
 The present study investigated the role of a low JAK2V617F AB in a cohort of subjects that 
received the molecular test in the suspect of MPN. All mutational studies were performed 
according to international recommendations over a 1-year period and patients were 
homogeneously followed at a single Institution. BM histology was always decisive to direct 
diagnosis. When histology was unavailable, molecular monitoring together with clinical 
observation were utmost importance. 
 Among the 42 patients with low (0.1-3%) JAK2V617F AB, 7 had a confirmed diagnosis of 
non-classical MPNs by BM histology, 11 were classified as reactive hematological 
abnormalities due to the presence of additional causes of thrombocytosis (5 cases) or 
polyglobulia (6 cases) whereas 24 received a diagnosis of classical MPNs. JAK2V617F mutation 
represents a non-driver and subclonal event in non-classical MPNs, occurring most frequently 
with low mutation burden [11]. As a consequence, the percentage of subjects with an AB ≤3 
that were finally diagnosed as MPDs was higher (7/23, 30.4%) compared to MPNs 24/716 
(3.3%).   
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 Also, the present study demonstrates that within low AB patients a higher mutation 
load is associated with a higher probability to receive a hematological diagnosis, with an AB 
≥0.8% always corresponding to an overt MPN phenotype. Moreover, while higher hemoglobin 
levels significantly correlated with a diagnosis of WHO-defined PV, platelet count was similar 
in patients with or without a final diagnosis of ET/early-PMF, and was therefore not indicative 
per se of a hematological disorder. Another interesting observation is that histology, when 
performed, was diagnostic for a full-blown disease regardless of the JAK2V617F AB. This not only 
further confirms the central role of histology in MPN diagnosis, distinguishing true MPNs by 
small foci of clonal hematopoiesis that are not of clinical significance, but also indicate that 
the morphologic pattern is not strictly driven by the molecular aberrancy. As a result, 
evaluation of BM histology could be useful especially for patients with a suspicion of PV and 
an AB below 0.8% to confirm MPNs diagnosis. Accordingly, revised WHO classifications for 
myeloproliferative neoplasm indicated BM morphology as one of three major diagnostic 
criteria, also in PV [43]. Nonetheless, BM biopsy is not feasible in all patients, because of older 
age and/or patients’ refusal; also, the material may result inadequate for a correct histology 
evaluation. In these cases, the repetition of the molecular test over time timely detected the 
spontaneous expansion (11 cases) or reduction (4 cases) of the JAK2V617F -positive clones and 
significantly oriented the diagnostic process. Finally, the co-existence of additional CALR/MPL 
or JAK2 exon 14 and exon 12 mutations was routinely excluded in all cases of thrombocytosis 
or polyglobulia, respectively, that present with a low JAK2V617F AB [44]. Accordingly, many 
recent studies have demonstrated that CALR and MPL mutations may co-exist with JAK2 
mutations in chronic MPNs/MDS [45,46]. 
 From the biological point of view, our clinical results seem to sustain the hypothesis 
that a low JAK2V617F AB reflects the presence of a small mutated clone within an overall 
polyclonal hematopoiesis. Indeed, it was recently demonstrated that patients with early stage 
hematological malignancy may harbor distinct clones, and that such clones may arise 
independently [47]. Alternatively, we can also draw the assumption that, depending on 
whether the oncogenic hit marks the stem or the progenitor’s compartments, the mutation 
load might be more or less enlarged. In any case, this mutational event represents an early 
molecular onset and is probably not sufficient per se to induce the malignant MPN phenotype. 
Consequently, the detection of low AB in one single occasion is likely not appropriate to 
determine the diagnosis. Therefore, the molecular monitoring over time may allow knowing 
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whether this is a temporary clone (a condition which is likely to occur in healthy subjects) or 
may expand and give origin to the disease. 
In conclusion, our results highlight that the detection of a JAK2V617F mutation at low 
levels is difficult to be interpreted in everyday clinical practice, since not all positive patients 
received a hematological diagnosis. However, all patients with an AB ≥0.8% finally received a 
diagnosis of MPN; therefore, a mutation load above this cut-off may be considered very 
indicative for the presence of a myeloproliferative disease. Additionally, the study identified 
the prospective evaluation of JAK2V617F mutation load as a convenient and non-invasive 
method to evaluate patients with small mutated clones in order to timely detect the 
expansion of clonal hematopoiesis and diagnose a full blown disease. The study should require 
validation in larger cohorts of patients prospectively examined with standardized molecular 
methods.  
MATERIALS AND METHODS 
Study population 
Between January 2013 and January 2015, 1087 JAK2V617F mutational studies were 
performed at the Institute of Hematology “L. e A. Seràgnoli”, Bologna. The clinical suspicions 
that motivated the request for JAK2V617F evaluation were: essential thrombocytemia (ET) (299 
cases, 27.5%); polycythemia vera (PV) (272 cases, 25.1%); myelodysplasia (MDS) (23 cases, 
2.1%); atypical thrombosis (12 cases, 1.1%); myelofibrosis (MF) (133 cases, 12.2%); others/not 
specified (348 cases, 32.0%) (Figure 1). Clinical and laboratory data of patients with a 
suspected ET, PV or MF and an allele burden ≤3% were prospectively monitored for 1 year. All 
patients provided an informed written consent in accordance with the Declaration of Helsinki 
for the use of remnant DNA for investigational purposes. The study was approved by the local 
Ethics Committee. 
 
Patient samples 
Polymorphonuclear cells were isolated from peripheral blood samples by density 
centrifugation with Polymorphoprep (Axis-Shield, Scotland) [48-50]. Genomic DNA was 
extracted using the QIAamp DNA Blood Mini kit (QIAGEN-Werfen) on QIAcube (QIAGEN 
GmbH, Hilden, Germany) and was quantified with the NanoDrop spectrophotometer 
(Wilmington, DE, USA). 
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Molecular evaluations 
Molecular analyses were assessed at diagnosis or before treatment start on DNA 
obtained from granulocytes. When clinical, laboratory and/or histological data were not 
decisive for the diagnosis of MPN, mutational status was prospectively evaluated at a 12-
month interval. A second JAK2V617F molecular test was not performed in patients that had 
already started cytoreductive therapy due to high thrombotic risk. JAK2V617F mutation was 
evaluated with ipsogen JAK2 MutaQuant Kit, which is based on allele specific real time 
quantitative polymerase chain reaction (qPCR) technology on 7900 HT Fast Real Time PCR 
System (Applied Biosystem) [21]. The percentage of mutant JAK2V617F allele was expressed as 
the ratio of JAK2V617F copies to total copy number (CN) of JAK2 (CN of JAK2V617F + CN of JAK2 
wild type). Even if the lower detection limit (LOD) of the assay was 0.01% (See Supplemental 
File), we identified the 0.1% as cut-off of positivity as also suggested by several studies [23-
24, 27-29]. All samples were tested in duplicate with both qPCR and also with digital PCR 
(ddPCR) to confirm the evaluation [51-52] (See Supplemental File). In addition to JAK2V617F 
mutation, CALR and MPL mutations were screened for all patients to obtain a comprehensive 
molecular characterization and to exclude the co-existence of additional mutations [44-46, 
53-54]. CALR exon 9 sequencing was performed by Next Generation Sequencing (NGS) 
approach with GS Junior (Roche 454 platform); analysis was carried out with AVA software 
(GRCh38 as references). CALR mutations identified by NGS were confirmed by Sanger 
sequencing. MPL mutations were investigated by ipsogen MPLW515K/L MutaScreen Kit and 
by Sanger sequencing (for MPLS505N and other secondary exon 10 mutations), as previously 
described [55]. Additional masking mutations in JAK2 exon 14 were investigated by Sanger 
sequencing [39]. In case of clinical suspicion of PV, JAK2 exon 12 mutations were also tested 
by Denaturing High Pressure Liquid Chromatography (DHPLC) and confirmed by Sanger 
sequencing [55-58]. Diagnoses of all hematological diseases were made according to the 
WHO2008 criteria [1].  
 
Statistical methods 
Numerical variables have been summarized by their median and range, and categorical 
variables by count and relative frequency (%) of each category. Comparisons of quantitative 
variables between groups of patients were carried out by the nonparametric Wilcoxon rank-
sum test. Association between categorical variables (2-way tables) was tested by the Fisher 
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exact test or χ2, as appropriate. All p values were two-sided and statistical significance was 
defined as p <0.05. All statistical analyses were computed with SPSS software (SPSS Inc., 
Chicago, IL, USA). 
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Supplementary Data 
The relevance of a low JAK2V617F allele burden in clinical practice: a 
monocentric study 
 
RESULTS 
Detection and quantitation of JAK2V617F AB by both qPCR and ddPCR  
Overall, 48 samples (18 at diagnosis and 15 both at diagnosis and during the follow-
up) were tested for JAK2V617F with both qPCR and ddPCR. The median mutation burden 
obtained was 0.59% (range: 0–9.2%) and 0.52% (range: 0–6.77%), respectively.  
As the AB did not follow a normal distribution, Spearman’s rho test was used for 
correlation analysis. As shown in Figure S1, there was a high degree of correlation between 
data obtained with the two methods (R = 0.924; p < 0.0001).  
 
 
 
 
 
 
 
Supplementary Figure S1- Correlation between qPCR and ddPCR. Each point represents a 
sample where JAK2V617F AB has been evaluated, according to qPCR (Y-axis) and ddPCR (X-
axis). The calculated Spearman’s rho value is 0,924 (p <0,0001). 
 
Limit of detection (LOD) determination  
As shown in Supplementary Figure 2, both the qPCR and the ddPCR achieved a 
sensitivity of 0.01% . 
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Supplementary Figure S2- Limit Of Detection (LOD) determination. Ipsogen JAK2 MutaQuant 
kit (qPCR) (A) and ddPCR (B-C) sensitivity was assessed by quantifying a serial dilution of a 
mutant genomic DNA into a wild-type DNA. For simplicity, only selected dilutions of the entire 
standard curve (prepared as described in the Methods) are shown. (A) Amplification plot of 
mutant genomic DNA serial dilutions (Mut, 1:2, 1:10, 1:100, 1:1000, and WT, respectively). (B) 
The blue dots indicate the number of mutated copies/µl; the green dots indicate the number 
of wild-type copies/µl. (C) Fractional abundance plot shows the frequency of the mutant DNA 
into total genomic DNA. 
Supplementary Figure 2: Limit of detection (LOD) determination. Ipsogen JAK2 MutaQuant kit (qPCR) (A) and dd-PCR 
(B–C) sensitivity was assessed by quantifying a serial dilution of a mutant genomic DNA into a wild-type DNA. For simplicity, only 
selected dilutions of the entire standard curve (prepared as described in the Methods) are shown. (A) Amplifica t ion plot of mutant genomic 
DNA serial dilutions (Mut, 1:2, 1:10, 1:100, 1:1000, and WT, respectively). (B) The blue dots indicate the number of mutated copies/µl; 
the green dots indicate the number of wild-type copies/µl. (C) Fractional abundance plot shows the frequency of the mutant DNA into total 
genomic DNA.
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MATERIALS AND METHODS  
Digital PCR 
In order to demonstrate repeatability of qPCR results, all samples were tested also with 
digital PCR (ddPCR) assay. ddPCR was performed using the specific PrimePCR ddPCR Mutation 
Detection Kit Assay for JAK2 wild-type and the V617F mutation on the QX200 platform 
(BioRad, Milan, Italy). The data analysis was performed using the QuantaSoft analysis software 
and results were expressed as the fractional abundance (FA) of mutant (a) to wild type (b) 
template (a/a+b).  
A comparison between qPCR and ddPCR was performed through a nonparametric 
correlation analysis (Spearman’s rho). 
 
Analytic sensitivity test  
The Limit Of Detection (LOD) is defined as the lowest mutant concentration that can 
be consistently detected above the limit of blank.  
In order to compare the ability of both qPCR and ddPCR of detecting diluited mutant 
alleles, a sensitivity curve was performed. We prepared serial dilutions (1:2, 1:10, 1:100, 
1:1000, 1:5000, 1:10000) of an already quantitated JAK2V617F mutant genomic DNA into a 
genomic wild-type DNA. We include also “WT only” control wells and no template control 
(NTC) wells. All the dilutions were tested in duplicate.  
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ABSTRACT 
To date, a plenty of techniques for the detection of JAK2V617F is used over different 
laboratories, with substantial differences in specificity and sensitivity. Therefore, to provide 
reliable and comparable results, the standardization of molecular techniques is mandatory. 
A network of 19 centers was established to 1) evaluate the inter- and intra- laboratory 
variability in JAK2V617F quantification, 2) identify the most robust assay for the standardization of 
the molecular test and 3) allow consistent interpretation of individual patient analysis results. The 
study was conceived in 3 different rounds, in which all centers had to blindly test DNA samples 
with different JAK2V617F allele burden (AB) using both quantitative and qualitative assays. 
The positivity of samples with an AB < 1% was not detected by qualitative assays. 
Conversely, laboratories performing the quantitative approach were able to determine the 
expected JAK2V617F AB. Quantitative results were reliable across all mutation loads with moderate 
variability at low AB (0.1 and 1%; CV = 0.46 and 0.77, respectively). Remarkably, all laboratories 
clearly distinguished between the 0.1 and 1% mutated samples. 
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In conclusion, a qualitative approach is not sensitive enough to detect the JAK2V617F 
mutation, especially at low AB. On the contrary, the ipsogen JAK2 MutaQuant CE-IVD kit resulted 
in a high, efficient and sensitive quantification detection of all mutation loads. This study sets the 
basis for the standardization of molecular techniques for JAK2V617F determination, which will 
require the employment of approved operating procedures and the use of certificated standards, 
such as the recent WHO 1st International Reference Panel for Genomic JAK2V617F. 
 
INTRODUCTION 
The JAK2V617F mutation represents a hallmark of Philadelphia (Ph)- negative 
myeloproliferative neoplasms (MPNs), fulfilling a 2008 World Health Organization (WHO) major 
criterion for the diagnosis of MPNs [1–2]. The JAK2V617F mutation is an acquired, somatic mutation 
carried by almost all patients (approximately 95%) with polycythemia vera (PV) and in more than 
half (approximately 50–60%) of those with essential thrombocythemia (ET) or primary 
myelofibrosis (PMF) [3, 4].  
The assessment of the JAK2V617F allele burden (AB) is a common practice either at 
diagnosis, for prognostic information, or during treatment as a means to assess minimal residual 
disease [5]. Indeed, JAK2V617F AB seems to be correlated with an increased risk of thrombosis and 
evolution in a secondary myelofibrosis in PV (PPV-MF) and, possibly, in ET (PET-MF) [6,7]. 
Additionally, low AB is associated with a reduced survival in PMF [8–11]. With regard to drug 
therapy, several studies showed that interferon-alpha, and the most recent telomerase inhibitors 
(Imetelstat), significantly reduces JAK2V617F mutation burden, whereas, JAK inhibitors and 
hydroxyhurea (HU) did not have any significant effects [12–21]. Moreover, JAK2V617F 
quantification has been incorporated as a potentially useful tool to predict relapse in those 
patients who underwent allogeneic stem-cell transplantation (alloHSCT). In this setting of 
patients, early monitoring of the AB (1, 3 and 6 months post alloHSCT) is crucial to predict overall 
survival and risk of relapse and might guide therapeutic decisions [22–24].  
To date, a plenty of techniques for JAK2V617F determination is used over different 
laboratories, with substantial differences in specificity and sensitivity [5, 25–31]. The extensive 
and worldwide use of molecular techniques with high sensitivity has significantly increased our 
ability to detect small mutated clones, with low AB (i.e. <1% of mutation loads) [5, 26, 32]. 
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Additionally, many recent studies have shown that a small clonal hematopoiesis may be present 
also in otherwise healthy subjects at low level (0.03–1%) [27, 32–38]. In the context of highly 
sensitive allele-specific assays and low mutant AB in the peripheral blood, the possibility of both 
false-positive and false-negative test results is not negligible [5, 32].  
Therefore, to provide a reliable and comparable molecular results, the standardization of 
molecular techniques is urgently needed. In a recent study by European 
LeukemiaNet/MPN&MPNr-EuroNet group, nine different JAK2V617F quantitative assays were 
evaluated by the 12 participant laboratories, with the aim to identify the most robust one for 
routine diagnostic purpose and also for post alloHSCT monitoring [39]. Therefore, a network of 
19 Italian laboratories was established with the aim 1) to evaluate the inter- and intra-laboratory 
variability in JAK2V617F quantification in these 19 centers, 2) to identify the most robust assay for 
the standardization of the molecular test and 3) to allow consistent interpretation of individual 
patient analysis results.  
 
RESULTS  
Between 2014 and 2015, a network of 19 Italian laboratories, routinely involved in the 
molecular diagnosis of MPNs, was established. The study was coordinated by the Institute of 
Hematology “L. e A. Seràgnoli”, Bologna, and conceived in 3 different rounds in which seven, ten 
and nineteen laboratories were included over time, respectively (Figure 1). Overall, one 
quantitative (ipsogen JAK2 MutaQuant kit, QIAGEN) and four qualitative assays were evaluated. 
Of these latter, two were commercial (ipsogen JAK2 MutaSearch kit, QIAGEN, and GeneQuality 
JAK-2, AB Analitica) and two were built “in-house” methods: allele specific polymerase chain 
reaction (AS-PCR) and Amplification-refractory mutation system (ARMS) analysis [25, 30].  
 
I Round: proficiency test  
In order to obtain information about the variability in JAK2V617F quantification between 
different centers, seven laboratories were employed to evaluate several DNA samples with their 
own established JAK2V617F qualitative and/or quantitative method. Precisely, four DNA samples 
derived from granulocytes of patients with a diagnosis of MPNs were analyzed. All laboratories 
using the quantitative assay (ipsogen JAK2 MutaQuant kit) were able to determine the expected 
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JAK2V617F AB, as summarized in Table 1. Only in one case (i.e. DNA sample 1), the Center 3 
obtained a false positive result. Indeed, the sample was found to be positive with an AB of 0.13%. 
On the contrary, two Centers (i.e. 6 and 7), using a qualitative approach, were not able to detect 
the positivity of the DNA sample 2 (with an expected AB of 0.15%).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Design of the study. A network of 19 Italian Centers was established and the study was 
conceived in 3 different rounds, in which seven, ten and nineteen laboratories participated, 
respectively. Each laboratory had to blindly test DNA samples with different JAK2V617F allele 
burden (AB). Overall, one quantitative and four qualitative assays were evaluated.  
 
 
 
 
 
 
 
 
 
 
Table 1: I Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coef cient of variation) of results obtained by the seven participating 
laboratories, using their everyday analysis method. The expected JAK2V617F allele burden (AB, %) 
was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) and 20 (DNA 4). Centers 1–5 performed quantitative 
assay (ipsogen JAK2 MutaQuant kit) whereas Centers 6 and 7 used a qualitative approach: allele 
specific polymerase chain reaction (AS-PCR) and ipsogen JAK2 MutaSearch kit, respectively.  
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“in -hous e” m ethods : allele s pecific polym eras e chain  
reaction  (A S -PC R ) an d A m plifica tion -refractory m utation  
system (ARMS) analysis [25, 30].
I  Round: profici ency test
In  order to obtain  in form ation  about the variability 
in JAK2V617F quan tific
a
tion  betw een  differen t cen ters , 
s even  laboratories  w ere em ployed to evaluate s everal 
D N A  s am ples  w ith their o w n  es tablis hed JAK2V617F 
qualitative an d/or quan titative m ethod. Precis ely, four 
D N A  s am ples  derived from  gran ulocytes  of patien ts  w ith 
a diagn o s is  of M PN s   w ere an alyzed. A ll laboratories  
us in g the quan titative as s ay (ip s ogen  JAK2 MutaQuant 
kit) w ere able to determ in e the expected JAK2V617F A B , 
as  s um m arized in  T able 1. O n ly in  on e cas e (i.e. D N A  
s am ple 1), the C en ter 3  obtain ed a fals e po s itive res ult. 
In deed, the s am ple w as  foun d to be po s itive w ith an  A B  of 
0.13 % . O n  the con trary, tw o C en ters  (i.e. 6  an d 7), us in g a 
qualitative approach, w ere n ot able to detect the po s itivity 
of the DNA sample 2 (with an expected AB of 0.15%).
I I  Round: comparison between molecular assays
W ith the aim  to further in ves tigate on  the 
in ter-laboratory variability in  quan tifyin g JAK2V617F 
m utation , es pecially at lo w  m utation  burden , a s econ d 
standardization round was developed and three additional 
laboratories  w ere in cluded. E ight D N A  s am ples , derived 
from  dilution  of cell lin es  n egative an d po s itive for the 
JAK2V617F m utation , w ere tes ted by each laboratory w ith 
both ip s ogen  JAK2 M utaQ uan t kit an d their o w n  routin e 
qualitative or quantitative method.
W e firs t exam in ed the m ethod s  s en s itiv ity, an d the 
detectio n  ability of the ip s ogen  JAK2 MutaQuant kit at 
lo w -po s itiv e s am p les  (i.e. 0.1 an d 1% ) w as  co m pared to 
tho s e of qualitative JAK2 com m ercial an d validated “in -
hous e” m ethods . O verall, the A R M S -PC R  “in -hous e” 
method and the ipsogen JAK2 M utaS earch kit w ere able 
to detect the po s itiv ity of the s am p le w ith A B  of 1% , 
w hereas  n o n e of the labo rato ries  us in g an y qualitative 
m ethod s  w ere able to detect the lo w -p o s itive s am p le 
(i.e. A B  <  0.1% ). R em arkably, labo rato ries  us in g the 
quan titative app roach clearly defin ed the p o s itiv ity of 
bo th 1%  an d 0.1%  m utated s am p les . S pecifically, 10 
out of 16 JAK2V617F determinations were clearly defined 
po s itive, w ith an  A B  ≥  0.091%  w hich is  the L im it O f 
D etectio n  (L O D ) of the ip s ogen  JAK2 MutaQuant 
kit. In  the rem ain in g 6  cas es , the JAK2V617F mutation 
percen tage w as  foun d betw een  L im it o f B lan k (L O B  =  
0.014%) and LOD. 
A dditio n ally, the in ter-laboratory variability 
evaluatio n  w as  res tricted to the ip s ogen  JAK2 
M utaQ uan t kit, as  s ix out of 10 participatin g laboratories  
already us ed this  as s ay in  their routin e practice. T he 
data from  tw o laboratories  (i.e. C en ters  3  an d 8) w ere 
excluded from  s tatis tical an alys is , as  N egative C o n tro ls  
of JAK2V617F m utation  (N C -V F ) w ere foun d to be 
po s itive (>  0.1% ) for each run , an d co n s idered as  in valid 
run s . T his  w as  m ain ly due to either operator error or to 
in s trum en tatio n  s uitability, in s tead of an  in trin s ic bias  
of the kit. O verall, quan titative res ults  betw een  the 
laboratories  w ere reliable as  s um m arized in  T able 2  an d 
s ho w ed in  F igure 2 . A  s m all variability w as  ob s erved 
es pecially at lo w  A B  (0.1 an d 1% , C V  =  0.42  an d 0.2 4, 
respectively).
Figure 1: Design of the study. A network of 19 Italian Centers was established and the study was conceived in 3 different rounds, 
in which s ven, tn and nineeen laboratories participated,respectively. Each laboratory hdto blindy test DNA sample with different 
JAK2V617F allele burden (AB). Overall, one quantitative and four qualitative assays were evaluated.
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Table 1: I  Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coeffici ent  of variation) of results obtained by the seven participating 
laboratories, using their everyday analysis method
Sample
Expected
JAK2V617F 
AB
(%)
C1 C2 C3 C4 C5 Min Median Max
CV
(Coeffic
i
ent  of
Variation)
C6 C7
DNA 1 0.005 0.0056 0.00013 0.13 0 0.0007 0 0.00315 0.13 2.1 Neg Neg
DNA 2 0.15 0.18 0.13 0.19 0.15 0.15 0.13 0.15 0.19 0.15 Neg Neg
DNA 3 5 7.84 4.19 6.2 8.22 6.25 4.19 6.225 8.22 0.24 Pos Pos
DNA 4 20 23.17 25.95 20.24 19.44 19.82 19.44 20.03 25.95 0.08 Pos Pos
The expected JAK2V617F allele burden (AB, %) was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) and 20 (DNA 4). Centers 1–5 
performed quantitative assay (ipsogen JAK2 MutaQuant kit) whereas Centers 6 and 7 used a qualitative approach: allele 
specific
 
pol yme rase chai n react ion (AS - PCR)  and ipsogen JAK2 MutaSearch kit, respectively.
Table 2: I I  Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coeffici ent  of variatio ) of results obtain d by th  ten participating 
laboratories with ipsogen JAK2 MutaQuant kit
Sample Expected JAK2V617F AB (%) Min. Median Max CV (Coeffic
i
ent  of  Variation)
DNA G 0 0.002 0.008234 0.02 0.73
DNA E 0.1 0.03 0.09874 0.17 0.42
DNA C 1 0.39 0.8471 1.12 0.24
DNA B 5 2.38 3.643 4.66 0.18
DNA F 10 6.04 8.794 17.65 0.38
DNA H 20 13.12 15.2 19.35 0.11
DNA D 50 30.54 42.62 46.76 0.12
DNA A 100 99.76 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the eight DNA samples was 0, 0.1, 1, 10, 20, 50 and 100%.
Figure 2: I I  Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2 total (A) and JAK2V617F mutation percentage boxplot (B) for each of the 8 DNA samples. Red dots are expected values.
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II Round: comparison between molecular assays  
With the aim to further investigate on the inter-laboratory variability in quantifying 
JAK2V617F mutation, especially at low mutation burden, a second standardization round was 
developed and three additional laboratories were included. Eight DNA samples, derived from 
dilution of cell lines negative and positive for the JAK2V617F mutation, were tested by each 
laboratory with both ipsogen JAK2 MutaQuant kit and their own routine qualitative or 
quantitative method.  
We first examined the methods sensitivity, and the detection ability of the ipsogen JAK2 
MutaQuant kit at low-positive samples (i.e. 0.1 and 1%) was compared to those of qualitative 
JAK2 commercial and validated “in- house” methods. Overall, the ARMS-PCR “in-house” method 
and the ipsogen JAK2 MutaSearch kit were able to detect the positivity of the sample with AB of 
1%, whereas none of the laboratories using any qualitative methods were able to detect the low-
positive sample (i.e. AB < 0.1%). Remarkably, laboratories using the quantitative approach clearly 
defined the positivity of both 1% and 0.1% mutated samples. Specifically, 10 out of 16 JAK2V617F 
determinations were clearly defined positive, with an AB ≥ 0.091% which is the Limit Of Detection 
(LOD) of the ipsogen JAK2 MutaQuant kit. In the remaining 6 cases, the JAK2V617F mutation 
percentage was found between Limit of Blank (LOB = 0.014%) and LOD.  
Additionally, the inter-laboratory variability evaluation was restricted to the ipsogen JAK2 
MutaQuant kit, as six out of 10 participating laboratories already used this assay in their routine 
practice. The data from two laboratories (i.e. Centers 3 and 8) were excluded from statistical 
analysis, as Negative Controls of JAK2V617F mutation (NC-VF) were found to be positive (> 0.1%) 
for each run, and considered as invalid runs. This was mainly due to either operator error or to 
instrumentation suitability, instead of an intrinsic bias of the kit. Overall, quantitative results 
between the laboratories were reliable as summarized in Table 2 and showed in Figure 2. A small 
variability was observed especially at low AB (0.1 and 1%, CV = 0.42 and 0.24, respectively). 
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Table 2: II Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coefficient of variation) of results obtained by the ten participating 
laboratories with ipsogen JAK2 MutaQuant kit. The expected JAK2V617F mutation burden of the 
eight DNA samples was 0, 0.1, 1, 10, 20, 50 and 100%.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: II Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type 
(WT), JAK2 mutated (V617F) and JAK2 total (A) and JAK2V617F mutation percentage boxplot (B) 
for each of the 8 DNA samples. Red dots are expected values. 
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Table 1: I  Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coeffici ent  of variation) of results obtained by the seven participating 
laboratories, using their everyday analysis method
Sample
Expected
JAK2V617F 
AB
(%)
C1 C2 C3 C4 C5 Min Median Max
CV
(Coeffic
i
ent  of
Variation)
C6 C7
DNA 1 0.005 0.0056 0.00013 0.13 0 0.0007 0 0.00315 0.13 2.1 Neg Neg
DNA 2 0.15 0.18 0.13 0.19 0.15 0.15 0.13 0.15 0.19 0.15 Neg Neg
DNA 3 5 7.84 4.19 6.2 8.22 6.25 4.19 6.225 8.22 0.24 Pos Pos
DNA 4 20 23.17 25.95 20.24 19.44 19.82 19.44 20.03 25.95 0.08 Pos Pos
The expected JAK2V617F allele burden (AB, %) was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) and 20 (DNA 4). Centers 1–5 
performed quantitative assay (ipsogen JAK2 MutaQuant kit) whereas Centers 6 and 7 used a qualitative approach: allele 
specific
 
pol yme rase chai n react ion (AS - PCR)  and ipsogen JAK2 MutaSearch kit, respectively.
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DNA E 0.1 0.03 0.09874 0.17 0.42
DNA C 1 0.39 0.8471 1.12 0.24
DNA B 5 2.38 3.643 4.66 0.18
DNA F 10 6.04 8.794 17.65 0.38
DNA H 20 13.12 15.2 19.35 0.11
DNA D 50 30.54 42.62 46.76 0.12
DNA A 100 99.76 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the eight DNA samples was 0, 0.1, 1, 10, 20, 50 and 100%.
Figure 2: I I  Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2 total (A) and JAK2V617F mutation percentage boxplot (B) for each of the 8 DNA samples. Red dots are expected values.
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DNA E 0.1 0.03 0.09874 0.17 0.42
DNA C 1 0.39 0.8471 1.12 0.24
DNA B 5 2.38 3.643 4.66 0.18
DNA F 10 6.04 8.794 17.65 0.38
DNA H 20 13.12 15.2 19.35 0.11
DNA D 50 30.54 42.62 46.76 0.12
DNA A 100 99.76 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the eight DNA samples was 0, 0.1, 1, 10, 20, 50 and 100%.
Figure 2: I I  Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2 total (A) and JAK2V617F mutation percentage boxplot (B) for each of the 8 DNA samples. Red dots are expected values.
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III Round: inter-laboratory standardization by ipsogen JAK2 MutaQuant kit  
The study was extended to 9 additional centers to confirm the robustness of the ipsogen 
JAK2 MutaQuant kit in a larger cohort. Each participating laboratory had to test four DNA samples, 
derived from dilution of cell lines as described above, only with ipsogen JAK2 MutaQuant kit.  
The quantification data from Center 11 were excluded from statistical analysis, as NC-VF 
was found to be positive (> 0.1%) for each run and Positive Control of JAK2V617F mutation (PC-VF) 
did not reach the recommended value (> 99.9%). Moreover, Center 9 failed to perform correctly 
both runs due to instrument failure. Of note, both Center 9 and Center 11 did not assess JAK2V617F 
AB in their own routine practice. Among the remaining laboratories, Centers 2, 6 and 17 did not 
reach the minimum number of JAK2 total copy number required (10.000 copies) in five different 
determinations (two at 0.1% AB sample, two at 1% and one at 10%, respectively), and, therefore, 
these points were not included in the analysis. Quantitative results were reliable across all 
mutation loads, as reported in Table 3 and showed in Figure 3. All the 17 laboratories were able 
to quantify the 0.1% AB sample with the same variability observed in the previous II round (CV = 
0.46 and 0.42, respectively). Specifically, 23 out of 32 JAK2V617F determinations were clearly 
defined positive, with an AB > 0.091% (LOD). In the remaining 9 cases, the JAK2V617F mutation 
percentage was found between LOB and LOD. Surprisingly, a higher variability between 
laboratories was observed at 1% of AB (CV = 0.77, vs 0.24 in the II round). More importantly, all 
laboratories clearly distinguished between the 0.1 and 1% mutated samples.  
We also evaluated the robustness of the quantitative approach in terms of amplification 
efficiency. It is well known that amplification efficiency in PCR measures the amount of template 
converted into amplified product during each cycle of the exponential phase of the reaction. At 
100% efficiency, the quantity of product exactly doubles each cycle, thus an efficiency close to 
100% is the best indicator of a robust, reproducible assay. An amplification efficiency of 90–105% 
is recommended for each assay. In our study, the mean value of amplification efficiency obtained, 
with respect to all runs performed, was of 92% with a CV value of 0.065, confirming the sensitivity 
and the robustness of the ipsogen JAK2 MutaQuant kit.  
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Table 3: III Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coefficient of variation) of results obtained by the nineteen participating 
laboratories with ipsogen JAK2 MutaQuant kit. The expected JAK2V617F mutation burden of the 
four DNA samples was 0.1, 1, 10 and 100%.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 3: III Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type 
(WT), JAK2 mutated (V617F) and JAK2V617F mutation percentage boxplot for each of the 4 DNA 
samples. Red dots are expected values. 
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approach (2 “in-house” and 1 commercial assays), 7 
performed only a qualitative evaluation (1 “in-house” 
and 3 commercial assay) of JAK2V617F mutation whereas 2 
laboratories used both qualitative and quantitative 
approaches (2 “in-house” and 1 commercial assays). 
Regarding real-time PCR instruments used during the 
study: most (13 out of 19) of the laboratories used Applied 
Biosystem platforms (ABI7300/7500/7900; Applied 
Biosystem, Foster City, CA, USA); two laboratories used 
a Lightcycler LC480 platform (Roche Applied Science, 
Penzberg, Germany), and the remaining four laboratories 
used a Rotor-Gene Q 2plex/MDx 5plex HRM instrument 
(QIAGEN GmbH, Hilden, Germany) (Table 4). 
I  Round
In the I round, we aimed to investigate the inter-
laboratory variability on different mutation loads. In this 
firt  step, seven laboratories were involved (Center 1–7). 
Four of them routinely performed quantitative analysis of 
JAK2V617F with ipsogen JAK2 MutaQuant Kit (QIAGEN), 
two used a qualitative approach for JAK2V617F evaluation 
(1 “in-house” method, 1 ipsogen JAK2 MutaScreen Kit 
- QIAGEN) whereas one laboratory (Center 5) assessed 
both qualitative and quantitative assays. Each center had 
to test four DNA samples (DNA 1–4) with the method 
routinely employed in their own laboratory. DNA samples 
were isolated from granulocytes of patients with diagnosis 
of MPNs. The expected mutation burden of the 4 DNA 
samples was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) 
and 20% (DNA 4), as previously quantified  by Bologna’s 
laboratory with ipsogen JAK2 MutaQuant Kit.
All patients provided an informed written consent in 
accordance with the Declaration of Helsinki for the use of 
remnant DNA for investigational purposes. The study was 
approved by the local Ethics Committee. 
I I  Round
To further investigate the inter-laboratory variability 
on low-positive samples, a II round was developed. The 
two main objectives of this round were to assess inter-
laboratory variability across the 10 participating clinical 
centers and to compare the low-positive sample detection 
ability of the ipsogen JAK2 MutaQuant kit with the JAK2 
validated “in-house” methods. Compared to the first round, 
three additional centers (Centers 8–10) were included 
in this step: only Center 8 and 10 routinely performed 
JAK2V617F evaluation (1 with a qualitative and 1 with a 
quantitative method, respectively). Eight DNA test samples 
(DNA Sa ples A-H) were manufactured by QIAGEN and 
were centrally distributed by Werfen. The DNA samples 
were derived from dilution of cell lines: K562 (JAK2V617F 
negative) and MUTZ-8 (JAK2V617F positive). The ipsogen 
JAK2 MutaQuant kits and associated master-mix were 
provided by QIAGEN and Werfen. Each center had to 
Table 3: I I I  Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coeffici ent  of variation) of results obtained by the nineteen participating 
laboratories with ipsogen JAK2 MutaQuant kit
Sample Expected JAK2V617F AB (%) Min. Median Max CV (Coeffic
i
ent  of  Variation)
S02 0.1 0.07 0.11 0.27 0.46
S04 1 0.64 1.05 4.90 0.77
S01 10 6.67 10.04 24.37 0.37
S03 100 99.79 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the four DNA samples was 0.1, 1, 10 and 100%. 
Figure 3: I I I  Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2V617F mutation percentage boxplot for each of the 4 DNA samples. Red dots are expected values.
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approach (2 “in-house” and 1 commercial assays), 7 
performed only a qualitative evaluation (1 “in-house” 
and 3 commercial assay) of JAK2V617F mutation whereas 2 
laboratories used both qualitative and quantitative 
approaches (2 “in-house” and 1 commercial assays). 
Regarding real-time PCR instruments used during the 
study: most (13 out of 19) of the laboratories used Applied 
Biosystem platforms (ABI7300/7500/7900; Applied 
Biosystem, Foster City, CA, USA); two laboratories used 
a Lightcycler LC480 platform (Roche Applied Science, 
Penzberg, Germany), and the remaining four laboratories 
used a Rotor-Gene Q 2plex/MDx 5plex HRM instrument 
(QIAGEN GmbH, Hilden, Germany) (Table 4). 
I  Round
In the I round, we aimed to investigate the inter-
laboratory variability on different mutation loads. In this 
firt  step, seven laboratories were involved (Center 1–7). 
Four of them routinely performed quantitative analysis of 
JAK2V617F with ipsogen JAK2 MutaQuant Kit (QIAGEN), 
two used a qualitative approach for JAK2V617F evaluation 
(1 “in-house” method, 1 ipsogen JAK2 MutaScreen Kit 
- QIAGEN) whereas one laboratory (Center 5) assessed 
both qualitative and quantitative assays. Each center had 
to test four DNA samples (DNA 1–4) with the method 
routinely employed in their own laboratory. DNA samples 
were isolated from granulocytes of patients with diagnosis 
of MPNs. The expected mutation burden of the 4 DNA 
samples was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) 
and 20% (DNA 4), as previously quantified  by Bologna’s 
laboratory with ipsogen JAK2 MutaQuant Kit.
All patients provided an informed written consent in 
accordance with the Declaration of Helsinki for the use of 
remnant DNA for investigational purposes. The study was 
approved by the local Ethics Committee. 
I I  Round
To further investigate the inter-laboratory variability 
on low-positive samples, a II round was developed. The 
two main objectives of this round were to assess inter-
laboratory variability across the 10 participating clinical 
centers and to compare the low-positive sample detection 
ability of the ipsogen JAK2 MutaQuant kit with the JAK2 
validated “in-house” methods. Compared to the first round, 
three additional centers (Centers 8–10) were included 
in this step: only Center 8 and 10 routinely performed 
JAK2V617F evaluation (1 with a qualitative and 1 with a 
quantitative method, respectively). Eight DNA test samples 
(DNA Samples A-H) were manufactured by QIAGEN and 
were centrally distributed by Werfen. The DNA samples 
were derived from dilution of cell lines: K562 (JAK2V617F 
negative) and MUTZ-8 (JAK2V617F positive). The ipsogen 
JAK2 MutaQuant kits and associated master-mix were 
provided by QIAGEN and Werfen. Each center had to 
Table 3: I I I  Round JAK2V617F mutation burden and summary statistics (minimum, maximum, 
calculation of median, coeffici ent  of variation) of results obtained by the nineteen participating 
laboratories with ipsogen JAK2 MutaQuant kit
Sample Expected JAK2V617F AB (%) Min. Median Max CV (Coeffic
i
ent  of  Variation)
S02 0.1 0.07 0.11 0.27 0.46
S04 1 0.64 1.05 4.90 0.77
S01 10 6.67 10.04 24.37 0.37
S03 100 99.79 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the four DNA samples was 0.1, 1, 10 and 100%. 
Figure 3: I I I  Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2V617F mutation percentage boxplot for each of the 4 DNA samples. Red dots are expected values.
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approach (2 “in-house” and 1 commercial assays), 7 
performed only a qualitative evaluation (1 “in-house” 
and 3 commercial assay) of JAK2V617F mutation whereas 2 
laboratories used both qualitative and quantitative 
approaches (2 “in-house” an  1 commercial assays). 
Regarding real-ti e PCR instruments used during the 
study: most (13 out of 19) of the laboratories used Applied 
Biosystem platforms (ABI7300/7500/7900; Applied 
Biosystem, Foster City, CA, USA); two laboratories used 
a Lightcycler LC480 platform (Roche Applied Science, 
Penzberg, Germany), and the remaining four laborat ries 
used a Rotor-Gene Q 2plex/MDx 5plex HRM instrument 
(QIAGEN GmbH, Hilden, Germany) (Table 4). 
I  Round
In the I round, we aimed to investigate the inter-
laboratory variability on different mutation loads. In this 
firt  step, seven laboratories were involved (Center 1–7). 
Four of them routinely performed quantitative analysis of 
JAK2V617F with ipsogen JAK2 MutaQuant Kit (QIAGEN), 
two used a qualitative approach for JAK2V617F evaluation 
(1 “in-house” method, 1 ipsogen JAK2 MutaScreen Kit 
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samples was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) 
and 20% (DNA 4), as previously quantified  by Bologna’s 
laboratory with ipsogen JAK2 MutaQuant Kit.
All patients provided an informed written consent in 
accordance with the Declaration of Helsinki for the use of 
remnant DNA for investigational purposes. The study was 
approved by the local Ethics Committee. 
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To further investigate the inter-laboratory variability 
on low-positive samples, a II round was developed. The 
two main objectives of this round were to assess inter-
laboratory variability across the 10 participating clinical 
centers and to compare the low-positive sample detection 
ability of the ipsogen JAK2 MutaQuant kit with the JAK2 
validated “in-house” methods. Compared to the first round, 
three additional centers (Centers 8–10) were included 
in this step: only Center 8 and 10 routinely performed 
JAK2V617F evaluation (1 with a qualitative and 1 with a 
quantitative method, respectively). Eight DNA test samples 
(DNA Samples A-H) were manufactured by QIAGEN and 
wer  centrally distributed by Werfen. The DNA samples 
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S02 0.1 0.07 0.11 0.27 0.46
S04 1 0.64 1.05 4.90 0.77
S01 10 6.67 10.04 24.37 0.37
S03 100 99.79 99.92 99.97 0.0005
The expected JAK2V617F mutation burden of the four DNA samples was 0.1, 1, 10 and 100%. 
Figure 3: I I I  Round. ipsogen JAK2 MutaQuant kit Copy number (CN) boxplot of JAK2 wild-type (WT), JAK2 mutated (V617F) and 
JAK2V617F mutation percentage boxplot for each of the 4 DNA samples. Red dots are expected values.
 
96 
DISCUSSION AND CONCLUSIONS  
In this study we demonstrated that a qualitative approach is not sensitive enough to 
detect JAK2V617F mutation at low mutation burden (i.e. < 1%). Conversely, the quantitative 
approach proved to be highly efficient and sensitive, although a modest variability was observed 
between all participating centers, both in the II and in the III round (CV = 0.42 and 0.46, 
respectively). Interestingly, only the qualitative ARMS-PCR methods (both “in-house” and ipsogen 
JAK2 MutaSearch kit) and the quantitative approach were able to detect the positivity of samples 
with and AB of 1%. An acceptable variability was observed at this AB in the II round (CV = 0.24) 
whereas a higher inter-laboratory variability was registered in the III one (CV = 0.77). With regard 
to samples with AB > 1%, a lower inter-laboratory variability was observed, as demonstrated by 
CV which ranges from a minimum of 0.0005 to a maximum of 0.38.  
Overall, the quantitative ipsogen JAK2 MutaQuant kit assay performed consistently across 
different platforms, affirming itself as a robust method to obtain comparable results. This is 
confirmed by optimal amplification efficiency obtained from each laboratory involved in the 
study. Indeed, the mean efficiency obtained in this study was of 92% with a CV of 0.065. The 
observed variability can be explained with both differences in laboratory experience in JAK2V617F 
quantitative determination and intrinsic instrumental bias, as happened in our study, with some 
laboratories experiencing technical issues. This, together with the variability observed at low AB 
samples, highlights the need for the standardization of practices, including both pre-analytical 
and analytical phases. To this aim, the WHO 1st International Reference Panel for Genomic JAK2 
V617F (WHO document WHO/ BS/2016.2293) was established in 2016 by the Expert Committee 
on Biological Standardization of the World Health Organization [40]. The availability of JAK2V617F 
primary standards should improve the quality of MPN genomic diagnostics by enabling the 
calibration of assays and kits, and the derivation of secondary standards for routine diagnostic 
use in determining testing accuracy and sensitivity, thus providing inter-laboratory comparison 
towards the harmonization of JAK2V617F testing.  
Moreover, we are considering evaluating digital PCR (dPCR). This emerging technology 
may improve the ability to detect rare mutations and/or low-positive samples due to higher 
sensitivity and precision, especially during follow-up to assess minimal residual disease or to 
monitor patients post alloHSCT [41–42]. But further studies are needed on this technology to 
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reach the level of standardization of real-time qPCR.  
In conclusion, this study sets the basis for the standardization of molecular techniques for 
JAK2V617F determination which will require the employment of approved operating procedures 
and the use of certificated standards to calibrate JAK2V617F quantitative assays.  
 
MATERIALS AND METHODS  
The study was conceived in 3 different rounds, in which 19 Italian laboratories were 
employed. Centers 9 and 16 did not perform JAK2V617F molecular testing in their routine. Of the 
remaining centers, 8 used only a quantitative approach (2 “in-house” and 1 commercial assays), 
7 performed only a qualitative evaluation (1 “in-house” and 3 commercial assay) of JAK2V617F 
mutation whereas 2 laboratories used both qualitative and quantitative approaches (2 “in-house” 
and 1 commercial assays). Regarding real-time PCR instruments used during the study: most (13 
out of 19) of the laboratories used Applied Biosystem platforms (ABI7300/7500/7900; Applied 
Biosystem, Foster City, CA, USA); two laboratories used a Lightcycler LC480 platform (Roche 
Applied Science, Penzberg, Germany), and the remaining four laboratories used a Rotor-Gene Q 
2plex/MDx 5plex HRM instrument (QIAGEN GmbH, Hilden, Germany) (Table 4).  
 
I Round  
In the I round, we aimed to investigate the inter- laboratory variability on different 
mutation loads. In this first step, seven laboratories were involved (Center 1–7). Four of them 
routinely performed quantitative analysis of JAK2V617F with ipsogen JAK2 MutaQuant Kit 
(QIAGEN), two used a qualitative approach for JAK2V617F evaluation (1 “in-house” method, 1 
ipsogen JAK2 MutaScreen Kit-QIAGEN) whereas one laboratory (Center 5) assessed both 
qualitative and quantitative assays. Each center had to test four DNA samples (DNA 1–4) with the 
method routinely employed in their own laboratory. DNA samples were isolated from 
granulocytes of patients with diagnosis of MPNs. The expected mutation burden of the 4 DNA 
samples was 0.005 (DNA 1), 0.15 (DNA 2), 5 (DNA 3) and 20% (DNA 4), as previously quantified by 
Bologna’s laboratory with ipsogen JAK2 MutaQuant Kit.  
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All patients provided an informed written consent in accordance with the Declaration of 
Helsinki for the use of remnant DNA for investigational purposes. The study was approved by the 
local Ethics Committee.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Summary of participating centers, methods used in their routine practice for 
JAK2V617F detection and instrumentation used in their routine and/or in the study (specified 
when different). 
*Fast mode was not used, as the ipsogen JAK2 MutaQuant kit is not compatible with “Fast” mode.  
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blindly test the DNA samples in four different runs: 2 runs 
were performed with the ipsogen JAK2 MutaQuant kit 
and 2 runs with their validated qualitative or quantitative 
method. The expected mutation burden of the DNA 
samples was 0, 0.1, 1, 10, 20, 50 and 100%. 
I I I  Round
The III round was intended to confirm the robustness 
of the ipsogen JAK2 MutaQuant kit. Qualitative methods 
were therefore excluded and the study was extended to 9 
additional laborator es (Cente s 11–19). Centers 12, 13 and 
17 routinely assessed quantitative evaluation of JAK2V617F 
mutation (2 “in-house” and 1 commercial methods), 4 
laboratories (Centers 11, 15, 18 and 19) used qualitative 
assays (1 “ n-house” and 1 commercial method ), Center 
14 performed both qualitative (“in-house”) and quantitative 
(ipsogen JAK2 MutaQuant kit) analysis whereas Center 16 
did not perform JAK2V617F molecular testing in its routine. 
Four DNA test samples (DNA Samples S01-S04), provided 
Table 4: Summary of participating centers, methods used in their routine practice for JAK2V617F 
detection and instrumentation used in their routine and/or in the study (specified  when di ffer ent)
ID Center Method Instrumentation
1 Quantitative ipsogen JAK2 MutaQuant kit
Applied Biosystem 7900HT Fast* Real-Time PCR 
System
2 Quantitative ipsogen JAK2 MutaQuant kit Applied Biosystems 7300 Real-Time PCR System
3 Quantitative ipsogen JAK2 MutaQuant kit
Rotor-Gene Q 2plex HRM System
Rotor-Gene Q MDx 5plex HRM System (3rd 
Round)
4 Quantitative ipsogen JAK2 MutaQuant kit Applied Biosystems 7300 Real-Time PCR System
5
Qualitative
home-made
Quantitative
ARMS PCR (Chen et al., 2007) [30]
ipsogen JAK2 MutaQuant kit
7500 Real Time PCR System Life Technologies
6
Qualitative 
home-made
Allele-specificPCR
(Baxter et al, Lancet 2005) [25]
LightCycler 480
(2nd and 3rd Round)
7 Qualitative ipsogen JAK2 MutaSearch Applied Biosystems 7300 Real-Time PCR System
8 Qualitative AB Analitica GeneQuality JAK-2 kit Applied Biosystems 7300 Real-Time PCR System
9 N.A. N.A.
LightCycler 480 
(2nd and 3rd Round)
10 Quantitative ipsogen JAK2 MutaQuant kit
Applied Biosystems 7500 Fast* Real-time PCR 
System
11
Qualitative 
home-made
Allele-specific
 
PCR
(Baxter et al, Lancet 2005) [25]
Rotor-Gene Q MDx 5plex HRM (3rd Round) 
12 Quantitative ipsogen JAK2 MutaQuant kit Rotor-Gene Q MDx 5plex HRM 
13
Quantitative 
home-made
Allele-specific
 
primers (0,1-25%) Allele-
specific
 
hydr ol ys i s pr obes (10–90%)
ABI PRISM 7900 HT
Real-Time PCR System
14
Qualitative 
home-made
Quantitative
Allele-specific
 
PCR 
(Baxter et al, Lancet 2005) [25]
ipsogen JAK2 MutaQuant kit
Applied Biosystems 7500 Real-time PCR System
15 Qualitative ipsogen JAK2 MutaScreen Applied Biosystems 7500 Fast* Dx PCR System
16 N.A. N.A.
Applied Biosystems 7500 Fast* Real-time PCR 
System
17
Quantitative 
home-made
Allele-specific
 
PCR
(Søren Germer et al, Genome Res. 2000)
ABI PRISM 7900 HT SDS
18 Qualitative ipsogen JAK2 MutaScreen Applied Biosystems 7500 Real-time PCR System
19 Qualitative ipsogen JAK2 MutaScreen
StepOnePlus Real-Time PCR System
Rotor-Gene Q MDx 5plex HRM (3rd Round)
*Fast mode was not used, as the ipsogen JAK2 MutaQuant kit is not compatible with “Fast” mode.
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II Round  
To further investigate the inter-laboratory variability on low-positive samples, a II round 
was developed. The two main objectives of this round were to assess inter- laboratory variability 
across the 10 participating clinical centers and to compare the low-positive sample detection 
ability of the ipsogen JAK2 MutaQuant kit with the JAK2 validated “in-house” methods. Compared 
to the first round, three additional centers (Centers 8–10) were included in this step: only Center 
8 and 10 routinely performed JAK2V617F evaluation (1 with a qualitative and 1 with a quantitative 
method, respectively). Eight DNA test samples (DNA Samples A-H) were manufactured by QIAGEN 
and were centrally distributed by Werfen. The DNA samples were derived from dilution of cell 
lines: K562 (JAK2V617F negative) and MUTZ-8 (JAK2V617F positive). The ipsogen JAK2 MutaQuant 
kits and associated master-mix were provided by QIAGEN and Werfen. Each center had to blindly 
test the DNA samples in four different runs: 2 runs were performed with the ipsogen JAK2 
MutaQuant kit and 2 runs with their validated qualitative or quantitative method. The expected 
mutation burden of the DNA samples was 0, 0.1, 1, 10, 20, 50 and 100%. 
 
III Round  
The III round was intended to confirm the robustness of the ipsogen JAK2 MutaQuant kit. 
Qualitative methods were therefore excluded and the study was extended to 9 additional 
laboratories (Centers 11–19). Centers 12, 13 and 17 routinely assessed quantitative evaluation of 
JAK2V617F mutation (2 “in-house” and 1 commercial methods), 4 laboratories (Centers 11, 15, 18 
and 19) used qualitative assays (1 “in-house” and 1 commercial methods), Center 14 performed 
both qualitative (“in-house”) and quantitative (ipsogen JAK2 MutaQuant kit) analysis whereas 
Center 16 did not perform JAK2V617F molecular testing in its routine. Four DNA test samples (DNA 
Samples S01-S04), provided from the same batches as II round’s DNA Samples, were centrally 
distributed by Werfen. The ipsogen JAK2 MutaQuant kits and associated master-mix were 
provided by QIAGEN and Werfen. Each laboratory had to blindly test the DNA samples in 2 runs 
with the ipsogen JAK2 MutaQuant kit. The expected mutation burden of the four DNA samples 
was 0.1, 1, 10 and 100%. 
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 Moreover, amplification efficiency (E) was calculated from the slope of the standard curve 
using the following formula: E = 10-1/slope. Amplification efficiency was expressed as a percentage, 
that is the percent of template that was amplified in each cycle. To convert E into a percentage 
we used the following formula: % Efficiency = (E – 1) × 100%.  
Data collection and run validity check  
Raw data were collected and run validity was checked according to manufacturer’s 
instructions in the kit’s handbook.  
Statistical method  
Statistical analysis was carried out by QIAGEN and by Bologna University. Wild type and 
mutation copy numbers together with mutation percentage were summarized by mean, median, 
first and third quartiles, standard deviation and coefficient of variation and plotted by sample for 
the ipsogen JAK2 MutaQuant kit.  
Inter-laboratory variability: II round  
Fisher test was performed by sample to compare variance in order to conclude on the 
acceptability of the inter-laboratory variability.  
Inter-laboratory variability: III round  
Shapiro-Wilk normality test was performed to check for data normality and quantile-
quantile normal plots were employed for data visual inspection. Kruskall-Wallis test was applied 
and multiple comparison post-hoc test (Wilcoxon test) was carried out to identify the significant 
differences. False discovery rate correction was applied to avoid increase in type I error (false 
positive) because of multiple testing following the Benjamini and Hochberg procedure.  
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ABSTRACT 
Along with molecular abnormalities (mutations in JAK2, Calreticulin (CALR) and MPL 
genes), chronic inflammation is the major hallmark of Myelofibrosis (MF). Here, we investigated 
the in vitro effects of crucial factors of the inflammatory microenvironment (Interleukin (IL)-1β, 
Tumor Necrosis Factor (TNF)-α, Tissue Inhibitor of Metalloproteinases (TIMP)-1 and ATP) on the 
functional behaviour of MF-derived circulating CD34+ cells. 
We found that, regardless mutation status, IL-1β or TNF-α increases the survival of MF-
derived CD34+ cells. In addition, along with stimulation of cell cycle progression to the S-phase, 
IL-1β or TNF-α ± TIMP-1 significantly stimulate(s) the in vitro clonogenic ability of CD34+ cells from 
JAK2V617F mutated patients. Whereas in the JAK2V617F mutated group, the addition of IL-1β or TNF-
α + TIMP-1 decreased the erythroid compartment of the CALR mutated patients. Megakaryocyte 
progenitors were stimulated by IL-1β (JAK2V617F mutated patients only) and inhibited by TNF-α. 
IL-1β + TNF-α + C-X-C motif chemokine 12 (CXCL12) ± TIMP-1 highly stimulates the in vitro 
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migration of MF-derived CD34+ cells. Interestingly, after migration toward IL-1β + TNF-α + CXCL12 
± TIMP-1, CD34+ cells from JAK2V617F mutated patients show increased clonogenic ability. 
Here we demonstrate that the interplay of these inflammatory factors promotes and 
selects the circulating MF-derived CD34+ cells with higher proliferative activity, clonogenic 
potential and migration ability. Targeting these micro-environmental interactions may be a 
clinically relevant approach. 
 
INTRODUCTION  
Myelofibrosis (MF) is a life-threatening chronic myeloproliferative neoplasia (MPN) of the 
hematopoietic stem/progenitor cell (HSPC) clinically characterized by progressive anemia, 
splenomegaly and constitutional symptoms and by an increased risk to develop acute leukemia 
(AL). It can arise de novo (primary MF; PMF) or can evolve from Polycythemia Vera (PV; PPV MF) 
or Essential Thrombocythemia (ET; PET MF) [1–3].  
Approximately 50 to 60% of MF patients carry a mutation in the Janus kinase 2 (JAK2) 
gene, while 20–25% of patients show recurrent mutations in the Calreticulin (CALR) and an 
additional 5 to 10% have activating mutations in the myeloproliferative leukemia virus oncogene 
(MPL) gene. Around 10% of patients have non-mutated JAK2, MPL and CALR genes (“triple 
negative”). Regardless of molecular status, all patients have a deregulation in the JAK/STAT 
signalling [4–9].  
Besides molecular abnormalities, the inflammatory microenvironment has emerged in the 
last few years as a key-player in MF pathogenesis [10]. Abnormal expression and activity of several 
cytokines involved in inflammation and immunoregulation are associated with MF [11] and 
correlate with more severe marrow fibrosis [12, 13], worsening systemic symptoms [14] and 
decreased survival [15]. Also, the constitutive mobilization of CD34+ cells into the peripheral 
blood has been associated with profound alterations in the CXC chemokine receptor 4 (CXCR4)/ 
C-X-C motif chemokine 12 (CXCL12) axis [16–18]. Up-regulated production of proinflammatory 
cytokines by HSPCs and surrounding stromal cells generates a microenvironment that selects for 
the malignant clone [11, 19–23].  
Interestingly, HSPCs actively sense pro-inflammatory factors [24]. However, the key 
players linking inflammation and cancer in MF are still to be defined. Particularly, the plasma 
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levels of Interleukin (IL)-1β, Tumor Necrosis Factor (TNF)-α and Tissue Inhibitor of 
Metalloproteinases (TIMP)-1 are increased in MF patients [5, 15, 25], but their contribution to 
disease pathogenesis in MF has been poorly [26] or never investigated. This is also true for the 
extracellular ATP nucleotide [27]. Under inflammatory conditions, IL-1β stimulates leukocytosis 
and thrombocytosis by inducing various cytokines (i.e. Granulocyte-Colony Stimulating Factor, IL-
6) that are overexpressed in MF; also, IL-1β regulates the survival/proliferation of AL cells [27–
30]. IL-1β has been recognized as the main trigger for neural damage and Schwann cell death 
caused by bone marrow mutant HSPC. Notably, mutant-HSPC- driven niche damage seems to 
critically contribute to MPN pathogenesis [31]. TNF-α promotes survival of human quiescent bone 
marrow-derived CD34+ Burst Forming Unit-Erythrocyte (BFU-E) and facilitates the clonal 
expansion of JAK2V617F -positive cells in MPNs [26,32]. TIMP-1, through receptor (CD63) binding, 
promotes cell survival, differentiation and migration; also, TIMP-1 displays cytokine-like features 
in the HSPC compartment [33–35]. It was initially found to enhance the proliferation of erythroid 
cells [36]; also, we recently demonstrated that TIMP-1 increases the clonogenic efficiency of 
normal CB-derived progenitor cells [37]. Finally, extracellular nucleotides, mainly ATP, are 
important mediators in inflammation and modulation of cell proliferation, migration and death, 
including AL CD34+ stem/progenitor cells [24, 37–41].  
Here, we addressed the functional effects of these pro-inflammatory factors on the in vitro 
behaviour of HSPCs derived from MF patients, with the aim to investigate their putative role in 
disease pathogenesis. 
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RESULTS 
Regardless of mutational status, the plasma levels of IL-1β, TNF-α and TIMP-1 are increased in 
MF patients  
To evaluate the pro-inflammatory pro le, selected plasma cytokines were measured. 
Compared with controls, IL-1β, TNF-α and TIMP-1 plasma levels were significantly increased in 
MF patients (regardless of IPSS risk stratification values) (Figure 1A, 1B, 1C). We found a trend, 
albeit not statistically significant (p = 0.06), toward increased IL-1β plasma levels in CALR mutated 
patients. Targeting TNF-α and TIMP-1, no significant differences were observed between 
JAK2V617F and CALR mutated groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Regardless mutation status, the plasma levels of IL-1β, TNF-α and TIMP-1 are increased 
in MF patients. IL-1β (A), TNF-α (B) and TIMP-1 (C) plasma levels were measured by ELISA in MF 
patients. (n = 26; JAK2V617F positive n =16; CALR positive n = 10) and healthy controls (n = 15). 
Compared with controls, cytokines plasma levels were significantly increased in MF patients. Of 
note, there was no signi cant difference between JAK2V617F or CALR mutated patients. All data are 
presented as mean ± SEM (**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001). 
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Survival of CD34+ cells from MF patients is 
increased by IL-1β and TNF-α
To investigate whether inflam ma t or y signals may 
regulate the survival of HSPCs, CD34+ cells from MF 
patients or CB were in vitro cultured with the selected 
pro-infla
m
ma t or y factors, alone or in combination, at 
concentrations previously shown to be effective in dose-
response experiments (Supplementary Figure 1). 
We firstly assessed the effects of factors alone on the 
in vitro survival of CD34+ cells. As shown in Figure 3A, the 
survival of CD34+ cells from MF patients was significantly 
promoted by IL-1β or TNF-α as compared with the CB 
CD34+ cells (p ≥ 0.01 and p ≥ 0.05, respectively) or with the 
untreated MF cells (p ≥  0.001 and p ≥  0.01,  respectively). No 
significant differences in survival were observed between the 
two mutated groups in all tested conditions (data not shown).
As shown in Supplementary Figure 2, the 
combinations of factors two-by-two significantly promoted 
the MF-derived CD34+ cells survival as compared with 
untreated cells. However, no significant differences in cell 
viability were observed as compared with factors alone. 
Interestingly, the two by two combined factors did not 
signific
a
nt ly enhance the survival of CB-derived CD34+ 
cells, except for IL-1β + TNF-α (p ≥  0.01). Comparing MF 
vs CB-derived cells, the survival of MF CD34+ cells was 
signific
a
nt ly enhanced by IL-1β + TIMP-1 (p ≥  0.01) and 
IL-1β + ATP (p ≥0.01).
When multiple factors were combined no significa nt  
differences were observed between MF and CB-derived 
CD34+ cells. Only TNF-α + TIMP-1 + ATP signific
a
nt ly 
promoted the survival of JAK2V617F CD34+ cells as 
compared with the CALR (p ≥  0.01) or CB counterparts 
(p ≥ 0.001) (data not shown).
Figure 1: Regardless mutation status, the plasma levels of IL-1β, TNF-α and TIMP-1 are increased in MF patients. 
IL-1β (A), TNF-α (B) and TIMP-1 (C) plasma levels were measured by ELISA in MF patients. (n = 26; JAK2V617F positive n =16; CALR 
positive n = 10) and healthy controls (n = 15). Compared with controls, cytokines plasma levels were significa nt ly increased in MF patients. 
Of note, there was no signific
a
nt  difference between JAK2V617F or CALR mutated patients. All data are presented as mean ± SEM (**p ≤ 0.01; 
***p ≤ 0.001; ****p ≤ 0.0001).
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Selected subsets of circulating HSPCs are expanded in MF patients  
To determine the extent of the circulating HSPCs compartment according to mutations, 
we phenotypically analyzed the whole blood of MF patients.  
Irrespective of mutation status, the mean number of circulating CD34+ cells was 
significantly higher in MF patients than in controls (p ≤ 0.0001). No significant differences were 
observed between the two mutated groups (Figure 2A). Of note, the number of CD34+ cells 
correlated with IPSS risk in JAK2V617F mutated patients (r = 0.88; p = 0.02; data not shown).  
Along with CD34+CD38- and CD34+CD133+ cells (Figure 2B, 2C), circulating CD34+ cells co- 
expressing adhesion molecules (CD49d, CD47 and CD44; Figure 2D–2F) were also significantly 
increased in MF patients. Once again, no significant difference was observed between the two 
mutated groups.  
The median number of circulating MF-derived CD34+ cells co-expressing the TIMP-1 
(CD63) or the CXCL12 receptor (CD184; CXCR4) was significantly higher (p ≤ 0.001 and p ≤ 0.01, 
respectively) than the CB counterparts (Figure 2G, 2H). CALR mutated patients showed increased 
number of circulating CD34+CD63+ and CD34+CD184+ cells compared to JAK2V617F mutated 
patients (p ≤ 0.01 for CD34+CD63+) or the CB-counterparts (p ≤ 0.01 and p ≤ 0.05, respectively). 
CD34+CD63+ cells of JAK2V617F mutated patients were also increased compared with the CB- 
derived cells (p ≤ 0.05).  
As shown in Figure 2I, circulating megakaryocyte (MK) progenitors (CD34+CD41+) were 
also significantly increased (p ≤ 0.01). CALR mutated patients showed increased number of 
CD34+CD41+ cells compared to JAK2V617F mutated patients (p ≤ 0.01 ) or the CB-counterparts (p 
≤ 0.001).  
Of note, except of the decreased expression of CD184 in MF cells, the analysis of mean 
fluorescence intensity (MFI) of CD133, CD63,CD41, CD49d, CD44 and CD47 antigens on the CD34+ 
cells did not reveal any difference between patients and controls or between the two mutated 
groups (data not shown).  
These data demonstrate that in MF, irrespective of mutation status, there is an in vivo 
expansion of the HSPCs compartment. However, the CALR mutated patients show an increased 
number of circulating CD34+CD63+ and CD34+CD41+ cells compared to the JAK2V617F mutated 
counterparts. 
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Figure 2: Selected subsets of circulating HSPCs are expanded in MF patients. The circulating 
absolute number of MF (total (n = 30) and subdivided into JAK2V617F (n = 20) or CALR (n = 10) 
mutated groups) and CB (n = 10) CD34+ cells coexpressing the CD133, CD49d, CD47, CD44, CD63, 
CD184 and CD41 antigens together with the CD34+ CD38− subset are shown (A–I). All subsets 
were increased in MF patients as compared with the CB counterparts. No significant differences 
were observed between the two mutated groups, except the CD34+ CD63+ and the CD34+ CD41+ 
cells of CALR mutated patients which were significantly increased as compared with the JAK2V617F 
counterparts. All data are presented as mean ± SEM (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p 
≤ 0.0001). 
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When we analyzed the CD34+ CD38- cells 
(Figure 3B), we found that multiple factors combinations 
(particularly those including IL-1β) significantly 
stimulated the cell survival of MF and CB-derived 
cells as compared with untreated cells. However, no 
signific
a
nt  differences were observed between patients/
controls (Figure 3B) or the two mutated groups (data 
not shown)
Taken together these data demonstrate that, 
regardless of mutation status, the survival of MF-derived 
CD34+ cells is highly stimulated by the in vitro treatment 
with IL-1β or TNF-α.  Combinations of pro-infla
m
ma t or y 
factors do not have synergistic effects. 
Clonogenic output of circulating MF-derived 
CD34+ cells is positively enhanced by IL-1β + 
TNF-α ± TIMP-1 combinations 
To analyse the functional role of the selected pro-
infla
m
ma t or y cytokines on HSPCs, we investigated their 
effects on the clonogenic output of circulating MF and 
CB-derived CD34+ cells. 
Figure 2: Selected subsets of circulating HSPCs are expanded in MF patients. The circulating absolute number of MF 
(total (n = 30) and subdivided into JAK2V617F (n = 20) or CALR (n = 10) mutated groups) and CB (n = 10) CD34+ cells coexpressing the 
CD133, CD49d, CD47, CD44, CD63, CD184 and CD41 antigens together with the CD34+ CD38− subset are shown (A–I ). All subsets were 
increas d in MF patients as compared with the CB ounterparts. No significnt  differences were observed between the two mutat d groups, 
except the CD34+ CD63+ and the CD34+ CD41+ cells of CALR mutated patients which were significa nt ly increased as compared with the 
JAK2V617F counterparts. All data are presented as mean ± SEM (*p ≥ 0.05; **p ≥ 0.01; ***p ≥ 0.001; ****p ≥ 0.0001).
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Survival of CD34+ cells from MF patients is increased by IL-1β and TNF-α  
To investigate whether inflammatory signals may regulate the survival of HSPCs, CD34+ 
cells from MF patients or CB were in vitro cultured with the selected pro-inflammatory factors, 
alone or in combination, at concentrations previously shown to be effective in dose-response 
experiments (Supplementary Figure 1).  
We firstly assessed the effects of factors alone on the in vitro survival of CD34+ cells. As 
shown in Figure 3A, the survival of CD34+ cells from MF patients was significantly promoted by 
IL-1β or TNF-α as compared with the CB CD34+ cells (p ≤ 0.01 and p ≤ 0.05, respectively) or with 
the untreated MF cells (p ≤ 0.001 and p ≤ 0.01, respectively). No significant differences in survival 
were observed between the two mutated groups in all tested conditions (data not shown).  
As shown in Supplementary Figure 2, the combinations of factors two-by-two significantly 
promoted the MF-derived CD34+ cells survival as compared with untreated cells. However, no 
significant differences in cell viability were observed as compared with factors alone. 
Interestingly, the two by two combined factors did not significantly enhance the survival of CB-
derived CD34+ cells, except for IL-1β + TNF-α (p ≤ 0.01). Comparing MF vs CB-derived cells, the 
survival of MF CD34+ cells was significantly enhanced by IL-1β + TIMP-1 (p ≤ 0.01) and IL-1β + ATP 
(p ≤ 0.01).  
When multiple factors were combined no significant differences were observed between 
MF and CB-derived CD34+ cells. Only TNF-α + TIMP-1 + ATP significantly promoted the survival of 
JAK2V617F CD34+ cells as compared with the CALR (p ≤ 0.01) or CB counterparts (p ≤ 0.001) (data 
not shown). 
When we analyzed the CD34+ CD38- cells (Figure 3B), we found that multiple factors 
combinations (particularly those including IL-1β) significantly stimulated the cell survival of MF 
and CB-derived cells as compared with untreated cells. However, no significant differences were 
observed between patients/ controls (Figure 3B) or the two mutated groups (data not shown) 
Taken together these data demonstrate that, regardless of mutation status, the survival 
of MF-derived CD34+ cells is highly stimulated by the in vitro treatment with IL-1β or TNF-α. 
Combinations of pro-inflammatory factors do not have synergistic effects. 
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Clonogenic output of circulating MF-derived CD34+ cells is positively enhanced by IL-1β + TNF-
α ± TIMP-1 combinations 
To analyze the functional role of the selected pro-inflammatory cytokines on HSPCs, we 
investigated their effects on the clonogenic output of circulating MF and CB-derived CD34+ cells. 
Factors alone did not induce a significant CFU-C growth from MF CD34+ cells (data not 
shown). However, when MF-derived CD34+ cells were tested in the presence of combinations of 
factors two-by-two, the IL-1β + TIMP-1 combination was the only one effective in stimulating the 
CFU-C growth as compared with untreated cells (p ≤ 0.05) or CB-derived CD34+ cells (p ≤ 0.05) 
(Figure 4A). IL-1β + TNF-α and IL-1β + TIMP-1 significantly promoted the BFU-E growth of the MF- 
derived CD34+ cells as compared with the untreated samples and the CB counterparts. The CFU-
GM growth was positively enhanced by IL-1β + TIMP- 1 (Supplementary Figure 3A, 3B). Of note, 
when combinations of multiple factors were tested, only IL-1β + TNF-α + TIMP-1 significantly 
promoted the CFU-C growth (p ≤ 0.05) of CD34+ cells from CB (data not shown).  
As shown in Figure 4B, when the growth of MK progenitors was investigated in the 
presence of inflammatory factors alone, we found that, at variance with CB, the MF-derived CFU-
MK growth was significantly inhibited by TNF-α. By contrast, IL-1β has stimulatory activity on MK 
colony formation. Factors in combination did not significantly modify the growth of patients/CB 
pure CFU-MK as compared with factors alone.  
We also examined the cell-cycle pro le of MF- derived and CB-derived CD34+ cells after in 
vitro exposure to the cytokines. We found that most of the untreated CD34+ cells from MF 
patients were in a dormant state. Factors alone did not significantly increased the percentage of 
CD34+ cells in S phase as compared with untreated cells, both in MF patients and CB (data not 
shown). Conversely, in MF patients, irrespective of mutation status, cell-cycle progression was 
observed in presence of various cytokines combinations, with the notable exception of ATP + TNF-
α + TIMP-1 (Figure 4C, 4D). 
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Figure 3: Survival of CD34+ cells from MF patients is increased by IL-1β and TNF-α. (A) CD34+ 
cells from MF patients (n = 20) or CB (n = 8) were in vitro treated for 4 days with factors alone and 
the percentage of cell viability was assessed after Annexin V/PI staining, as described in Methods. 
At variance with CB-derived cells, TNF-α and IL-1β alone significantly stimulated the survival of 
MF-derived CD34+ cells as compared with untreated cells and the CB-derived counterparts. 
Conversely, ATP and TIMP-1 were ineffective in normal and diseased cells.(B) In selected 
experiments, before Annexin V/PI staining, MF- (n = 10) and CB- (n = 6) derived CD34+ cells were 
also labeled with a MoAb against the human CD38 antigen and the CD34+ CD38− cells were gated 
and cell viability was analyzed. Once again, multiple combinations of cytokines with IL-1β or TNF-
α significantly stimulated the survival of MF- and CB-derived CD34+ CD38− cells. Notably, this was 
not true for ATP+ TNF-α+ TIMP-1. No differences were observed between MF patients and CB. All 
data are presented as mean ± SEM. (**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 vs untreated cells 
(CTR)) (#p ≤ 0.05; ##p ≤ 0.01 vs CB). 
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Factors alone did not induce a significnt  CFU-C 
growth from MF CD34+ cells (data not shown). However, 
when MF-derived CD34+ cells were tested in the presence 
of combinations of factors two-by-two, the IL-1β + TIMP-1 
combination was the only one effective in stimulating 
the CFU-C growth as compared with untreated cells 
(p ≤ 0.05) or CB-derived CD34+ cells (p ≤ 0.05) 
(Figure 4A). IL-1β + TNF-α and IL-1β + TIMP-1 
signific
a
nt ly promoted the BFU-E growth of the MF-
derived CD34+ cells as compared with the untreated 
samples and the CB counterparts. The CFU-GM 
growth was positively enhanced by IL-1β + TIMP- 1 
(Supplementary Figure 3A, 3B). Of note, when 
combinations of multiple factors were tested, only IL-1β + 
TNF-α + TIMP-1 signific
a
nt ly promoted the CFU-C 
growth (p ≤ 0.05) of CD34+ cells from CB (data not 
shown).  
As shown in Figure 4B, when the growth of 
MK progenitors was investigated in the presence of 
infla
m
ma t or y factors alone, we found that, at variance with 
CB, the MF-derived CFU-MK growth was significa nt ly 
inhibited by TNF-α. By contrast, IL-1β has stimulatory 
activity on MK colony formation. Factors in combination 
did not signific
a
nt ly modify the growth of patients/CB 
pure CFU-MK as compared with factors alone.
We also examined the cell-cycle profile of MF-
derived and CB-derived CD34+ cells after in vitro exposure 
to the cytokines. We found that most of the untreated 
CD34+ cells from MF patients were in a dormant state. 
Factors alone did not significantly increased the percentage 
of CD34+ cells in S phase as compared with untreated cells, 
both in MF patients and CB (data not shown).  Conversely, 
in MF patients, irrespective of mutation status, cell-cycle 
progression was observed in presence of various cytokines 
combinations, with the notable exception of ATP + TNF-α + 
TIMP-1 (Figure 4C, 4D).
Opposite effects of pro-inflam ma t ory cyt oki nes 
on clonogenic potential of CD34+ cells from 
JAK2V617F or CALR mutated patients
When clonogenic potential was analysed 
according to mutation status and in the presence of pro-
infla
m
ma t or y factors alone, no differences were observed 
between the two mutated groups. Colony composition 
analysis demonstrated that only IL-1β enhanced the 
erythroid compartment of the JAK2V617F mutated group 
(Supplementary Figure 4A and 4B).
By contrast, (Figure 5A), the combination of IL-1β 
+ TIMP-1 and IL-1β + TNF-α signific
a
nt ly promoted the 
CFU-C growth of JAK2V617F mutated patients compared 
with the CALR mutated counterparts. Similar results 
were obtained when CFU-GM and BFU-E growth were 
distinctly analysed (data not shown). 
When colony composition was analysed according 
to mutation status (Figure 5B), both mutated groups 
showed reduced BFU-E growth of the untreated samples 
as compared with the CB counterparts. Interestingly, in 
the JAK2V617F mutated group, the addition of different 
combinations of pro-inflam ma t or y factors enhanced 
Figure 3: Survival of CD34+ cells from MF patients is increased by IL-1β and TNF-α. (A) CD34+ cells from MF patients 
(n = 20) or CB (n = 8) were in vitro treated for 4 days with factors alone and the percentage of cell viability was assessed after Annexin 
V/PI staining, as described in Methods. At variance with CB-derived cells, TNF-α and IL-1β alone significa nt ly stimulated the survival of 
MF-derived CD34+ cells as compared with untreated cells and the CB-derived counterparts. Conversely, ATP and TIMP-1 were ineffective 
in normal and diseased cells.(B) In selected experiments, before Annexin V/PI staining, MF- (n = 10) and CB- (n = 6) derived CD34+ cells 
were also labeled with a MoAb against he human CD38 antigen and the CD34+ CD38− cells were gated and cell viabil ty was analyz d. 
Once again, multiple combinations of cytokines with IL-1β or TNF-α significa nt ly stimulated the survival of MF- and CB-derived CD34+ 
CD38− cells. Notably, this was not true for ATP+ TNF-α+ TIMP-1. No differences were observed between MF patients and CB. All data are 
presented as mean ± SEM. (**p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 vs untreated ells (CTR)) (#p ≤ 0.05; ##p ≤ 0.01 s CB).
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Figure 4: Proliferation of circulating MF-derived CD34+ cells is positively enhanced by IL-1β + 
TNF-α ± TIMP-1 combinations. Circulating CD34+ cells were isolated from MF patients (n = 20) 
and CB units (n = 8) and cultured in the presence of the selected two-by-two pro-inflammatory 
factors. After 14 days, the total CFU-C output was assessed as described in Methods (A). 
Circulating CD34+ cells were isolated from MF patients (n =10) and CB units (n =8) and cultured 
in the presence or absence of inflammatory factors alone or combined. After 12 days, the CFU-
MK growth was assessed as described in Methods (B). The results are expressed as growth fold 
change versus untreated CTR samples. (A) The clonogenic output of the MF-derived CD34+ cells 
was significantly stimulated by the IL-1β + TIMP-1 combination as compared with untreated cells 
or the CB-derived counterparts. No other combinations of factors two-by- two were effective. 
The mean number of colonies in MF-derived and CB-derived untreated samples was 59 ± 8 and 
63 ± 6, respectively. (B) The MF-derived CFU-MK growth was significantly inhibited by TNF-α. By 
contrast, IL-1β has stimulatory activity on MK colony formation. Factors in combination did not 
significantly modify the growth of patients/CB CFU-MK as compared with factors alone. Factors 
alone or in combination did not significantly modify the CFU-MK growth of the CB counterparts. 
The mean number of CFU-MK in MF- and CB-derived untreated samples was 26 ± 11 and 46 ± 10, 
respectively. In (C and D) are shown the results of cell-cycle analysis of MF-derived (n =10) and 
CB-derived (n =8) CD34+ cells after in vitro incubation for 24 hours in the presence or absence of 
various combinations of pro-inflammatory factors. Results are expressed as the percentage of 
cells in different phases of the cell cycle. IL-1β plus TNF-α highly promote cell cycling of CD34+ 
cells from MF patients. IL-1β + TNF-α + TIMP-1 and IL-1β + TNF-α + TIMP-1 + ATP were also 
effective (C). Conversely, no significant differences were observed when CB-derived cells were 
analyzed (D). All data are presented as mean ± SEM. (*p ≤0.05; **p ≤0.01; ***p ≤0.001 vs 
untreated cells) (#p ≤0.05; ##p ≤0.01 vs CB). 
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derived HSPCs. Second, HSPCs from JAK2V617F show 
in vi tro enhanced proliferation over untreated cells and the 
CB counterparts in response to  IL-1β, TNF-α ± TIMP-1 
exposure (alone or, mostly, in combination). Accordingly, 
IL-1β + TNF-α stimulates cell cycle progression of 
MF-derived CD34+ cells to the S-phase. Third, IL-1β + 
TNF-α combination promotes the in vi tro migration of 
MF-derived HSPCs. Interestingly, after migration  toward 
IL-1β + TNF-α + CXCL12 ± TIMP-1, MF-derived CD34+ 
cells show increased clonogenic ability as compared with 
CXCL12 alone or the CB counterparts. This finding was 
mainly due to stimulation of the clonogenic growth of 
HSPCs from JAK2V617F mutated patients. 
TNF-α has already been shown to facilitate clonal 
expansion of JAK2V617F-positive cells in MF [26]. The 
results of this study provide new evidences that, in 
addition to TNF-α, IL-1β and TIMP-1 promote the in vitro 
maintenance of the HSPCs. 
Figure 4: Proliferation of circulating MF-derived CD34+ cells is positively enhanced by IL-1β + TNF-α ± TIMP-1 
combinations. Circulating CD34+ cells were isolated from MF patients (n =  20) and CB units (n = 8) and cultured in the presence of the 
selected two-by-two pro-inflam ma t o ry factors. After 14 days, the total CFU-C output was assessed as described in Methods (A). Circulating 
CD34+ cells were isolated from MF patients (n = 10) and CB units (n = 8) and cultured in the presence or absence of inflam ma t or y fact or s 
alone or combined. After 12 days, the CFU-MK growth was assessed as described in Methods (B). The results are expressed as growth 
fold change versus untreated CTR samples. (A) The clonogenic output of the MF-derived CD34+ cells was significa nt ly stimulated by the 
IL-1β + TIMP-1 combination as compared with untreated cells or the CB-derived counterparts. No other combinations of factors two-by-
two were effective. The mean number of colonies in MF-derived and CB-derived untreated samples was 59 ± 8 and 63 ± 6, respectively. 
(B) The MF-derived CFU-MK growth was significa nt ly inhibited by TNF-α. By contrast, IL-1β has stimulatory activity on MK colony 
formation. Factors in combination did n t significa nt ly modify the growth of patients/CB CFU-MK as compared with factors alone. 
Factors alone or in combination did not significa nt ly modify the CFU-MK growth of the CB counterparts. The mean number of CFU-MK 
in MF- and CB-derived untreated samples was 26 ± 11 and 46 ± 10, respectively.In (C and D ) are shown the results of cell-cycle analysis 
of MF-derived (n = 10) and CB-derived (n = 8) CD34+ cells after in vitro incubation for 24 hours in the presence or absence of various 
combinations of pro-inflam ma t or y factors. Results are expressed as the percentage of cells in different phases of the cell cycle. IL-1β plus 
TNF-α highly promote cell cycling of CD34+ cells from MF patients. IL-1β + TNF-α + TIMP-1 and IL-1β + TNF-α + TIMP-1 + ATP were 
also effective (C). Conversely, no significa nt  differences were observed when CB-derived cells were analysed (D). All data are presented 
as mean ± SEM. (*p ≥ 0.05; **p ≥ 0.01; ***p ≥ 0.001 vs untreated cells) (#p ≥ 0.05; ##p ≥ 0.01 vs CB).
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Opposite effects of pro-inflammatory cytokines on clonogenic potential of CD34+ cells from 
JAK2V617F or CALR mutated patients  
When clonogenic potential was analyzed according to mutation status and in the presence 
of pro-inflammatory factors alone, no differences were observed between the two mutated 
groups. Colony composition analysis demonstrated that only IL-1β enhanced the erythroid 
compartment of the JAK2V617F mutated group (Supplementary Figure 4A and 4B).  
By contrast, (Figure 5A), the combination of IL-1β + TIMP-1 and IL-1β + TNF-α significantly 
promoted the CFU-C growth of JAK2V617F mutated patients compared with the CALR mutated 
counterparts. Similar results were obtained when CFU-GM and BFU-E growth were distinctly 
analyzed (data not shown).  
When colony composition was analyzed according to mutation status (Figure 5B), both 
mutated groups showed reduced BFU-E growth of the untreated samples as compared with the 
CB counterparts. Interestingly, in the JAK2V617F mutated group, the addition of different 
combinations of pro-inflammatory factors enhanced the erythroid compartment as compared 
with untreated samples. Conversely, some cytokines combinations significantly decreased BFU-E 
growth in CALR-mutated patients.  
Multiple combinations did not significantly modify the clonogenic activity and colony 
composition of the two mutated groups (data not shown).  
When we analyzed the percentage of JAK2V617F and CALR mutant colonies in the absence 
or presence of IL- 1β + TNFα, we found that the percentage of JAK2V617F, but not CALR, mutated 
colonies was increased (data not shown).  
MK progenitors of JAK2V617F mutated patients were highly stimulated by IL-1β alone. By 
contrast, TNF-α significantly inhibited the CFU-MK growth of both JAK2V617F and CALR mutated 
patients as compared with CB counterparts (Supplementary Figure 5).  
Taken together these results demonstrate that the hemopoietic function of MF-derived 
CD34+ cells is highly promoted by the IL-1β or TNF-α ± TIMP-1 combinations, even though TNF-α 
alone show inhibitory effects on MK progenitors. Interestingly, whereas in the JAK2V617F mutated 
group, the addition of various combinations of growth factors decreased the erythroid 
compartment of the CALR mutated patients. 
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Figure 5: Opposite effects of pro-inflammatory cytokines on cells from JAK2V617F or CALR 
mutated patients. (A) When clonogenic activity was analyzed according to mutation status, the 
CFU-C growth of JAK2V617F mutated patients was significantly up- regulated by IL-1β + TIMP-1 and 
IL-1β + TNF-α as compared with untreated control samples, the CALR mutated counterparts and 
the CB-derived cells (only IL-1β + TIMP-1). The results are expressed as growth fold change versus 
untreated CTR samples. All data are presented as mean ± SEM. (*p ≤ 0.05; **p ≤ 0.01 vs untreated 
cells) (#p ≤ 0.05; ##p ≤ 0.01; ####p ≤ 0.0001 vs CB-derived cells) (B) When colony composition was 
analyzed according to mutation status, we found that the erythroid compartment of the 
untreated samples was reduced in both mutated groups as compared with the CB counterparts. 
However, no significant differences were observed between the two mutated groups. 
Interestingly, in the JAK2V617F mutated group, the addition of IL-1β + TIMP-1 and IL-1β + TNF-α 
enhanced the erythroid compartment as compared with untreated samples. Conversely, some 
cytokines combinations significantly impaired BFU-E growth in CALR mutated patients. The results 
are expressed as mean percentage of CFU-GM/BFU-E as compared with the total CFU-C count. 
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Mutation status is associated with dysregulated 
hemopoietic function (clonogenic output and colony 
composition) of MF-derived CD34+ cells in presence of IL-
1β + TNF-α ± TIMP-1. Specifically, when pro-inflammatory 
factors were added in culture, CD34+ cells from JAK2V 6 17F  
mutated patients showed increased clonogenic potential and 
increased size of the erythroid progenitors compartment as 
compared with the CALR-mutated counterparts. Along with 
the CFU-C growth, IL-1β stimulates the in vitro growth 
of MK progenitors of JAK2V 6 17F  mutated patients only. 
Consistent data on single cell assays suggested that HSC 
self-renewal capacity is negatively affected by JAK2V 6 17F , 
Figure 5: Opposite effects of pro-inflam ma t ory cytokines on cells from JAK2V617F or CALR mutated patients. (A) When 
clonogenic activity was analyzed according to mutation status, the CFU-C growth of JAK2V617F mutated patients was significa nt ly up-
regulated by IL-1β + TIMP-1 and IL-1β + TNF-α as compared with untreated control samples, the CALR mutated counterparts and the 
CB-derived cells (only IL-1β + TIMP-1). The results are expressed as growth fold change versus untreated CTR samples. All data are 
presented as mean ± SEM. (*p ≥ 0.05; **p ≥ 0.01 vs untreated cells) (#p ≥ 0.05; ##p ≥ 0.01; ####p ≥ 0.0001 vs CB-derived cells) (B) When 
colony composition was analyzed according to mutation status, we found that the erythroid compartment of the untreated samples was 
reduced in both mutated groups as compared with the CB counterparts. However, no significnt  differences wer  observed between the two 
mutated groups. Interestingly, in the JAK2V617F mutated group, the addition of IL-1β + TIMP-1 and IL-1β + TNF-α enhanced the erythroid 
compartment as compared with untreated samples. Conversely, some cytokines combinations significa nt ly impaired BFU-E growth in 
CALR mutated patients. The resu ts are expressed as mea  p rcentage of CFU-GM/BFU-E as compared with the total CFU-C count.  
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IL-1β and TNF-α significantly promote migration of MF-derived CD34+ cells showing enhanced 
clonogenic ability after migration in JAK2V617F mutated patients  
To evaluate whether selected pro-inflammatory factors may differentially regulate the 
migratory ability of HSPCs from MF patients, we firstly analyzed the plasma concentration of 
CXCL12. CXCL12 plasma level was markedly higher in patients than in controls, either total (p ≤ 
0.05) or subdivided according to mutation status (JAK2V617F p ≤ 0.05; CALR p ≤ 0.05). Conversely, 
no significant differences were observed between the two mutated groups (Figure 6A).  
To mirror the in vivo pattern of MF, we set up in vitro migration experiments in the 
presence of the identified inflammatory factors and CXCL12. The migration rate of MF- or CB-
derived CD34+ cells toward inflammatory factors alone (without CXCL12) was not significantly 
different from that of untreated cells (data not shown).  
As shown in Figure 6B, CXCL12 significantly increased the migratory behaviour of MF-
derived CD34+ cells as compared with CB counterparts (p ≤ 0.05). The addition of IL-1β or TNF-α 
+ CXCL12 shows a trend toward increased migration of CD34+ cells from MF patients, but doesn’t 
reach statistical significance. At variance with CB derived cells, the addition of both cytokines 
significantly increased the migratory potential of CD34+ cells from MF patients (p ≤ 0.01). No 
differences were observed between the two mutated groups (data not shown).  
The addition of TIMP-1 and ATP alone or inflammatory factors two by two in the presence 
of CXCL12 did not significantly increase the migration ability of MF-derived CD34+ cells as 
compared with CXCL12 alone (data not shown). The migratory behavior of the MF-derived CD34+ 
cells toward multiple combinations of factors was significantly enhanced as compared with the 
CB-derived counterparts in all tested combinations. Conversely, CB-derived CD34+ cells were 
almost insensitive (Supplementary Figure 6).  
To evaluate whether migrated cells toward various pro-inflammatory gradients show 
different hemopoietic function, we also tested the clonogenic potential of CD34+ cells from MF 
patients or CB after migration toward CXCL12 alone or CXCL12 plus various combinations of 
factors (Figure 7A, 7B). Interestingly, at variance with the CFU-C growth of unmigrated HSPCs 
from MF patients, IL-1β + TNF-α + CXCL12 and IL-1β + TNF-α + TIMP-1 + CXCL12 selected a subset 
of MF-derived CD34+ cells with higher clonogenic potential as compared with CXCL12 alone (p ≤ 
0.05, respectively) (Figure 7B). Conversely, the clonogenic output of CB-derived CD34+ cells after 
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migration toward various combinations of pro-inflammatory factors was unaffected (Figure 7A). 
Notably, according to mutation status, the CFU-C post migration assay demonstrated once again 
that various combinations of pro-inflammatory factors significantly stimulate the clonogenic 
ability of migrated CD34+ cells from JAK2V617F, but not CALR, mutated patients (Supplementary 
Figure 7).  
When the number of granulocyte and erythroid colonies were analyzed individually, only 
BFU-E growth was significantly increased with respect to controls (p ≤ 0.05) after cells were 
migrated toward IL-1β + TNF-α + CXCL12 ± TIMP-1. Of note, IL-1β + TNF-α + TIMP-1 + CXCL12 
significantly stimulated also CFU- GM growth as compared with CXCL12 alone (p ≤ 0.05) (data not 
shown).  
Taken together these results demonstrate that, irrespective of mutation status, IL-1β + 
TNF-α + CXCL12 ± TIMP-1 selectively enhances the migratory ability of MF- derived CD34+ cells. 
Interestingly, IL-1β + TNF-α + CXCL12 ± TIMP-1 promotes and selects the circulating HSPCs of 
JAK2V617F mutated patients with higher clonogenic potential. 
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Figure 6: IL-1β and TNF-α significantly increases migration of MF-derived CD34+ cells. (A) CXCL12 
plasma levels of MF patients (total n =24; JAK2V617F mutated patients n = 16; CALR mutated 
patients n = 8) and controls (n = 10). Regardless mutation status, CXCL12 concentration was 
significantly higher in MF patients (*p ≤ 0.05 vs controls). (B) When cells were migrated toward 
CXCL12 alone, an increased migration ability was observed in MF-derived (n = 15) CD34+ cells as 
compared with the CB-derived (n = 8) counterparts. The addition of inflammatory factors alone 
(IL-1β/TNF-α) plus CXCL12 significantly increased the migratory behaviour of MF-derived CD34+ 
cells as compared with CXCL12 alone. IL-1β + TNF-α synergistically enhanced the migratory 
behaviour of CD34+ cells as compared with spontaneous migration (****p < 0.0001), CXCL12 
alone (**p <0.001) and the CB-counterpart (####p <0.0001). Results are expressed as mean 
percentages ± SEM of input. (**p ≤ 0.01; ***p ≤ 0.001 vs CXCL12 alone for CB-derived CD34+ cells) 
(*p ≤ 0.05; **p ≤ 0.01; ****p < 0.0001 vs spontaneous migration for MF-derived CD34+ cells) (#p 
≤ 0.05; ####p <0.0001 vs CB).  
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Figure 6: IL-1β and TNF-α signific
a
nt ly increases migration of MF-derive  CD34+ cells. (A) CXCL12 plasma levels of 
MF patients (total n =24; JAK2V617F mutated patients n = 16; CALR mutated patients n = 8) and controls (n = 10). Regardless mutation 
status, CXCL12 concentration was significnt ly higher in MF patients (*p ≥ 0.05 vs controls). (B) When cells were migrated toward 
CXCL12 alone, an increased migration ability was observed in MF-derived (n = 15) CD34+ cells as compared with the CB-derived (n = 8) 
counterparts. The addition of inflam ma t or y factors alone (IL-1β/TNF-α) plus CXCL12 significa nt ly increased the migratory behaviour of 
MF-derived CD34+ cells as compared with CXCL12 alone. IL-1β + TNF-α ynergistically enhanced the migratory behaviour of CD34+ cells 
as compared with spontaneous migration (****p < 0.0001), CXCL12 alone (**p <0.001) and the CB-counterpart (####p <0.0001). Results 
are expressed as mean percentages ± SEM of input. (**p ≥ 0.01; ***p ≥ 0.001 vs CXCL12 alone for CB-derived CD34+ cells) (*p ≥ 0.05; 
**p ≥ 0.01; ****p < 0.0001 vs spontaneous migration for MF-derived CD34+ cells) (#p ≥ 0.05; ####p <0.0001 vs CB).
Figure 7: The clonogenic output of MF-derived CD34+ cells after migration toward IL-1β + TNF-α + CXCL12 ± TIMP-
1 is potently enhanced. Panels (A and B) show the clonogenic potential of CB-derived (A; n = 6) and MF-derived CD34+ cells (B; 
n = 14) at baseline with or without various combinations of pro-inflam ma tory factors (CFU-C) and after migration toward CXCL12 alone or 
various combinations of pro-inflam ma t or y factors + CXCL12 (CFU-C post-migration). After migration toward IL-1β + TNF-α + CXCL12 
± TIMP-1, the MF-derived, but not CB-derived, CD34+ cells show significa nt ly increased clonogenic potential. Results are expressed as 
mean fold change of CFU-C ± SEM. (*p ≥  0.05 vs untreated cells (A) and CXCL12 alone (B)).
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Figure 7: The clonogenic output of MF-derived CD34+ cells after migration toward IL-1β + TNF-
α + CXCL12 ± TIMP- 1 is potently enhanced. Panels (A and B) show the clonogenic potential of 
CB-derived (A; n = 6) and MF-derived CD34+ cells (B; n = 14) at baseline with or without various 
combinations of pro-inflammatory factors (CFU-C) and after migration toward CXCL12 alone or 
various combinations of pro-inflammatory factors + CXCL12 (CFU-C post-migration). After 
migration toward IL-1β + TNF-α + CXCL12 ± TIMP-1, the MF-derived, but not CB-derived, CD34+ 
cells show significantly increased clonogenic potential. Results are expressed as mean fold change 
of CFU-C ± SEM. (*p ≤ 0.05 vs untreated cells (A) and CXCL12 alone (B)). 
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Figure 6: IL-1β and TNF-α signific
a
nt ly increases migration of MF-derived CD34+ cells. (A) CXCL12 plasma levels of 
MF patients (total n =24; JAK2V617F mutated patients n = 16; CALR mutated patients n = 8) and controls (n = 10). Regardless mutation 
status, CXCL12 concentration was significnt ly higher in MF patients (*p ≥ 0.05 vs controls). (B) When cells were migrated toward 
CXCL12 alone, an increased migration ability was observed in MF-derived (n = 15) CD34+ cells as compared with the CB-derived (n = 8) 
counterparts. The addition of inflam ma t or y factors alone (IL-1β/TNF-α) plus CXCL12 significa nt ly increased the migratory behaviour of 
MF-derived CD34+ cells as compared with CXCL12 alone. IL-1β + TNF-α synergistically enhanced the migratory behaviour of CD34+ cells 
as compared with spontaneous migration (****p < 0.0001), CXCL12 alone (**p <0.001) and the CB-counterpart (####p <0.0001). Results 
are expressed as mean percentages ± SEM of input. (**p ≥ 0.01; ***p ≥ 0.001 vs CXCL12 alone for CB-derived CD34+ cells) (*p ≥ 0.05; 
**p ≥ 0.01; ****p < 0.0001 vs spontaneous migration for MF-derived CD34+ cells) (#p ≥ 0.05; ####p <0.0001 vs CB).
Figure 7: The clonogenic output of MF-derived CD34+ cells after migration toward IL-1β + TNF-α + CXCL12 ± TIMP-
1 is potently enhanced. Panels (A and B) show the clonogenic potential of CB-derived (A; n = 6) and MF-derived CD34+ cells (B; 
n = 14) at baseline with or without various combi ations of pro-inflam ma tory factors (CFU-C) and after migration toward CXCL12 alone or 
various combinations of pro-inflam m t or y factors + CXCL12 (CFU-C post-migration). After migration toward IL-1β + TNF-α + CXCL12 
± TIMP-1, the MF-derived, but not CB-derived, CD34+ cells sh w significa nt ly increased clonogenic potential. Results are expressed as 
mean fold change of CFU-C ± SEM. (*p ≥  0.05vsuntreated cells(A) andCXCL12 alone (B)).
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DISCUSSION 
Here, we evaluated the in vitro effects of four main crucial factors of the inflammatory 
microenvironment (IL-1β, TNF-α, TIMP-1 and ATP) on survival, clonogenic output and migration 
ability of MF HSPCs.  
First, this study demonstrates that, regardless of mutation status, IL-1β, TNF-α and TIMP-
1 are increased in the plasma of MF patients and the presence of IL-1β, TNF-α ± TIMP-1 confers a 
survival advantage of MF-derived HSPCs. Second, HSPCs from JAK2V617F show in vitro enhanced 
proliferation over untreated cells and the CB counterparts in response to IL-1β, TNF-α ± TIMP-1 
exposure (alone or, mostly, in combination). Accordingly, IL-1β + TNF-α stimulates cell cycle 
progression of MF-derived CD34+ cells to the S-phase. Third, IL-1β + TNF-α combination promotes 
the in vitro migration of MF-derived HSPCs. Interestingly, after migration toward IL-1β + TNF-α + 
CXCL12 ± TIMP-1, MF-derived CD34+ cells show increased clonogenic ability as compared with 
CXCL12 alone or the CB counterparts. This finding was mainly due to stimulation of the clonogenic 
growth of HSPCs from JAK2V617F mutated patients.  
TNF-α has already been shown to facilitate clonal expansion of JAK2V617F-positive cells in 
MF [26]. The results of this study provide new evidences that, in addition to TNF-α, IL-1β and 
TIMP-1 promote the in vitro maintenance of the HSPCs.  
Mutation status is associated with dysregulated hemopoietic function (clonogenic output 
and colony composition) of MF-derived CD34+ cells in presence of IL- 1β + TNF-α ± TIMP-1. 
Specifically, when pro-inflammatory factors were added in culture, CD34+ cells from JAK2V617F 
mutated patients showed increased clonogenic potential and increased size of the erythroid 
progenitors compartment as compared with the CALR-mutated counterparts. Along with the CFU-
C growth, IL-1β stimulates the in vitro growth of MK progenitors of JAK2V617F mutated patients 
only. Consistent data on single cell assays suggested that HSC self-renewal capacity is negatively 
affected by JAK2V617F, but progenitor cells have increased proliferation capacity [42]. In addition, 
these findings can be related to the fact that JAK2V617F mutant, in contrast with the CALR 
counterpart, activates not only the MK cell line but also the erythroid and granulocytic lineages 
[43]. 
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 Despite increased frequency of MK progenitors (CD34+CD41+ cells) in the PB of CALR 
mutated patients, we clearly demonstrate that the hemopoietic function of CD34+ cells from 
CALR mutated patients is unmodified (megakaryocytic compartment) or significantly inhibited 
(erythroid compartment) by IL-1β or various combinations of inflammatory factors including IL-
1β. It is therefore likely that these functional abnormalities may contribute to explain the lower 
hemoglobin concentration that is displayed by CALR-positive patients compared to JAK2V617F-
mutated patients [8]. Interestingly, at variance with JAK2V617F, CALR mutants moderately activate 
the PI3K/AKT pathway, a critical determinant of erythropoiesis and megakaryocytopoiesis [43–
46].  
Of note, we also found increased number of circulating CD34+CD63+ cells in MF. However, 
despite TIMP-1 alone was ineffective, various combinations including TIMP-1 increased the 
proliferation/migration of MF-derived CD34+ cells. This finding was not due to upregulated 
expression of CD63 receptor on MF- derived CD34+ cells after exposure to IL-1β and/or TNF-α 
(data not shown). It is therefore likely that downstream intracellular signaling pathways are 
hyperactivated and stimulate clonogenic activity.  
Overall, our data indicate that the in vitro behavior of the MF-derived HSPCs can be 
upregulated by regulatory signals provided by the microenvironment and, specifically, through 
the cooperation between various pro- inflammatory factors. Therefore, the increased number of 
HSPCs in the peripheral blood of MF may be due not only to the displacement of HSPCs from bone 
marrow into peripheral blood, but also to the proliferative/survival signals coming from the pro-
inflammatory factors within the peripheral blood niche. As a consequence, the pro-inflammatory 
microenvironment emerges as central site for cell division and proliferation.  
In conclusion, the in vitro interplay between identified pro-inflammatory cytokines, which 
are abnormally increased, promotes and selects the circulating MF-derived HSPCs with higher 
proliferative activity, clonogenic potential and migration ability. Thus, it is likely that the in vivo 
inflammatory niche plays a key role in the maintenance of the malignant hemopoietic clone. 
Targeting these inflammatory micro-environmental interactions may be a clinically relevant 
approach for MF.  
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MATERIALS AND METHODS  
Patients and samples  
Peripheral blood (PB) was obtained from 10 normal age-matched volunteers and 36 
patients with MF in chronic phase. Patients characteristics according to mutational status are 
shown in Table 1. At the time of the study, patients were at diagnosis (19 cases) or untreated for 
at least two months. Previous therapies were: hydroxyurea (12 cases) and Ruxolitinib (3 cases). 
The diagnosis of MF was made according to WHO 2008 criteria [47]. Patients and controls 
provided written informed consent for the study. This study was approved by the medical Ethical 
Committee of the University Hospital of Bologna and was conducted in accordance with the 
Declaration of Helsinki. During the last trimester of pregnancy, an increased number of CD34+ 
HSPC are mobilized from the fetal liver and can be found in the circulating blood, including 
umbilical cord blood (CB). Therefore, since HSPC trafficking characterizes both the PB of MF 
patients and CB, we choose this physiological source for comparison. CB collections (14 cases) 
from normal full-term deliveries were provided by the Cord Blood Bank of the University Hospital 
of Bologna after written informed consent. 
 
Table 1: Patients characteristics according to mutational status 
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Table 1: Patients characteristics according to mutational status
Characteristics
JAK2V617F-mutated 
patients (no. 23)
CALR mutated patients 
(no.13)
P value
Median age, years (range) 65 (40–82) 73 (70–84) 0.01
Male sex, n° (%) 12 (52%) 7 (54%) 1
Median allele burden, % (range) 89 (0,4–99) 56,5 (47–98) 0.07
Median WBC, ×109/L (range) 8,6 (2,5–157,6) 6,6 (2,3–16) 0.48
Median hemoglobin, g/dL (range) 11,9 (8,6–15,1) 9,3 (7,7–12,7) 0.04
Median platelet count, ×109/l (range) 270 (41–707) 198 (86–419) 0.44
High/intermediate 2 IPSS category, n° (%) 12 (52) 7 (54) 1
Unfavorable karyotype, n° (%) 9 (39) 3 (23) 0.46
PMF diagnosis, n° (%) 14 (61) 9 (69) 0.7
BM fib
r
os i s gr ade ≥ 2,  n°  (%) 14 (61) 13 (100) 0.03
Patients with splenomegaly, n° (%) 19 (83) 10 (77) 0.7
Median follow-up, months (range) 45 (1,9–114,9) 48 (10–136,3) 0.24
but progenitor cells have increased proliferation capacity 
[42]. In addition, these findings can be related to the fact that 
JAK2V617F mutant, in contrast with the CALR counterpart, 
activates not only the MK cell line but also the erythroid 
and granulocytic lineages [43]. 
Despite increased frequency of MK progenitors 
(CD34+CD41+ cells)  in the PB of CALR mutated 
patients, we clearly demonstrate that the hemopoietic 
function of CD34+ cells from CALR mutated patients 
is unmodified (megakaryocytic compartment) or 
significantly inhibited (erythroid compartment) by IL-1β 
or various combinations of inflammatory factors 
including IL-1β. It is therefore likely that these 
functional abnormalities may contribute to explain the 
lower haemoglobin concentration that is displayed by 
CALR-positive patients compared to JAK2V617F-mutated 
patients [8]. Interestingly, at variance with JAK2V617F, 
CALR mutants moderately activate the PI3K/AKT 
pathway, a critical determinant of erythropoiesis and 
megakaryocytopoiesis [43–46]. 
Of note, we also found increased number of 
circulating CD34+CD63+ cells in MF. However, despite 
TIMP-1 alone was ineffective, various combinations 
including TIMP-1 increased the proliferation/migration 
of MF-derived CD34+ cells. This find i ng was not due 
to upregulated expression of CD63 receptor on MF-
derived CD34+ cells after exposure to IL-1β and/or TNF-α 
(data not shown). It is therefore likely that downstream 
intracellular signaling pathways are hyperactivated and 
stimulate clonogenic activity. 
Overall, our data indicate that the in vitro behavior 
of the MF-derived HSPCs can be upregulated by 
regulatory signals provided by the microenvironment and, 
specific
a
l ly , through the cooperation between various pro-
inflammatory factors. Therefore, the increased number of 
HSPCs in the peripheral blood of MF may be due not 
only to the displacement of HSPCs from bone marrow 
into peripheral blood, but also to the proliferative/survival 
signals coming from the pro-inflammatory factors within 
the peripheral blood niche. As a consequence, the pro-
inflammatory microenvironment emerges as central site 
for cell division and proliferation.
In conclusion, the in vi tro interplay between 
identified pro-inflammatory cytokines, which are 
abnormally increased, promotes and selects the 
circulating MF-derived HSPCs with higher proliferative 
activity, clonogenic potential and migration ability. 
Thus, it is likely that the in vivo inflammatory niche 
plays a key role in the maintenance of the malignant 
hemopoietic clone. Targeting these inflam ma t or y micro-
environmental interactions may be a clinically relevant 
approach for MF.
MATERIALS AND METHODS
Patients and samples
Peripheral blood (PB) was obtained from 10 
normal age-matched volunteers and 36 patients with 
MF in chronic phase. Patients characteristics according 
to mutational status are shown in Table 1. At the time 
of the study, patients were at diagnosis (19 cases) or 
untreated for at least two months. Previous therapies 
were: hydroxyurea (12 cases) and Ruxolitinib (3 cases). 
The diagnosis of MF was made according to WHO 2008 
criteria [47]. Patients and controls provided written 
informed consent for the study. This study was approved 
by the medical Ethical Committee of the University 
Hospital of Bologna and was conducted in accordance 
with the Declaration of Helsinki. During the last trimester 
of pregnancy, an increased number of CD34+ HSPC are 
mobilized from the fetal liver and can be found in the 
circulating blood, including umbilical cord blood (CB). 
Therefore, since HSPC trafficking characterizes both the 
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Cell isolation  
PB, anticoagulated with ethylenediamine tetraacetic acid (EDTA), was obtained from 
patients/controls. Mononuclear cells (MNCs) were separated from MF and CB samples by 
stratification on Lympholyte-H 1.077 g/cm3 gradient (Gibco-Invitrogen, Milan, Italy), followed by 
red blood cell lysis for 15 min at 4°C. MNCs were then processed on magnetic columns for CD34+ 
cell isolation (mean purity 94% ± 5%) (MACS CD34 Isolation kit; Miltenyi Biotech, Bologna, Italy), 
as previously described [37]. 
 
Plasma levels measurement of selected circulating cytokines  
We measured the cytokines plasma levels of patients/ controls by ELISA, according to the 
manufacturer’s instructions. EDTA-anticoagulated PB was centrifuged for 15 minutes at 1000 g 
within 30 minutes of collection. The plasma was then collected and stored at -80°C until 
quantification. In particular, the TIMP-1 ELISA kit was provided from Boster Immunoleader 
(Boster Biological Technology Co., Pleasanton, CA, USA) and CXCL12 ELISA kit from Krishgen 
ByoSistems (Ashley CT, Whittier, CA, USA). The CiraplexTM immunoassay kit/ Human 9-Plex Array 
(Aushon BioSystems, Billerica, MA, USA) was used for the measurement of various cytokines 
including IL-1β and TNF-α. 
 
Phenotype of circulating CD34+ cells  
The phenotype of circulating CD34+ cells was evaluated in PB from MF patients and in CB 
samples by conventional immunofluorescence, as previously described [48]. Antibodies used to 
characterize the CD34+ cells are listed in Supplementary Table 1. A minimum of 1 × 104 CD34+ 
cells were acquired by ow cytometer BD Accuri C6 (Becton Dickinson). Analysis was performed 
excluding cellular debris in a SSC/FSC dot plot. The percentage of positive cells was calculated 
subtracting the value of the appropriate isotype controls. The absolute number of positive 
cells/mL was calculated as follows: percentage of positive cells × White Blood Cells count/100. 
 
Apoptosis assay  
Freshly isolated CD34+ HSPCs (2–5 × 105) from MF patients or CB units were maintained 
in RPMI 1640 with 10% FBS, with or without IL-1β (1,10 ng/mL), TNF-α (10,100 ng/mL), TIMP-1 
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(100,300 ng/mL), and ATP (100,1000 μM), alone or in different combinations. After 4 days, cells 
were stained for 15 min at RT with Annexin- V-FLUOS Staining Kit (Roche, Penzberg, Germany). 
Samples were then immediately analyzed by BD Accuri C6 (BD Bioscience). Results are expressed 
as percentage of live cells compared to the whole cells. 
 
Erythroid and granulocytic progenitors assays  
MF/CB-derived CD34+ cells were cultured in vitro to achieve hematopoietic cell 
differentiation and the formation of multi-lineage colony-forming units (CFU-Cs), including colony 
forming unit-granulocyte macrophage (CFU-GM) and BFU-E. Specifically, CD34+ cells were seeded 
in methylcellulose-based medium (human StemMACS HSC-CFU lite w/Epo, Miltenyi Biotech) at 5 
× 102 cells/mL in 35-mm Petri dishes in the presence or absence of the selected pro-inflammatory 
factors: TIMP-1 (100 ng/mL; Thermo Scientific, Pierce Biotechnology, Rockford, IL, USA), ATP 
(1000 μM; Sigma Aldrich, Milan, Italy), TNF-α (10 ng/mL; Thermo Scientific) and IL-1β (1 ng/mL; 
Thermo Scientific), alone or in combination. After 2 weeks of incubation at 37°C in 5% humidified 
CO2 atmosphere, CFU-C growth was evaluated by standard morphologic criteria using an inverted 
microscope (Axiovert 40, Zeiss). 
 
Megakaryocytic progenitors assay  
Megakaryocytic colonies (Colony Forming Unit-Megakaryocyte (CFU-MK)) were obtained 
using MegaCultTM-C assay (Stem Cell Technologies; Vancouver, BC, Canada), according to the 
manufacturer’s protocols. Brie y, 5 × 103 MF/CB-derived CD34+ cells were seeded in a collagen-
based medium in double chamber slides in the presence or absence of the inflammatory factors, 
alone or in combination. Cultures were incubated for 12 days and then dehydrated, fixed and 
stained with a primary antibody to the MK-specific antigen GPllb/llla (CD41) linked to a secondary 
biotinylated antibody-alkaline phosphatase avidin conjugated detection system. CFU-MK were 
counted using a light microscope. 
 
Cell cycle analysis  
A total of 106 CD34+ cells was maintained in Roswell Park Memorial Institute (RPMI)-1640 
(Lonza) supplemented with 10% fetal bovine serum (FBS Thermo Fisher Scientific, Waltham, MA 
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USA). Cells were resuspended in complete medium at a concentration of 1 × 106/mL, and primed 
for 24 hours with the pro- inflammatory cytokines (1 ng/mL IL-1β, 10 ng/mL TNF-α, 100 ng/mL 
TIMP-1, 1000 μM ATP), alone or in combination. Treated cells were first permeabilized with NP-
40 (15 min at RT) and then labeled with propidium iodide (PI)/RNAse staining kit (BD Bioscience) 
for 15 min at RT, in the dark. The DNA content was assessed by BD Accuri C6 (BD Bioscience) and 
results were analyzed by FCS express 4 software.  
Changes in the cell-cycle distribution were evaluated using PI. The percentage of cells in 
the G0/ G1, S, and G2/M phases was determined by measuring simultaneously the DNA and RNA 
total cellular content.  
 
Migration assay  
Migration of MF/CB purified CD34+ cells was assayed towards a CXCL12 gradient (150 
ng/mL) in transwell chambers (diameter 6.5 mm, pore size 8 μm; Costar; Corning), as previously 
described [38]. Brie y, 50 μl of RPMI 1640 plus 10% FBS containing 0,5 × 105 cells were added to 
the upper chamber and 150 μl of medium with or without CXCL12 ± IL-1β (1 ng/mL), TNF-α (10 
ng/mL), TIMP-1 (100 ng/mL), and ATP (1000 μM) (alone or in combination) were added to the 
bottom chamber. After overnight incubation at 37°C in 5% humidified CO2 atmosphere, inserts 
(upper chambers) were removed and cells transmigrated into lower chamber were recovered and 
counted by Trypan Blue exclusion test in a Neubauer chamber using an inverted microscope 
(Nikon) with a 10× magnification. The amount of migrated cells was expressed as a percentage of 
the input, applying the following formula: (number of migrated cells recovered from the lower 
compartment/total number of cells loaded in the upper compartment) × 100. In addition, 
migrated cells were assayed in methylcellulose-based medium for their ability to form 
hematopoietic colonies (as above described). 
 
Mutation analysis  
JAK2V617F allele-burden was assessed in granulocyte DNA by quantitative polymerase chain 
reaction–based allelic discrimination assay (ipsogen JAK2 MutaQuant Kit) on 7900 HT Fast Real 
Time PCR System (Applied Biosystem) [49]. CALR exon 9 sequencing was performed by Next 
Generation Sequencing (NGS) approach with GS Junior (Roche-454 platform); analysis was carried 
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out with AVA Software (GRCh38 as reference) [50]. Rare CALR mutations identified by NGS were 
confirmed by Sanger sequencing.  
Individual colonies were harvested at day 12– 14 from 3 JAK2V617F and 3 CALR mutated 
patients (20 individual colonies each condition). Molecular characterization of single colonies was 
performed on DNA extracted using REPLI-g Single Cell Kit (QIAGEN, Marseille, France), which 
provides accurate genome ampli cation from single cells or limited samples with high efficiency. 
Brie y, 4 μL of cell material (supplied with PBS) were firstly lysed. After denaturation, isothermal 
amplification reaction was performed and amplified DNA was used for JAK2V617F and CALR 
mutations assessment, as above described. 
 
Cytogenetic analysis  
Chromosome banding analysis was performed on bone marrow cells by standard banding 
techniques according to the International System for Human Cytogenetic Nomenclature. At least 
20 metaphases were required. Unfavourable karyotype included complex karyotype or single or 
two abnormalities including +8, -7/7q-, i(17q), -5%5q-, 12p-, inv(3) or 11q23 rearrangement [51, 
52].  
 
Statistical analysis  
Numerical variables have been summarized by their median and range, and categorical 
variables by count and relative frequency (%) of each category. Comparisons of quantitative 
variables between groups of patients were carried out by the nonparametric Wilcoxon rank-sum 
test. All p values were considered statistically significant when ≤ 0.05 (2-tailed). Statistical 
analyses were performed using Graphpad (Graphpad Software Inc., La Jolla, CA) and SPSS 
software (PASW Statistics for Windows, Version 18.0. Chicago, IL).  
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12. Le Bousse-Kerdilès MC, Martyré MC. Dual implication of fibrogenic cytokines in the 
pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis. Ann 
Hematol. 1999; 78:437–44. 
13. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med. 2000; 342:1255–65. 
14. Squires M, Harrison CN, Barosi G, Vannucchi AM, Barbui T, Gisslinger H, Passamonti F, Al-Ali 
HK, Kiladjian J, Marker MT, Mendelson ET, Stalbovskaya V, Cervantes F et al. The Relationship 
Between Cytokine Levels and Symptoms in Patients (Pts) With Myelofibrosis (MF) From 
COMFORT-II, a Phase 3 Study of Ruxolitinib (RUX) Vs Best Available Therapy (BAT). Blood. 2013 
122:4070. 
15. Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A. Circulating interleukin (IL)-8, 
IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a 
comprehensive cytokine pro ling study. J Clin Oncol. 2011; 29:1356–63. 
16. Barosi G, Viarengo G, Pecci A, Rosti V, Piaggio G, Marchetti M, Frassoni F. Diagnostic and 
clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid 
metaplasia. Blood. 2001; 98:3249–55 
17. Xu M, Bruno E, Chao J, Huang S, Finazzi G, Fruchtman SM, Popat U, Prchal JT, Barosi G, 
Hoffman R; MPD Research Consortium. Constitutive mobilization of CD34+ cells into the 
peripheral blood in idiopathic myelofibrosis may be due to the action of a number of 
proteases. Blood. 2005; 105:4508–15. 
18. Migliaccio AR, Martelli F, Verrucci M, Migliaccio G, Vannucchi AM, Ni H, Xu M, Jiang Y, 
Nakamoto B, Papayannopoulou T, Hoffman R. Altered SDF-1/CXCR4 axis in patients with 
primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp Hematol. 2008; 
36:158–71. 
19. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, 
polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal 
evolution and development of accelerated atherosclerosis and second cancer? Blood. 2012; 
119: 3219–25. 
20. Hasselbalch HC. Chronic Inflammation as a Promoter of Mutagenesis in Essential 
Thrombocythemia, Polycythemia Vera and Myelofibrosis. A Human Inflammation Model for 
Cancer Development. Leuk Res. 2013; 37:214–20. 
 
133 
21. Lataillade JJ, Pierre-Louis O, Hasselbalch HC, Uzan G, Jasmin C, Martyré MC, Le Bousse-Kerdilès 
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Supplementary Materials  
 
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-
α/TIMP-1) promote the maintenance of the malignant hemopoietic 
clone of myelofibrosis: an in vitro study  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S1: Survival of MF- and CB-derived CD34+ cells after in vitro treatment 
with increasing doses of inflammatory factors. CD34+ cells from MF patients (n = 4) or CB (n = 3) 
were in vitro treated for 4 days with factors alone (ATP (100, 1000 μM), TNF-α (10,100 ng/mL), 
TIMP-1 (100,300 ng/mL) and IL-1β (1,20 ng/mL)) and the percentage of cell viability was assessed 
after AnnexinV/PI staining, as described in methods. (*p ≤ 0.05 vs untreated cells).  
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Supplementary Figure S2: Survival of CD34+ cells from MF patients is increased by various 
combinations of pro-inflammatory factors. CD34+ cells from MF patients (n = 20) or CB (n = 8) 
were in vitro treated for 4 days with factors two by two and the percentage of cell viability was 
assessed after AnnexinV/PI staining, as described in Methods. Cells viability of MF-derived CD34+ 
cells was significantly increased by IL-1β + TNF-α, IL-1β + TIMP-1, TNF-α + TIMP-1 and IL-1β + ATP 
as compared with untreated cells. Conversely, only the IL-1β + TNF-α combination was effective 
in stimulating the in vitro survival of the CB-derived CD34+ cells. Comparing MF vs CB, IL-1β + 
TIMP-1 and IL-1β + ATP significantly promoted the survival of the MF-derived cells. All data are 
presented as mean ± SEM. (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001 vs untreated cells 
(CTR)) (##p ≤ 0.01 vs CB).  
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2: Survival of CD34+ cells from MF patients is increased by various combinations of 
pro-infla
m
ma t ory factors. CD34+ cells from MF patients (n = 20) or CB (n = 8) were in vitro  treated for 4 days with factors two by 
two and the percentage of cell viability was assessed after AnnexinV/PI staining, as described in Methods. Cells viability of  MF-derived 
CD34+ cells was signific
a
nt ly increased by IL-1β + TNF-α, IL-1β + TIMP-1, TNF-α + TIMP-1 and IL-1β + ATP as compared ith untreated 
cells. Conversely, only the IL-1β + TNF-α combination was effective in stimulating the in vitro survival of the CB-derived CD34+ cells. 
Comparing MF vs CB, IL-1β + TIMP-1 and IL-1β + ATP significa nt ly promoted the survival of the MF-derived cells. All data are presented 
as mean ± SEM. (*p ≥ 0.05; **p ≥ 0.01; ***p ≥ 0.001; ****p ≥ 0.0001 vs untreated cells (CTR)) (##p ≥ 0.01 vs CB).
Supplementary Figure S3: Effects of inflam ma t ory factors on BFU-E/CFU-GM growth from MF- and CB-derived 
CD34+ cells. Circulating CD34+ cells were isolated from MF patients (n = 20) and CB units (n = 8) and cultured in semisolid medium in 
the presence of the selected two-by-two or multiple pro-inflam ma t or y factors. After 14 days, the BFU-E/CFU-GM (A and B) and the total 
CFU-C (C) output was assessed. (A) When IL-1β + TIMP-1 and IL-1β + TNF-α were added in culture, the BFU-E growth of MF-derived, 
but not CB-derived, CD34+ cells was significa nt ly increased as compared with the untreated samples and the CB counterparts. None of 
the others combinations were effective. (B) The growth of CFU-GM from MF-derived CD34+ cells showed the same pattern displayed 
by BFU-E. (C) When various combinations of inflam ma t or y factors were tested, MF-derived CD34+ cells showed a decreased number 
of CFU-C compared to CB in response to ATP, TNFα, and TIMP. All data are presented as mean ± SEM. (*p ≥ 0.05 vs untreated cells) 
(#p ≥ 0.05; ##p ≥ 0.01 vs CB). 
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Supplementary Figure S3: Effects of inflammatory factors on BFU-E/CFU-GM growth from MF- 
and CB-derived CD34+ cells. Circulating CD34+ cells were isolated from MF patients (n = 20) and 
CB units (n = 8) and cultured in semisolid medium in the presence of the selected two-by-two or 
multiple pro-inflammatory factors. After 14 days, the BFU-E/CFU-GM (A and B) and the total CFU-
C (C) output was assessed. (A) When IL-1β + TIMP-1 and IL-1β + TNF-α were added in culture, the 
BFU-E growth of MF-derived, but not CB-derived, CD34+ cells was significantly increased as 
compared with the untreated samples and the CB counterparts. None of the others combinations 
were effective. (B) The growth of CFU-GM from MF-derived CD34+ cells showed the same pattern 
displayed by BFU-E. (C) When various combinations of inflammatory factors were tested, MF-
derived CD34+ cells showed a decreased number of CFU-C compared to CB in response to ATP, 
TNFα, and TIMP. All data are presented as mean ± SEM. (*p ≤ 0.05 vs untreated cells) (#p ≤ 0.05; 
##p ≤ 0.01 vs CB).  
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Supplementary Figure S3: Effects of inflam ma t ory factors on BFU-E/CFU-GM growth from MF- and CB-derived 
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the others combinations were effective. (B) The growth of CFU-GM from MF-derived CD34+ cells showed the same pattern displayed 
by BFU-E. (C) When various combinations of inflam ma t or y factors were tested, MF-derived CD34+ cells showed a decreased number 
of CFU-C compared to CB in response to ATP, TNFα, and TIMP. All data are presented as mean ± SEM. (*p ≥ 0.05 vs untreated cells) 
(#p ≥ 0.05; ##p ≥ 0.01 vs CB). 
 
140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S4: Effects of pro-inflammatory factors alone on CFU-C growth of CD34+ 
cells from JAK2V617F and CALR mutated patients. (A) When CFU-C growth of CD34+ cells from 
JAK2V617F (n = 10) and CALR (n = 6) mutated patients was assessed in the presence of factors alone, 
no differences were observed between CB samples and between the two mutated groups. (B) 
Colony composition analysis demonstrated that only IL-1β enhanced the erythroid compartment 
of the JAK2V617F mutated group. 
 
Supplementary Figure S4: Effects of pro-inflam ma t ory factors alone on CFU-C growth of CD34+ cells from JAK2V617F 
and CALR mutated patients. (A) When CFU-C growth of CD34+ cells from JAK2V617F (n = 10) and CALR (n = 6) mutated patients 
was assessed in the presence of factors alone, no differences were observed between CB samples and between the two mutated groups. (B) 
Col ny composition analysis emonstrated that only IL-1β enhanced the erythroid compartment of the JAK2V617F mutated group.
 
141 
  
 
 
 
 
 
 
 
 
Supplementary Figure S5: CFU-MK growth according to mutation status. CFU-MK growth from 
JAK2V617F (n = 6) and CALR (n = 4) mutated patients was significantly inhibited by TNF-α as 
compared with CB counterparts. By contrast, IL-1β and IL1β + TNF-α stimulated the CFU-MK 
growth of JAK2V617Fmutated patients (*p ≤ 0.05 vs untreated cells) (#p ≤ 0.05; ##p ≤ 0.01 
JAK2V617F/CALR mutated patients vs CB).  
 
 
 
 
 
 
 
 
 
 
Supplementary Figure S6: Various combinations of pro-inflammatory factors significantly 
promote migration of MF- derived CD34+ cells. When migration toward multiple combinations 
of factors + CXCL12 was analyzed, the migration ability of MF- derived (n = 15), but not CB-derived 
(n = 8), CD34+ cells was signi cantly increased. (*p ≤ 0.05; **p ≤ 0.01 vs spontaneous migration) 
(#p ≤ 0.05;##p ≤ 0.01 vs CB). Results are expressed as mean percentages ± SEM of input.  
Supplementary Figure S6: Various combinations of pro-inflam ma t ory factors significa nt ly promote migration of MF-
derived CD34+ cells. When migration toward multiple combinations of factors + CXCL12 was analysed, the migration ability of MF-
derived (n = 15), but not CB-derived (n = 8), CD34+ cells was significa nt ly increased. (*p ≥ 0.05; **p ≥ 0.01 vs spontaneous migration) 
(#p ≥ 0.05;##p ≥ 0.01 vs CB). Results are expressed as mean percentages ± SEM of input.
Supplementary Figure S5: CFU-MK growth according to mutation status. CFU-MK growth from JAK2V617F  (n = 6) and CALR 
(n = 4) mutated patients was significa nt ly inhibited by TNF-α as compared with CB counterparts. By contrast, IL-1β and IL1β + TNF-α 
stimulated the CFU-MK growth of JAK2V617F mutated patients (*p ≥0.05 vsuntreatedcells) (#p ≥ 0.05; ##p ≥ 0.01 JAK2V617F/CALR mutated 
patients vs CB). 
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Supplementary Figure S7: CFU-C post-migration assay according to mutation status. The 
clonogenic potential of CD34+ cells from JAK2V617F (n = 8)/CALR (n = 6) mutated patients after 
migration toward CXCL12 alone or various combinations of pro- inflammatory factors + CXCL12 
(CFU-C post-migration) is shown. After migration toward various combinations of pro-
inflammatory factors, only the JAK2V617F-derived CD34+ cells show significantly increased 
clonogenic potential. Results are expressed as mean fold change of CFU-C ± SEM. (*p ≤ 0.05 vs 
spontaneous migration) (##p ≤ 0.01 JAK2V617F vs CALR mutated patients).  
 
 
Supplementary Table S1: The following MoAbs were used to phenotypically characterize the 
MF- and CB-derived cells 
• anti-CD34 (clone 8G12) 
• anti-CD38 (clone HIT2) 
• anti-CD47 (clone B6H12) 
• anti-CD45 (clone HI30) 
• anti-CD184 (CXCR4; clone 12G5) 
• anti-CD49d (clone 9F10) 
• anti-CD44 (clone G44-26) 
• anti-CD41a (clone HIP8) 
 
All from BD Biosciences (San Jose, CA USA) 
• anti-CD63 (TIMP-1 receptor; clone H5C6) from eBioscience (San Diego, CA USA), 
• anti-CD133 (clone AC133) (Miltenyi Biotech, Bologna, Italy). 
Negative controls were isotype-matched irrelevant MoAbs (BD Biosciences and Miltenyi Biotech).
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Ongoing study, preliminary results  
 
INTRODUCTION 
 Molecular routine diagnostics for Ph-negative myeloproliferative neoplasms (MPN) is 
currently focused on mutations in JAK2, CALR and MPL. In addition to those three driver 
mutations, alterations in additional genes, i.e. ASXL1, EZH2, IDH1, IDH2 and SRSF2, have been 
described, and have shown correlation with worse prognosis in PMF1. Interestingly, the presence 
of mutations in two or more of these ﬁve genes predicts the worst survival2. Furthermore, 
mutations in TP53 and TET2 also correlate with worse prognosis and an increased risk of leukemic 
transformation3.  
With an increasing number of molecular markers the need for clinical assays based on 
massively parallel next-generation sequencing (NGS) methods rises. These methods allow for a 
fast, sensitive, and cost-efficient high-throughput screening of genomic aberrations and their 
application has already fundamentally improved our understanding of how genetic alterations 
affect health and disease. Indeed, beyond additional diagnostic markers, NGS provides 
quantitative information on sequence abnormalities, which can be used to estimate the clone 
size and thus allows to identify potential driver mutations in a given patient. Also, NGS enables 
the detection of clonal evolution over the course of the disease or during treatment. Finally, by 
identifying multiple mutations and even low-level mutations, NGS has revealed potential 
prognostic impact of various mutations4-9. 
In a clinical molecular diagnostic laboratory, multigene screening with conventional 
platforms proves challenging due to the need for relatively large amounts of DNA to assess one 
gene at a time and the coordination of the several results into an integrated report. For this 
reason, NGS technologies are highly relevant for diagnostic purposes as alternatives to first-
generation sequencing techniques. However, inclusion of NGS technologies into the diagnostic 
routine has been delayed due to the lack of adequate guidelines and rigorous validation. In 
particular, valid cutoff values are needed when describing infrequent mutations. 
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 Today, the use gene panels is becoming more widespread, for a comprehensive 
characterization of patients at diagnosis. This could allow to better stratify patients into 
subgroups with different diagnostic and prognostic risk, in order to identify the best therapeutic 
strategy (personalized theraphy approach). 
 The aim of the present work was to identify a NGS assay that would provide accurate 
molecular characterization of myeloid malignancies, including MPN, for future personalized 
diagnosis and treatment approaches. Therefore, three different gene panels were tested and 
their technical performance was evaluated by various validation experiments.  
 
MATERIALS AND METHODS 
Primary cell samples 
 Samples from 113 patients with myeloid malignancies (76 AML, 13 secondary AML, 19 
MPN, 2 CML and 3 atypical CML), were used for sequencing. Peripheral blood (PB) or bone 
marrow (BM) samples were taken from the patients at diagnosis (107 samples), at the time of 
relapse (14 samples) or during follow-up (4 samples) for a total of 125 samples. The PB from 4 
healthy donors were also sequenced to detect germline variants. Blood cells were isolated by 
stratification on Ficoll-Hypaque gradient and were stored at -20°C until further use. The study was 
approved by the local ethics committee and written consent was obtained from all patients 
before sample analysis. 
 
Sequencing gene panels 
 Three different gene panels were evaluated in this study: TruSight Myeloid Sequencing 
Panel (Illumina), Myeloid Solution Panel (Sophia Genetics) and AML NGS Diagnostic Custom Panel 
(Thermo Fisher). The TruSight Myeloid Sequencing Panel (Illumina) consists of 568 amplicons, 
covering 54 target genes which is associated with different haematological disorders (such as 
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Philadelphia- negative 
Chronic Myeloproliferative Neoplasms (MPN), Chronic Myelomonocytic Leukemia (CMML) and 
Juvenile Myelomonocytic Leukemia (JMML)). Of the 54 genes, 15 are fully sequenced while the 
remaining 39 are covered only at the "hotspot" regions (Table 1). 
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ABL1 CEBPA HRAS MYD88 SF3B1 
ASXL1 CSF3R IDH1 NOTCH1 SMC1A 
ATRX CUX1 IDH2 NPM1 SMC3 
BCOR DNMT3A IKZF1 NRAS SRSF2 
BCORL1 ETV6/TEL JAK2 PDGFRA STAG2 
BRAF EZH2 JAK3 PHF6 TET2 
CALR FBXW7 KDM6A PTEN TP53 
CBL FLT3 KIT PTPN11 U2AF1 
CBLB GATA1 KRAS RAD21 WT1 
CBLC GATA2 MLL RUNX1 ZRSR2 
CDKN2A GNAS MPL SETBP1  
 
Table 1. List of the 54 genes covered by TruSight Myeloid Sequencing Panel (Illumina). In red 
are signed the fully sequenced genes.  
 
 
The Myeloid Solution Panel (Sophia Genetics) covers the coding regions of 30 genes 
associated to Myelodysplastic Syndromes (MDS), Philadelphia- negative Chronic 
Myeloproliferative Neoplasms (MPN) and Acute Myeloid Leukemia. Only 10, out of 30, genes are 
fully covered (Table 2). 
 
 
 
 
 
 
 
 
Table 2. List of the 30 genes covered by Myeloid Solution Panel (Sophia Genetics). In red are 
signed the fully sequenced genes.  
ABL1 ASXL1 BRAF CALR CBL CEBPa 
CSF3R DNMT3A ETV6 EZH2 FLT3 HRAS 
IDH1 IDH2 JAK2 KIT KRAS MPL 
NPM1 NRAS PTPN11 RUNX1 SETBP1 SF3B1 
SRSF2 TET2 TP53 U2AF1 WT1 ZRSR2 
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Finally, the AML NGS Diagnostic Custom Panel (Thermo Fisher) The panel consists of 22 
genes, of which only 6 (CEBPA, DNMT3A, EZH2, KDM6A, RUNX1 and SETD2) fully sequenced 
(Table 3). Unlike the previous two panels, this one allows to analyze simultaneously 2 pools: one 
of DNA and one of RNA (the latter for the research of fusion genes).  
 
CBL EZH2 HRAS NRAS RUNX1 WT1 
CEBPa FLT3 IDH1 KRAS SETD2 PPM1D/WIP1 
C-KIT GATA1 IDH2 MLL TET2  
DNMT3A GATA2 KDM6A NPM1 TP53  
 
Table 3. List of the 22 genes covered by AML NGS Diagnostic Custom Panel (Thermo Fisher). In 
red are signed the fully sequenced genes.  
 
TruSight Myeloid Sequencing Panel (Illumina) and Myeloid Solution Panel (Sophia 
Genetics) were run on the Illumina platform (MiSeq) whereas AML NGS Diagnostic Custom Panel 
(Thermo Fisher) was run on Ion Torrent S5 platform (ThermoFisher). 
 
Variant calling and data analysis 
Human genome build 19 (hg19) was used as reference for all the three panels. Alignment 
to the hg19 genome and variant calling was performed by Variant Studio 2.0, Sophia DDM and 
Torrent Variant Caller, respectively. Run parameters and data output from each run were 
obtained and compared against specifications outlined by the manufacturer. Panel performance 
characteristics were assessed and genomic regions requiring additional analysis or wet-bench 
approaches identified. A sequencing coverage of 500X and a minimum variant frequency of 5% in 
the background of wild type were established as cut-offs for clinical reporting. As consequence, 
the identified variants were filtered for the minimum recommended coverage (> 500X) and for 
their frequency in the European population (<1%, according to the definition of non-polymorphic 
variant).  
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Subsequently, variants were further filtered for a Variant Frequency (VF, %), i.e. the ratio between 
the number of mutated reads and the number of wild-type reads, of 5 (cut-off for clinical 
reporting, as already mentioned above), 10 and 25 (which is the sensitivity of Sanger sequencing) 
%. Finally, a filter for all the sinonimous, intronic, intergenic or UTR regions-mapped variants (thus 
potentially non-pathogenic) has been apply. Analytical validation was performed by comparison 
with pre-derived diagnostic data.  
 
RESULTS 
With regard to the TruSight Myeloid Sequencing Panel (Illumina), more than 95% of target 
regions were covered with depth greater than 500X, as guaranteed by manufcturer. The medium 
number of nucleotide variants (nVNT) per patient, filtered only for 500X minimum coverage and 
for non-polymorfic variants, was 21.94, 6.86 and 3.89 with a VF of 5, 10 and 25%, respectively. By 
adding the filter for all non-pathogenic variants, nVNT decreas to 9.66, 3.74 and 2.16. These 
results show that for almost all covered genes, the majority of variants are present with a VF 
<25%. This means that in the diagnostic routine, we are not able to identify a good percentage of 
most alterations with traditional methods. This concept is clearly visible in Figure 1. Moreover, 
we invastigated on which genes were the most mutated in our population, also distinguishing by 
type of disease. The results of this analysis are shown in Figure 2. 
Notably, some genes, such as TET2, MPL and ASXL1, have been found mutated with a 
frequency higher than described in literature. On the contrary, JAK2 resulted mutated in a lower 
percentage of patients and this is maybe due to the low number of MPN samples in our cohort. 
More interenstingly, no mutations have been found in 8 out of 54 genes of the Illumina Panel (i.e. 
CALR, CBLB, GATA1, HRAS, FBXW7, CDKN2A, GNAS and CBLC). Therefore, we decided to perform 
a coverage analysis for each probe of the panel, to define if the absence of mutations in these 
genes could be ascribed to a low (< 500X) depth of sequencing or to a systematic error in variant 
calling process. The resulting data demonstarted that only CALR, CBLB, GATA1 and HRAS have a 
poor coverage (Figure 3). Similarly, also CEBPA showed a poor coverage: indeed, a large 
proportion (5 of 6 amplicons) covering the clinically actionable CEBPA gene did not meet a 
minimum depth of coverage of 500X. 
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Figure 1. Schematic representation of number of variants per gene of the TruSight Myeloid 
Sequencing Panel (Illumina). For each gene, variants have been distributed for variant frequency 
(VF, %) at 5, 10 and 25%. 
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Figure 2. Graphical representation of the genes most frequently mutated in patients diagnosed 
with (2a) Ph-negative chronic myeloproliferative neoplasms (MPN) and (2b) with other 
myeloproliferative disorders. 
. 
 
2b 
2a 
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Figure 3. Boxplot of coverage data for each probe, grouped by gene. Coverage analysis has 
highlighted a low depth of sequencing of CALR, GATA1, CBLB, HRAS and CEBPA genes. Blu line 
represent the cut-off value of minimum recommended coverage (500X). 
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Based on these results, we decided to test the Genetics Myeloid Solution Panel (Sophia) 
in order to identify a gene panel with a better performance. A total of 16 samples (5 at diagnosis, 
7 relapses and 4 follow-up) of patients with myeloid disease have been sequenced. Panel 
performance characteristic were similar to Illumina panel. In this case, the medium number of 
nucleotide variants (nVNT) per patient, filtered only for 500X minimum coverage and for non-
polymorfic variants, was 11.62, 8.5, 7.2 with a VF of 5, 10 and 25%, respectively. As already 
described for Illumina gene panel, nVNT decreas to 3.43, 3.17 and 2.45 by adding the filter for all 
non-pathogenic variants. Also in this case, the variants of each gene have been subdivided 
according to their frequency, resulting in a different profile from the previous one: indeed, the 
majority of variants have been detected with a VF >25% (Figure 4). Finally, data of mean coverage 
per target region, extraxted from “Sophia QA” report file, has been plotted (Figure 5) keeping into 
account only genes with a coverage lower than guaranted from manufacturer (1000X). Overall, 
the Genetics Myeloid Solution Panel (Sophia) showed a better coverage than TruSight Myeloid 
Sequencing Panel (Illumina) except for CEPBA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Schematic representation of number of variants per gene of the Genetics Myeloid 
Solution Panel (Sophia). For each gene, variants have been distributed for variant frequency (VF, 
%) at 5, 10 and 25%. 
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Figure 5. Representation of coverage data for each probe, grouped by gene. Coverage analysis 
has highlighted a low depth of sequencing of CEBPA gene. Blu line represent the cut-off value of 
minimum recommended coverage (500X). 
 
However, these are preliminary data that need to be validated in a larger cohort, as well 
as the ones derived from AML NGS Diagnostic Custom Panel (Thermo Fisher). This latter gene 
panel has been recently acquired and, therefore, very few samples have been sequenced by using 
it. However, from an initial analysis, some genes (CEBPA above all) resulted to be poor covered. 
 
CONCLUSIONS 
Others have previously reported on the validation of custom NGS panels for hematologic 
malignancies10-17. These studies have shown the range of application of NGS in the context of 
molecular diagnostics for hematologic malignancies. 
Here we report on preliminary results of the evaluation of the analytical performances of 
three different gene panels: TruSight Myeloid Sequencing Panel (Illumina), Myeloid Solution 
Panel (Sophia Genetics) and AML NGS Diagnostic Custom Panel (Thermo Fisher).  
Our study demonstrated that both the TruSight Myeloid Sequencing Panel (Illumina) and 
Genetics Myeloid Solution Panel (Sophia) performed well across different myeloid malignancies, 
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covering more than 95% of target regions with depth greater than 500X. Moreover, they showed 
a high sensitivity, allowing to identify gene variants with very low mutation burden (<1%) in all 
tested patients. However, it remains to clarify how discriminate between relevant and irrelevant 
mutations as well as the precise pathogenetic and phenotypic role of the identified alterations.  
Notably, a comprehensive validation approach needs to establish both test performance 
characteristics and test limitations. This approach allows for the appropriate application of the 
test to routine diagnostic conditions. Although both the TruSight Myeloid Sequencing Panel 
(Illumina) and Genetics Myeloid Solution Panel (Sophia) showed an overall high analytical 
performance, covering analysis revealed a low (< 500X) depth of sequencing in some recurrent 
genes, i.e. CALR, GATA1, CBLCB, HRAS and CEBPA. Evaluating the ability of gene panels to detect 
large insertions or deletions (such as in CALR) or variations in regions with high GC content (such 
as in CEBPA) may enable an assessment of whether alternative approaches to improve sequence 
coverage are needed. More interestingly, on the other hands, the use of multiple bioinformatics 
approaches may allow for maximizing variant calling. Indeed, given the large amount of data 
generated by a NGS approach, the improvement of informatics tools is mandatory.  
In conclusion, the identification of factors contributing to disease initiation and 
progression, as well as the respective influence on the clinical disease course is needed to 
optimize the diagnosis, prognostic scoring and therapeutic approaches. Therefore, with improved 
turnaround time, decreasing costs, and an expanding knowledge of the therapeutic and 
prognostic significance of the detected variants, NGS-based panel testing is likely to play a major 
role in the management of patients with myeloid malignancies. However, some efforts are 
necessary to identify the most suitable approach in order to translate it into diagnostic process. 
Interestingly, setting of bioinformatics tools may simply the interpretatiosn of results.  
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The overall aim of this study was the molecular characterization of MPN patients, and the study 
of interactions between malignant hematopoietic stem/progenitor cell (HSC/PC) and the 
inflammatory cell micro-environment. 
 
 Mutational status and outcome of young (≤ 40 years old) ET and early-PMF patients have 
never been investigated. The comparison between the two groups of patients showed that 
mutation frequency were 61% for JAK2V617F, 25% for CALR and 1% for MPLW515K, and were 
comparable across WHO diagnosis; however, JAK2V617F allele burden was higher in the early-
PMF group. Compared with JAK2V617F-positive patients, CALR-mutated patients presented 
lower thrombotic risk (9.1% versus 21.7%, P = 0.04), longer survival (100% vs 96%, P = 0.05) 
and better combined-EFS (86% vs 71%, P = 0.02). Interestingly, non-type 1/type 2 CALR 
mutations (‘minor’ mutations) and abnormal karyotype were found to correlate with 
increased risk of disease evolution. The assessment of the molecular status is of utmost 
importance in these cohorts of patients, as both thrombosis and survival were significantly 
influenced by mutation type and burden.  
 The determination of the mutation load is becoming a standard diagnostic procedure in most 
molecular laboratories, though WHO criteria do not specify a cut-off value for the diagnosis 
of a MPN. Our results highlight that the detection of a JAK2V617F mutation at low levels (0.1-
3%) is difficult to be interpreted in everyday clinical practice, since not all positive patients 
received a hematological diagnosis. However, all patients with an AB ≥0.8% finally received a 
diagnosis of MPN; therefore, a mutation load above this cut-off may be considered very 
indicative for the presence of a myeloproliferative disease. Additionally, the study identified 
the prospective evaluation of JAK2V617F mutation load as a convenient and non-invasive 
method to evaluate patients with small mutated clones in order to timely detect the 
expansion of clonal hematopoiesis and diagnose a full blown disease. 
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 In the context of highly sensitive allele-specific assays and low mutant AB in the peripheral 
blood, the standardization of molecular techniques is urgently needed. We demonstrated that 
a qualitative approach is not sensitive enough to detect JAK2V617F mutation at low mutation 
burden (i.e. < 1%). Conversely, the quantitative approach proved to be highly efficient and 
sensitive, although a modest variability was observed between all participating centers. 
Interestingly, between all tested JAK2V617F mutation detection assays, only the qualitative 
ARMS-PCR methods (both “in-house” and ipsogen JAK2 MutaSearch kit) and the quantitative 
approach (ipsogen JAK2 MutaQuant kit) were able to detect the positivity of samples with an 
AB of 1%, with an acceptable variability observed at this AB. With regard to samples with AB 
>1%, both qualitative and quantitative methods allow to detect mutation burden with a lower 
inter-laboratory variability. Overall, the quantitative ipsogen JAK2 MutaQuant kit assay 
performed consistently across different platforms, affirming itself as a robust method to 
obtain comparable results. This study sets the basis for the standardization of molecular 
techniques. 
 
 The in vitro interplay between various pro-inflammatory cytokines, which are abnormally 
increased, promotes and selects the circulating MF-derived HSPCs. Interestingly, we found 
that IL-1 and TIMP1 (in addition to TNF-) confer a survival advantage of MF-derived HSPCs, 
enhancing their proliferation and in vitro migration. Additionally, after migration toward IL-1β 
+ TNF-α (± TIMP-1), MF-derived CD34+ cells show increased clonogenic ability. Therefore, the 
increased number of HSPCs in the peripheral blood of MF may be due not only to the 
displacement of HSPCs from bone marrow into peripheral blood, but also to the 
proliferative/survival signals coming from the pro-inflammatory factors within the peripheral 
blood niche. As a consequence, the pro-inflammatory microenvironment emerges as central 
site for cell division and proliferation. Thus, it is likely that the in vivo inflammatory niche plays 
a key role in the maintenance of the malignant hemopoietic clone. Targeting these 
inflammatory micro-environmental interactions may be a clinically relevant approach for MF. 
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 Althought NGS technologies proved to be highly efficient for diagnostic purposes, no 
adequate guidelines and rigorous validation have been done. Our preliminary date suggested 
that both the TruSight Myeloid Sequencing Panel (Illumina) and Genetics Myeloid Solution 
Panel (Sophia) performed well across different myeloid malignancies, covering more than 95% 
of target regions with depth greater than 500X. Moreover, they showed a high sensitivity, 
allowing to identify gene variants with very low mutation burden (<1%) in all tested patients. 
However, it remains to clarify how discriminate between relevant and irrelevant mutations as 
well as the precise pathogenetic and phenotypic role of the identified alterations. 
Interestingly, some recurrent genes (i.e. CALR, GATA1, CBLCB, HRAS and CEBPA) showed a 
lower depth of sequencing, requiring an alternative molecular approach. Alternatively, the 
optimization of bioinformatics tools could be utmost important to facilitate variant calling 
process and data interpretation. 
 
 
In conclusion, our study allows to better characterize MPN patients on a molecular level and from 
the point of view of the inflammation. Of note, we set the basis for the standardization of 
molecular techniques and for the validation of a robust NGS approach to be transferred into a 
diagnostic setting. An investigation on a larger cohort of patients might be useful to strengthen 
our data and to better stratify patients at diagnosis, in order to improve clinical outcome as well 
as to identify new potential molecular therapeutic targets for personalized therapies. 
On the other hand, we identify IL-1 and TIMP-1 as novel promoting factors of the in vitro 
maintenance of MF-derived HSPC. These results elucidate the mechanism of maintenance of the 
malignant hemopoietic clone and identified two molecular biomarkers that may be exploited as 
potential targets of therapy. The investigation on patients treated with ruxolitinib will allow to 
shed light into the effect of the therapy on the mutational status and the inflammatory 
microenvironment.   
 
